

5-2021

Investigating Mechanisms in Nociceptors Driving Ongoing Activity and Ongoing Pain

Elia Lopez

Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations



Part of the [Cellular and Molecular Physiology Commons](#), and the [Molecular and Cellular Neuroscience Commons](#)

Recommended Citation

Lopez, Elia, "Investigating Mechanisms in Nociceptors Driving Ongoing Activity and Ongoing Pain" (2021). *The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access)*. 1082.
https://digitalcommons.library.tmc.edu/utgsbs_dissertations/1082


This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact digitalcommons@library.tmc.edu.

INVESTIGATING MECHANISMS IN NOCICEPTORS DRIVING ONGOING ACTIVITY AND
ONGOING PAIN

by

Elia Rose Lopez, M.S.

APPROVED:



Edgar T. Walters, PhD
Advisory Professor



Carmen W. Dessauer, PhD
Co-Advisory Professor



Zhiqiang An, PhD



Annemieke Kavelaars, PhD



Michael X. Zhu, PhD

APPROVED:

Dean, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of
Biomedical Sciences

INVESTIGATING MECHANISMS IN NOCICEPTORS DRIVING
ONGOING ACTIVITY AND ONGOING PAIN

A

DISSERTATION

Presented to the Faculty of

The University of Texas

MD Anderson Cancer Center UTHealth

Graduate School of Biomedical Sciences

in Partial Fulfillment

of the Requirements

for the Degree of

DOCTOR OF PHILOSOPHY

by

Elia Rose Lopez, M.S.

Houston, Texas

May 2021

Dedication

To my mother, who has always been an endless source of support and encouragement.

And to Zach, who has been by my side every step of the way and always reassured me that I could accomplish whatever I set my mind to.

Acknowledgements

I would like to thank my advisor, Dr. Terry Walters, for his mentorship. He took a chance on me despite the fact that I had absolutely no prior experience in neuroscience and electrophysiology, and he supported, encouraged, and challenged me throughout my doctoral research journey. His wealth of knowledge and passion for science is incredibly inspiring. I am grateful for his willingness to help me through any research obstacle, provide feedback, and answer questions, even on weekends or at odd hours.

I would also like to thank my co-advisor, Dr. Carmen Dessauer. With her expertise and to-the-point approach, having her as a co-mentor elevated my PhD experience, and I am endlessly grateful to have her on my team. She is always willing to advise me in my research and in my career, and I always leave her office wondering why I didn't go sooner.

My experience was also shaped by others in the Walters and Dessauer labs. I feel lucky to have learned electrophysiology from Dr. Alexis Bavencoffe, who has shared boundless knowledge and shown exceptional patience. I am also grateful to have learned high content microscopy from Dr. Anibal Garza Carbajal, whose upbeat attitude creates a fun atmosphere in the lab and whose extensive knowledge of cell signaling make for intriguing and informative conversations. Additionally, I am glad that my time as a PhD student overlapped with that of Dr. Max Odem, whose exceptional integrity and critical thinking I strive to implement in my research. There are many others who have enriched my experienced, helped answer questions, assisted me in experiments, and assured things run smoothly, including Yong, Sammitha, Kerry, Michael, Jinbin, and Emily.

Lastly, I want to thank my advisory committee, which in addition to Dr. Walters and Dr. Dessauer includes, Dr. Zhiqiang An, Dr. Annemieke Kavelaars, and Dr. Michael X. Zhu, and formerly Dr. Darren Boehning. Each one of them significantly contributed to my growth as a scientist in training. I left every committee meeting with a sense of pride in my work and with stimulating questions and new directions to consider.

INVESTIGATING MECHANISMS IN NOCICEPTORS DRIVING ONGOING ACTIVITY AND ONGOING PAIN

Elia R. Lopez, M.S.

Advisory Professor: Edgar T. Walters, PhD

Co-Advisory Professor: Carmen W. Dessauer, PhD

Ongoing (apparently spontaneous) pain at rest is a major complaint of patients suffering from many forms of acute and chronic pain, including acute and persistent postsurgical pain. Accumulating evidence suggests ongoing activity in nociceptors is a major driver of ongoing pain. Ongoing activity can be generated in sensory neurons in the absence of sensory generator potentials if one or more of three neurophysiological alterations occur – prolonged depolarization of resting membrane potential (RMP), hyperpolarization of action potential (AP) threshold, and/or increased amplitude of depolarizing spontaneous fluctuations of membrane potential (DSFs) to bridge the gap between RMP and AP threshold. Cellular signaling pathways that increase DSF amplitude and promote ongoing activity acutely in nociceptors were unknown for any neuromodulator, as were the neurophysiological alterations that underly ongoing activity in nociceptors after deep tissue incision. The work presented in this dissertation sought to identify a cellular signaling pathway and injury- and inflammation-related neuromodulator that induces alterations that drive hyperexcitability, such as enhanced DSFs, and thereby potentiates ongoing activity in nociceptors, as well as to determine

the alterations that contribute to nociceptor hyperactivity associated with postsurgical pain.

A combination of whole-cell patch clamp electrophysiology, pharmacology, and high content microscopy was used to define the effects of low concentrations of the injury-related proinflammatory mediator serotonin and the major pathway by which it exerts its effects. This study shows that serotonin enhances DSFs, hyperpolarizes AP threshold, and thereby potentiates OA in isolated rat DRG neurons at a concentration of 100 nM, and serotonin exerts these effects on nonpeptidergic nociceptors via the 5-HT₄ receptor and downstream cAMP signaling via PKA and EPAC. Furthermore, whole-cell patch clamp recordings of primary DRG neurons, analysis of spontaneous pain behavior, and RNA sequencing were used to reveal an unexpected persistence of hyperexcitability in isolated DRG neurons and potentially associated differential gene expression, both of which were found after the behavioral expression of postsurgical pain had resolved. In addition to elucidating cell signaling mechanisms that can contribute to acute ongoing activity in nociceptors, these studies set the stage for future investigations addressing important questions about nociceptor contributions to pain.

Table of Contents

Approval Page.....	i
Title Page.....	ii
Dedication.....	iii
Acknowledgements.....	iv
Abstract.....	vi
Table of Contents.....	viii
List of Illustrations.....	xiii
List of Tables.....	xv
List of frequently used abbreviations.....	xvi
Chapter 1.....	1
Introduction.....	1
1.1. The physiology and pathophysiology of pain: an overview of the alterations that underly acute and chronic pain.....	2
1.2. Observing drivers of pain in isolated rodent DRG neurons.....	5
1.3. Injury- and inflammatory-related signals sensitize neurons.....	8
1.3.1. Neuroimmune interactions.....	9
1.3.2. Neuroglial interactions.....	11
1.4. cAMP signaling in nociceptors.....	13

1.5. Conclusions.....	15
Chapter 2.....	17
Materials and Methods.....	17
2.1. Animals.....	18
2.2. Dissociation and culture of DRG neurons.....	18
2.3. Whole-cell recordings from dissociated DRG neurons.....	19
2.4. High content microscopy and subpopulation analysis.....	21
2.5. Ca ²⁺ imaging.....	22
2.6. Surgical procedures.....	23
2.7. Measurement of guarding behavior.....	24
2.8. Statistical analysis.....	24
2.9. RNA sequencing.....	25
Chapter 3.....	27
5-HT enhances DSFs, excitability, and OA in isolated rat DRG neurons.....	27
3.1. Introduction.....	28
3.2. Results.....	29
3.2.1. Dose-dependent relationship of the effects of 5-HT on hyperexcitability.....	29
3.2.2. Exposure to 100 nM 5-HT potentiates OA in probable nociceptors, in part by enhancing DSFs.....	32

3.3. Conclusions.....	34
Chapter 4.....	36
5-HT potentiates OA in DRG neurons via 5-HT ₄ receptors.....	36
4.1. Introduction.....	37
4.2. Results.....	37
4.2.1. 5-HT ₄ receptors are required for potentiation of DSFs and OA induced by 5-HT.....	37
4.2.2. Selective 5-HT ₄ activation can induce hyperexcitability in DRG neurons....	42
4.3. Conclusions.....	47
Chapter 5.....	50
5-HT potentiates OA in DRG neurons via cAMP-dependent mechanisms.....	50
5.1. Introduction.....	52
5.2. Results.....	52
5.2.1. PKA activity is required for potentiation of DSFs and OA by 5-HT.....	52
5.2.2. EPAC activity contributes to induction of hyperexcitability by 5-HT.....	55
5.2.3. Nociceptor hyperexcitability induced by 5-HT does not require HCN activity.....	57
5.2.4. Activation of cAMP signaling is sufficient to induce hyperexcitability in probable nociceptors.....	58

5.3. Conclusions.....	64
Chapter 6.....	58
Effects in the DRG of deep tissue incision in a rat model of post-surgical pain.....	64
6.1. Introduction.....	65
6.2. Results.....	67
6.2.1. OA persists in isolated nociceptors after deep tissue incision.....	67
6.2.2. Global transcriptome analysis of rat DRG to identify genes involved in persistent nociceptor hyperexcitability after deep tissue incision.....	71
6.3. Conclusions.....	78
Chapter 7.....	83
Concluding remarks and future directions.....	83
7.1. Summary of Conclusions.....	84
7.2. Functional implications of 5-HT ₄ -dependent cAMP signaling in nociceptors.....	84
7.3. Advantages and potential pitfalls of a pharmacological approach to studying molecular mechanisms.....	86
7.4. Future directions.....	88
7.4.1. cAMP signaling in nociceptors – what about POPDC?.....	88
7.4.2. Role of 5-HT/cAMP signaling in postsurgical pain.....	89
7.4.3. Why does hyperactivity persist in isolated nociceptors longer than <i>in vivo</i>	

pain and OA?.....	90
7.4.4. Potential new molecular contributors to postsurgical pain suggested by transcriptional analysis.....	92
Bibliography.....	96
Vita.....	131

List of Illustrations

Figure 1. Summary of neurophysiological specializations that promote OA in nociceptors.....	7
Figure 2. Immune cells release mediators that produce peripheral sensitization of nociceptor sensory neurons and pain.....	10
Figure 3. Dose-response effects of 5-HT on RMP, AP threshold, DSFs, and OA.....	31
Figure 4. Potentiation by 5-HT of OA in probable nociceptors.....	33
Figure 5. Treatment with 5-HT before and during recording at -45 mV increases the number of medium amplitude and large DSFs in probable nociceptors from naïve rats.....	34
Figure 6. 5-HT ₄ receptor is required for potentiation of DSFs and OA by 5-HT.....	39
Figure 7. PKA activation measured by PKA-pR11 staining in rat DRG neurons.....	41
Figure 8. Ca ²⁺ responses to 5-HT measured by Fura-2.....	42
Figure 9. Dose-dependent PKA activation by 5-HT and the 5-HT ₄ agonist prucalopride.....	43
Figure 10. Effects of prucalopride on hyperexcitability of probable nociceptors.....	45
Figure 11. Selective 5-HT ₄ receptor activation of PKA in DRG neuron subpopulations.....	47
Figure 12. PKA activity is required for potentiation of DSFs and OA by 5-HT.....	54
Figure 13. EPAC activity contributes to hyperexcitability induced by 5-HT.....	56

Figure 14. Nociceptor hyperexcitability induced by 5-HT does not require HCN activity.....	58
Figure 15. Activation of cAMP signaling by the cAMP analog 8-Br-cAMP is sufficient to potentiate DSFs and OA in isolated DRG neurons.....	60
Figure 16. Hyperactivity persists in isolate DRG neurons after deep tissue incision....	68
Figure 17. Guarding pain behavior is resolved by POD7.....	70
Figure 18. Gene expression distribution and correlation between samples.....	72
Figure 19. Volcano plot of ipsilateral differentially expressed genes 7 days post-incision.....	74
Figure 20. Volcano plot of contralateral differentially expressed genes 7 days post-incision.....	76
Figure 21. Quantification of genes with expression above different FPKM cutoff values.....	77
Figure 22. Graphical summary of 5-HT ₄ -mediated potentiation of OA in nociceptors.....	85

List of Tables

Table 1. Genes differentially expressed in ipsilateral DRG at 7 days post-incision compared to naïve controls.....	75
Table 2. Genes differentially expressed in contralateral DRG at 7 days post-incision compared to naïve controls.....	76
Table 3. FPKM values of genes differentially expressed in ipsilateral and contralateral DRG at 7 days post-incision.....	78

List of frequently used abbreviations

5-HT: serotonin

5-HTR: serotonin receptor

8-Br-cAMP: 8-bromo-cyclic adenosine monophosphate

ANOVA: analysis of variance

AP: action potential

cAMP: cyclic adenosine monophosphate

[Ca²⁺]_i: intracellular Ca²⁺ concentration

Ca_v3.2: voltage-gated calcium channel 3.2

CGRP: calcitonin gene-related peptide;

CI: confidence interval

CSF: cerebrospinal fluid

DMEM: Dulbecco's Modified Eagle Medium

DMSO: dimethyl sulfoxide

DRG: dorsal root ganglion

DSF: depolarizing spontaneous fluctuation

EC₅₀: concentration that produces the half maximal stimulatory effect

ECS: extracellular solution

EPAC: exchange protein activated by cAMP

GPCR: G protein-coupled receptor

HCN: hyperpolarization-activated cyclic nucleotide-gated channel

IB4: isolectin B4

IC₅₀: concentration that produces the half maximal inhibitory effect

ICS: intracellular solution

myr-PKI 14-22: myristoylated protein kinase inhibitor 14-22

NA: nonaccommodating

OA: ongoing activity

PGE₂: prostaglandin E₂

PGP9.5: protein gene product 9.5

PKA: protein kinase A

RA: rapidly accommodating

RMP: resting membrane potential

RNA: ribonucleic acid

SCI: spinal cord injury

TRPV1: transient receptor potential vanilloid 1

TTX-R: tetrodotoxin-resistant

Veh: vehicle

Chapter 1

Introduction

Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage.” Pain, while unpleasant at the least and unbearable at the worst, is integral to survival. Pain tells us to remove ourselves from something or stop engaging in an activity that will cause harm. It is also pain that lets us know to protect ourselves when we are vulnerable while a wound or infection is healing. People with gene mutations that cause congenital insensitivity to pain often accumulate injuries that may go undetected and can ultimately lead to reduced life expectancy (Daneshjou et al., 2012; Mifsud et al., 2019; van den Bosch et al., 2014). Sensitivity to pain can help us live long and healthy lives. However, pain can become pathological; when pain is no longer alerting us to actual or potential injury but becomes persistent, it can exact a heavy toll on an individual and on society. Chronic pain is experienced by at least 11% of adults in the United States and is one of the most common reasons adults seek medical care (Dahlhamer et al., 2018). Ongoing spontaneous pain is often the worst complaint of patients suffering from many forms of pain (Backonja and Stacey, 2004; Bennett, 2012). Importantly, severe and persistent pain can tremendously impair quality of life, and current treatment options are often inadequate. Thus, it is important to better understand the mechanisms that drive pain and how it becomes pathological.

1.1. The physiology and pathophysiology of pain: an overview of the alterations that underly acute and chronic pain

Pain and other sensory information is transduced by primary afferents (sensory neurons). Different classes of sensory neurons are specialized to respond to different

types of stimuli. Low threshold mechanoreceptor neurons (LTMRs) are mostly made up of large myelinated A β -fibers and some of the smaller myelinated A δ -fibers. Many of these fast-conducting neurons respond to innocuous mechanical stimuli, such as light touch. Nociceptors, sensory neurons specialized for the detection of injury and inflammation (Basbaum et al., 2009; Das, 2015; Dubin and Patapoutian, 2010), mostly have unmyelinated, small-diameter C-fibers exhibiting low conduction velocity. These respond to noxious mechanical, heat, cold, and/or chemical stimuli. Many A δ neurons and a small subset of A β neurons are also nociceptors.

Under normal conditions tissue damage activates peripheral terminals of nociceptors. This initiates electrical signals, action potentials (APs), that travel along the axons of the nociceptors to the spinal cord, where they synapse with second-order interneurons in the dorsal horn of the spinal cord. The electrical signal is relayed to second-order neurons by synaptic release of the neurotransmitter glutamate and one or more neuropeptides, including substance P and calcitonin gene-related peptide (CGRP) (D'Mello and Dickenson, 2008; Yam et al., 2018). This signal excites second-order neurons, generating APs that travel along their axons, many of which cross over the spinal cord to the spinothalamic tract, then traveling up to the thalamus of the brain. Thalamic third-order neurons then relay the signal to the region of the somatosensory cortex which maps onto the region of the body where the signal originated, as well as to other brain regions such as the insula and anterior cingulate cortex (Bushnell and Apkarian, 2005). This results in the conscious perception of pain in the injured area. Additionally, there are descending pathways that enhance or suppress synaptic transmission in the ascending pain pathways (Ren and Dubner, 2008), but the focus here will be on the primary sensory neurons that initiate activity in the pain pathways.

Activation of nociceptors, which normally are electrically silent, produces immediate pain and protective reflexive responses. It also produces sensitization of neural and behavioral responses to subsequent noxious and innocuous stimuli. These sensitizing effects are mediated by alterations in pain pathways. One sensitizing effect is enhanced responsiveness of primary sensory neurons to stimulation of their receptive fields (peripheral sensitization). Another is enhanced responsiveness at the level of the spinal cord and brain to sensory input from the periphery (central sensitization) (Meacham et al., 2017). At the peripheral terminals, enhanced sensory generator potentials and reduced AP threshold lead to increases in nociceptor discharge and input to the central nervous system (CNS). If injury or infection is severe enough to damage peripheral nerves, ectopic generation of APs can occur in the axons (often at neuromas) or the cell bodies of sensory neurons (Walters, 2019), which are clustered in the dorsal root ganglia (DRG) or trigeminal ganglia.

Increased nociceptor activity can produce synaptic plasticity (Price and Inyang, 2015; Reichling and Levine, 2009), including long-term synaptic potentiation (LTP) and heterosynaptic facilitation (Klein et al., 2008; Pace et al., 2018), which amplifies signals in the pain pathways and contributes to central sensitization. A reduction in inhibitory tone at the presynaptic terminals of nociceptors may also accompany enhanced activity (Comitato and Bardoni, 2021; Gradwell et al., 2020; Guo and Hu, 2014; Hughes and Todd, 2020). In the brain, cortical remodeling can contribute to augmented pain perception (Puntillo et al., 2021). Furthermore, increased facilitation and decreased inhibition by descending modulatory pathways can further enhance transmission of nociceptive information at the level of the spinal cord (Ossipov et al., 2014).

Reduced threshold and subsequent enhanced responsiveness of nociceptors to stimulation underlies hyperalgesia, an increased sensation of pain from a stimulus that normally provokes pain. In addition, central sensitization allows for activity in LTMRs to activate pain pathways, resulting in allodynia, sensation of pain in response to normally innocuous stimuli. In addition to hyperalgesia and allodynia, ongoing (apparently spontaneous) pain at rest is a major complaint of patients suffering from many forms of acute and chronic pain. Accumulating evidence links ongoing pain with ongoing activity (OA, also known as spontaneous activity) that may occur in sensory neurons and their downstream targets in the spinal dorsal horn in the absence of an apparent stimulus. The findings that activation of even a few human nociceptors *in vivo* evokes immediate pain (Nagi et al., 2019; Ochoa and Torebjörk, 1989) and the high incidence of OA in C-fiber nociceptors in microneurographic recordings from patients with ongoing neuropathic pain (Kleggetveit et al., 2012; Serra et al., 2012) indicate that a major driver of ongoing human pain is OA in nociceptors.

1.2. Observing drivers of pain in isolated rodent DRG neurons

The OA observed *in vivo*, can be retained in nociceptor somata dissociated from excised DRG. Electrophysiological recordings from single DRG neurons dissociated from human patients (North et al., 2019) and recordings from rodent nociceptors in preclinical neuropathic, inflammatory, and incisional pain models (Bedi et al., 2010; Djouhri et al., 2006; North et al., 2019; Xu and Brennan, 2010) demonstrate an increased incidence of OA in DRG neurons linked to ongoing pain. The occurrence of pain-related OA in dissociated nociceptors *in vitro* that is similar in pattern and incidence to that occurring *in vivo* during persistent neuropathic pain (Bedi et al., 2010) provides a special

opportunity to define the cellular mechanisms in nociceptors that enable their ongoing and spontaneous activity.

Examination of OA in isolated DRG neurons has allowed us to make great strides in our understanding of the electrophysiological alterations that drive a sensory neuron from a silent state to a state of OA. As illustrated by our findings in a model of neuropathic pain (Odem et al., 2018), three basic neurophysiological alterations can generate OA in nociceptors in the absence of sensory generator potentials – prolonged depolarization of the resting membrane potential (RMP), hyperpolarization of the action potential (AP) threshold, and an increase in the incidence of large depolarizing spontaneous fluctuations (DSFs) of membrane potential that can intermittently bridge the gap between RMP and AP threshold (Figure 1). While alterations in RMP and AP threshold are commonly recognized contributors to neuronal excitability, the importance of DSFs has only recently been recognized. Large DSFs are prominent in neurons with OA, and they play a major role in controlling the low firing rate and irregular pattern of OA observed in DRG neurons dissociated in animal models of persistent pain, including chronic constriction injury of the sciatic nerve (Study and Kral, 1996), spinal cord injury (Berkey et al., 2020; Odem et al., 2018), and treatment with the chemotherapeutic cisplatin (Laumet et al., 2020), as well as in DRG neurons taken from humans with neuropathic pain (North et al., 2019).




Figure 1. Summary of neurophysiological specializations that promote OA in nociceptors. Representative traces from naïve rats (normal state) and rats with spinal cord injury (OA state). AP, action potential; DSF, depolarizing spontaneous fluctuation; MP, membrane potential; OA, ongoing activity; RMP, resting membrane potential. Reprinted from Title: Isolated nociceptors reveal multiple specializations for generating irregular ongoing activity associated with ongoing pain; Authors: Max A. Odem, Alexis G. Bavencoffe, Ryan M. Cassidy, Elia R. Lopez, Jinbin Tian, Carmen W. Dessauer, and Edgar T. Walters; Publication: *Pain*; Publisher: Wolters Kluwer Health, Inc.; Date: July 12, 2018. Use of the text and figures are granted for use in a dissertation by an author without formal licensing from Wolters Kluwer Health, Inc.

As described above, DRG neurons are a diverse population of sensory neurons that are specialized for different sensory modalities. Cutaneous LTMRs sense non-noxious mechanical force; cold receptors respond to cold; and overlapping subsets of nociceptors respond to noxious mechanical force, noxious heat, and noxious chemicals. DRG neurons can be classified based on a variety of molecular markers, cellular properties, and gene expression profiles. LTMRs are relatively large in size compared to nociceptors and express Tropomyosin receptor kinase B (TrkB, a receptor for brain-derived neurotrophic factor [BDNF]) or TrkC (a receptor for neurotrophin-3 [NT-3]). Cold

receptors have small somata, express transient receptor potential melastatin 8 (TRPM8), and do not express CGRP or bind isolectin B4 (IB4) (Dhaka et al., 2008; Peier et al., 2002; Takashima et al., 2007). Nociceptors are a diverse group with mostly small to medium soma sizes. One common way to classify nociceptors is by expression of CGRP (marking “peptidergic” nociceptors) or binding of IB4 (marking “non-peptidergic” nociceptors), as CGRP and IB4 binding distinguish largely separate populations in mice with only a relatively small subset of nociceptors positive for both. A larger overlap between CGRP-expressing and IB4-binding DRG neurons is observed in rats (Price and Flores, 2007). In mice, all peptidergic nociceptors express transient receptor potential vanilloid 1 (TRPV1), while a subset of non-peptidergic nociceptors express this channel, which is well known for its involvement in detection of heat and pain, especially in response to capsaicin, the component of chili peppers that causes a burning sensation. Recent findings in human DRG neurons show substantial differences from mice in the expression of these nociceptive markers (Shiers et al., 2020).

1.3. Injury- and inflammatory-related signals sensitize neurons

While it is usually nociceptive neurons that transduce the signals that lead to the sensation of pain, the transduction, transmission, and perception of pain are modified and often initiated by modulators released from non-neuronal cells. The peripheral terminals of nociceptors are packed with receptors and ion channels that detect molecular mediators released from immune cells and other cell types during injury and inflammation. During neuroinflammation, glial cells are activated and release pro-inflammatory cytokines and chemokines that contribute to peripheral and central sensitization. Neurons themselves can also release neuropeptides and other signals that influence inflammatory cells, leading to neurogenic inflammation.

1.3.1. Neuroimmune interactions

In response to injury, immune cells release a variety of inflammatory mediators that activate and/or sensitize nociceptors (Figure 2). Mast cells are tissue-resident immune cells found near externally exposed surfaces that act as “first responders” to foreign invaders and tissue damage. Mast cells are known to associate closely with nociceptors and to contribute to the pathobiology of several types of pain, including chemotherapy-induced peripheral neuropathy (CIPN), pelvic pain, and osteoarthritis (Azimi et al., 2016; Breser et al., 2017; Forsythe and Bienenstock, 2012; Gupta and Harvima, 2018; Jaggi et al., 2017; Sousa-Valente et al., 2018). Upon activation, mast cells immediately release preformed granules containing nociceptor-sensitizing mediators, including serotonin (which is of particular interest and will be introduced in detail in Chapter 3), histamine, cytokines (e.g. Interleukin 5 [IL-5], tumor necrosis factor alpha [TNF- α], IL-1 β , IL-6, and IL-17), and tryptase. Later, via de novo synthesis, mast cells release cytokines, growth factors (e.g. nerve growth factor), and neuropeptides (e.g. substance P). Meanwhile, macrophages and neutrophils are activated at and mobilized to the site of injury where they also release a host of inflammatory cytokines, growth factors, and lipids (e.g., IL-1 β , IL-6, and prostaglandin E₂ [PGE₂]) that can activate and sensitize nociceptors to increase pain. It was demonstrated recently that angiotensin receptor 2-expressing macrophages at the site of nerve injury are a critical component in triggering neuropathic pain after spared nerve injury in mice (Shepherd et al., 2018).




Figure 2. Immune cells release mediators that produce peripheral sensitization of nociceptor sensory neurons and pain. During inflammation, tissue-resident and recruited immune cells secrete molecular mediators that act on the peripheral nerve terminals of nociceptor neurons to produce pain sensitization. In these neurons, specific cytokine, lipid, and growth factor receptor intracellular signaling pathways lead to phosphorylation and/or gating of ion channels Nav1.7, Nav1.8, Nav1.9, TRPV1, and TRPA1, leading to increased action potential generation and pain sensitivity. Reprinted with permission under license. Title: Nociceptor Sensory Neuron–Immune Interactions in Pain and Inflammation; Authors: Felipe A. Pinho-Ribeiro, Waldiceu A. Verri, and Isaac M. Chiu; Publication: *Trends in Immunology*; Publisher: Elsevier; Date: January 1, 2017. License number 5032131331454.

In addition to their roles in nociceptor activation and sensitization at sites of injury, neuroimmune interactions are also known to take place in the DRG where immune cells interact with nociceptor somata to modulate pain. Mast cell activation in the DRG contributes to pain in rodent models of sickle cell disease, sciatic nerve injury, and CIPN (Gao et al., 2016; Saleem et al., 2019; Vincent et al., 2013). Macrophages, monocytes

and neutrophils increase in the DRG in rodent models of radiculopathy, systemic inflammation, CIPN and peripheral nerve injury (Kim and Moalem-Taylor, 2011; Liu et al., 2014; Yoon et al., 2012; Zhang et al., 2016, 2021), and expansion and proliferation of the macrophage populations near the somata of injured sensory neurons makes a critical contribution to the initiation and maintenance of neuropathic pain in a mouse spared nerve injury model (Yu et al., 2020).

Furthermore, mast cells, macrophages, neutrophils, and T cells express receptors for neurotransmitters and neuropeptides, such as vasoactive intestinal peptide, CGRP, and substance P, released from nociceptors during neurogenic inflammation and thus can respond directly to nociceptor activity. Neuropeptides potentiate activation of mast cells (Aich et al., 2015; Kim et al., 2014; Rosa and Fantozzi, 2013). Thus, a feedback mechanism in which mast cell activation in response to tissue damage leads to excitation of nociceptors, which in turn release neuropeptides that cause further activation of mast cells can sustain activity in pain pathways. This cycle of mast cell activation and peripheral nerve sensitization may play a role in the development and maintenance of chronic pain (Austin and Moalem-Taylor, 2010). Similarly, substance P induces the release of pro-inflammatory cytokines from macrophages and monocytes (Lotz et al., 1988; Sun et al., 2008).

1.3.2. Neuroglial interactions

In the move away from a neurocentric view of pain, another cell type that has come into focus as intimately coupled to neurons in pain sensitization is glial cells. Neuroglia include Schwann cells and satellite glial cells (SGCs) in the peripheral

nervous system (PNS) and microglia, astrocytes, and oligodendrocytes in the CNS. The focus here is on glial effects on nociceptors.

Schwann cells interact with sensory nerve fibers and under physiological conditions maintain the local environment, help form the myelin sheath around myelinated axons, and envelop bundles of unmyelinated C-fibers (Kidd et al., 2013). However, nerve injury triggers a phenotypic switch in Schwann cells, causing them to proliferate, migrate, and secrete factors that cause nerve degeneration, regeneration, and inflammation (Jessen and Mirsky, 2019). Secreted factors include the pro-inflammatory mediators TNF- α , IL-1 β , IL-6, and PGE₂ (Bolin et al., 1995; Muja and DeVries, 2004; Murwani et al., 1996; Shamash et al., 2002).

Satellite glial cells (SGCs) envelop neuronal somata in the DRG. SGCs couple to each other via gap junctions, and there is evidence suggesting they can synchronize the activity of sensory neurons (Spray et al., 2019). Noxious stimulation or injury of sensory neurons leads to increased gap junction coupling between SGCs and their release of proinflammatory mediators. This leads to increased activity of the sensory neurons and promotes infiltration of immune cells. For example, cisplatin effects on SGCs lead to increased release of TNF- α and IL-6, leading to increased excitability of sensory neurons (Leo et al., 2021).

Sensitized sensory neurons also release colony stimulating factor 1 (CSF1) in the spinal cord, which induces proliferation and activation of microglia (Guan et al., 2016), a specialized population of macrophages that function as glial cells in the CNS. Activated microglia in turn elicit activation and proliferation of astrocytes. These

activated CNS neuroglia contribute to neuroinflammation that can in turn contribute to central sensitization by impacting spinal circuits (Old et al., 2015).

1.4. cAMP signaling in nociceptors

Cyclic adenosine monophosphate (cAMP) is a major mediator of intracellular signal transduction in response to a number of hormones, neurotransmitters, and inflammatory mediators that bind G protein-coupled receptors (GPCRs). GPCRs are a large family of receptors that use G proteins to transduce signals to their effectors, which include enzymes such as adenylyl cyclase (AC) and phospholipase C (PLC) as well as Ca^{2+} channels (Ross and Kenakin, 2001). The G proteins are comprised of two subunits – the α subunit and the $\beta\gamma$ subunit. The major effector type and whether the activity of the effector is increased or decreased depends on the α subunit. $\text{G}\alpha_s$ stimulates AC activity, while $\text{G}\alpha_i$ inhibits AC activity; and $\text{G}\alpha_q$ stimulates PLC activity, leading to release of intracellular Ca^{2+} stores and activation of protein kinase C (PKC). Additionally, the $\text{G}\beta\gamma$ subunits regulate K^+ channels, AC, PLC, and phosphatidylinositol-3-kinase (PI3K). Ligands for GPCRs in sensory neurons include an array of biogenic amines (e.g. serotonin and histamine), eicosanoids (e.g. prostaglandins), lipids (e.g. cannabinoids), and peptides (e.g. opioids and vasoactive intestinal peptide). As a result of their abundance and physiological importance, GPCRs are common targets for therapeutics (Ross and Kenakin, 2001).

Several inflammatory mediators, including serotonin, activate GPCRs coupled to $\text{G}\alpha_s$, which in turn activate AC, leading to pain sensitization acutely (Villarreal et al., 2009). Recent studies also implicate signaling downstream of AC in the maintenance of chronic pain (Bavencoffe et al., 2016; Dessauer et al., 2017; Sadana and Dessauer,

2009; Vadakkan et al., 2006). AC synthesizes the second messenger cAMP from adenosine triphosphate (ATP). Cyclic AMP can then go on to activate its effectors – protein kinase A (PKA), exchange protein activated by cAMP (EPAC), hyperpolarization-activated cyclic nucleotide-gated channels (HCN), and popeye domain containing proteins (POPDC).

The most extensively studied cAMP effector, PKA, plays an important role in pain sensitization and nociceptor ongoing activity by phosphorylating a multitude of targets, and can exact longer-term changes by modulating gene expression via the transcription factor cAMP-response element binding protein (CREB). PKA-activating inflammatory mediators or direct activation of PKA increases activity of channels involved in nociceptor hyperexcitability, including TRPV1, T-type Ca²⁺ channels, and tetrodotoxin-resistant voltage-gated Na⁺ channels (Kim et al., 2006; Ohta et al., 2006; Vijayaragavan et al., 2004). PKA activation can also increase excitability by negatively regulating K⁺ channels that normally limit excitability and repetitive firing (Nuwer et al., 2010). Furthermore, inhibiting PKA activity or disrupting interaction with its AKAP scaffold in dissociated DRG neurons reduces nociceptor OA in a spinal cord injury model of neuropathic pain (Bavencoffe et al., 2016).

Recently, EPAC has also come to light as an important player with a role in the transition from acute to chronic pain. EPACs are guanine nucleotide exchange factors (GEFs) that catalyze the exchange of GDP for GTP for the Ras-like GTPases Rap1/2, thereby activating them. Downstream of EPAC-Rap, PLC and PLD mediate the translocation and activation of protein kinase C ϵ (PKC ϵ) (Schmidt et al., 2001), which contributes to sensitization in neuropathic and chronic inflammatory pain (Dina et al., 2001, 2000; Joseph and Levine, 2003a, 2003b; Khasar et al., 1999; Numazaki et al.,

2002; Sweitzer et al., 2004). Thus, EPAC mediates a connection between cAMP and PKC signaling (Hucho et al., 2005), which were previously thought to function as two separate pathways. It is thought that a transition to increased downstream cAMP signaling via EPAC-PKC is involved in nociceptor priming, which is likely a key factor in the transition from acute inflammatory pain to chronic pain (Eijkelkamp et al., 2010; Hucho et al., 2005; Vasko et al., 2014; Wang et al., 2018). In addition to nociceptor priming and persistent pain, there is evidence for the involvement of EPAC in mediating acute inflammatory pain (Goode and Molliver, 2021).

HCN channels represent another cAMP effector that is widely expressed in the PNS and plays a role in neuronal excitability and pain transduction. As the name suggests, these channels are activated by hyperpolarization and modulated by cAMP. In response to hyperpolarization, they conduct Na⁺ ions into the cell (and K⁺ ions out of the cell), resulting in net depolarization, which causes the channel to close again. Thus, HCN channels have the capacity to act as pacemakers, a function typically associated with HCN in the heart. Furthermore, studies suggest HCN channels in nociceptors are critical players in inflammatory and neuropathic pain (Emery et al., 2011; Ma et al., 2021).

1.5. Conclusions

Ongoing spontaneous pain is a major complaint of patients suffering from many forms of acute and chronic pain. Ongoing activity in nociceptors is a major driver of ongoing pain in humans, and similar OA is observed in isolated nociceptors in rodent pain models. Three neurophysiological alterations contribute to OA in the absence of sensory generator potentials – depolarization of RMP, hyperpolarization of AP

threshold, and enhancement of depolarizing spontaneous fluctuations of the membrane potential (DSFs). OA can be enhanced acutely in nociceptors by inflammatory mediators released by immune and glial cells, such as serotonin, which will be discussed in detail in later chapters. Cyclic AMP is a major mediator of intracellular signal transduction in response to a number of hormones, neurotransmitters, and inflammatory mediators, and cAMP and its effectors PKA and EPAC are known contributors to persistent OA after spinal cord injury (Bavencoffe et al., 2016; Berkey et al., 2020; Garza Carbajal et al., 2020). However, neuromodulators and cellular signaling pathways that increase DSF amplitude and thereby promote OA acutely in nociceptors are not known.

Chapter 2

Materials and Methods

Note: Text is partially reprinted from E. R. Lopez, A. Garza Carbajal, J. B. Tian, A. Bavencoffe, M. X. Zhu, C. W. Dessauer, and E. T. Walters. 2021. Serotonin enhances depolarizing spontaneous fluctuations, excitability, and ongoing activity in isolated rat DRG neurons via 5-HT₄ receptors and cAMP-dependent mechanisms. *Neuropharmacology* 184: 108408. Use of the text and figures are granted for use in a dissertation by an author without formal licensing from Elsevier Ltd.

2.1. Animals

All procedures were in accordance with the guidelines of the International Association for the Study of Pain and were approved by the Institutional Animal Care and Use Committee. Male Sprague-Dawley rats (200-300 g, 2 per cage) were maintained in the McGovern Medical School animal research facility under a 12:12 h reversed light/dark cycle, and experiments were performed during the dark phase. Rats had access to food and water ad libitum.

2.2. Dissociation and culture of DRG neurons

Rats were euthanized by intraperitoneal injection of pentobarbital/phenytoin (0.9 mL; Euthasol, Virbac AH, Inc) followed by transcardial perfusion of ice-cold phosphate-buffered saline (PBS, Sigma-Aldrich). DRG from spinal levels T8 to L6 (for pharmacological experiments) or L4 to L6 (for plantar incision experiments, keeping ipsilateral and contralateral DRG separate) were excised and digested with trypsin (0.3 mg/mL, Worthington) and collagenase D (1.4 mg/mL, Sigma-Aldrich) in Dulbecco's Modified Eagle Medium (DMEM; Sigma-Aldrich) for 40 min at 34°C. Digested DRG were washed twice with warm (37°C) DMEM followed by mechanical trituration in DMEM with fire-polished Pasteur pipettes. Dissociated cells were seeded on glass coverslips (for electrophysiological recordings or Ca²⁺ imaging) or a 96-well cell culture microplate (for high content microscopy) coated with poly-L-ornithine solution (0.01%). Cell cultures were incubated overnight (5% CO₂, 95% humidity, 37°C) in DMEM without serum, growth factors, or other supplements, and experiments were performed 18-28 h post-dissociation.

2.3. Whole-cell recordings from dissociated DRG neurons

Small- to medium-sized DRG neurons (soma diameter $\leq 30 \mu\text{m}$ and input capacitance $\leq 45 \text{ pF}$, to exclude most LTMRs and proprioceptors and patch predominantly nociceptors) that were not in visible contact with other neurons or debris were recorded in whole-cell configuration at room temperature using either a Zeiss Axiovert 200M with 40X magnification and a HEKA EPC10 amplifier or an Olympus IX-71 with 40X magnification and a MultiClamp 700B amplifier (Molecular Devices). Patch pipettes were pulled from borosilicate glass capillaries with a 1.5 mm outer diameter and 0.86 mm inner diameter (Sutter Instrument Co) using a Sutter P-97 Flaming/Brown Micropipette Puller followed by polishing. Patch pipettes were filled with an intracellular-like solution (ICS; in mM: 134 KCl, 1.6 MgCl_2 , 13.2 NaCl, 3 EGTA, 9 HEPES, 4 Mg-ATP, and 0.3 Na-GTP, adjusted to pH 7.2 with KOH and osmolarity 300 with sucrose) and had an electrode resistance of 2-10 $\text{M}\Omega$. The extracellular solution (ECS) contained (in mM): 140 NaCl, 3 KCl, 1.8 CaCl_2 , 2 MgCl_2 , 10 HEPES, and 10 glucose and was adjusted to pH 7.4 with NaOH and osmolarity 320 with sucrose. After forming a tight seal, the membrane was ruptured to establish whole-cell configuration under voltage clamp, and membrane resistance and input capacitance were measured. The liquid junction potential ($\sim -4.3 \text{ mV}$) was not corrected.

To measure OA at rest, neurons were recorded in current clamp with no current injection for a minimum of 1 min. Next, current was injected to maintain the membrane potential at approximately -60 mV while a series of 2-ms depolarizing current injections (200 ms sweep interval, +10 pA or +20 pA increments) were used to measure AP voltage threshold. This was followed by a series of 2-s depolarizing current injections

(4-s sweep intervals, increments of +5 pA, +10 pA, or +20 pA) to measure rheobase and to provide an additional measure of AP voltage threshold. Each of these procedures yields consistent estimates of AP voltage threshold (Odem et al., 2018); my primary measure was the AP threshold determined with 2-s pulses. To measure OA at -45 mV, current was injected to maintain a membrane potential of approximately -45 mV for at least 30 s. DSFs were quantified using our algorithm SFA.py coded in Python v3.5.2 (Python Software Foundation), as described previously (Odem et al., 2018), from the 30-s traces recorded at -45 mV. In addition to subthreshold DSFs identified by the program, suprathreshold DSFs were included, for which the amplitude was calculated as the difference between the start membrane potential of the event and the AP threshold. DSFs were not quantified from cells exhibiting firing frequencies above ~1.5 Hz.

For neurons treated with serotonin (5-HT, serotonin hydrochloride, Abcam and Sigma-Aldrich) or prucalopride (Sigma-Aldrich), recordings were made from cells that had been pre-exposed to the drug (at least 5 min), and the drug was continuously present during the recordings (up to 60 min). There was no apparent change in the effects on the properties measured over this period. To test the effects of 5-HT receptor antagonists, PKA inhibitors, EPAC inhibitors, or a hyperpolarization-activated cyclic-nucleotide-gated channel (HCN) inhibitor, coverslips were incubated at 37°C in ECS containing GR113808, ketanserin-tartrate salt, myristoylated PKI 14-22 amide (all from Sigma-Aldrich), RS127445, granisetron, SB269970, CE3F4, H-89, ZD7288 (all from Cayman Chemical), or ESI-05 (synthesized as described by Chen et al., 2013) for a minimum of 5 min before being transferred to the recording chamber containing the inhibitor plus 5-HT in ECS. With the exception of 8-Br-cAMP, all drugs were added to

the ECS. The chambers were not continuously perfused. 8-Br-cAMP (Sigma-Aldrich) was diluted in ICS for intracellular delivery via the patch pipette (resistance of 2-6 M Ω). For intracellular dialysis of 8-Br-cAMP, after obtaining whole-cell configuration, the cell was maintained at -60 mV under voltage clamp for at least 3 min before switching to current clamp and proceeding with data collection.

All data shown are from non-accommodating (NA) type neurons, excluding the rapidly accommodating (RA) type neurons (Odem et al., 2018). Thus, all electrophysiological data analyzed includes probable nociceptors (based on soma size) that are capable of repetitive firing. Additionally, our previous study using the same culture conditions and size selection criterion indicated 70% of NA neurons patched were sensitive to capsaicin and thus presumed TRPV1⁺ (Odem et al., 2018).

2.4. High content microscopy and subpopulation analysis

The following materials were used. Primary antibodies: chicken anti-PGP9.5 (1:4000, Novus Biologicals, # NB110-58872), rabbit monoclonal anti-phospho RII (S99) (1:1000, clone 151, Abcam, # ab32390), and mouse anti-CGRP (1:1000, Santacruz #SC-57053). Secondary antibodies (all 1:1000): goat anti-chicken-DyLight 755, goat anti-rabbit 568, donkey anti-mouse AF 647. Isolectin B4-FITC (1:1500, MilliporeSigma, #L2895) and DAPI.

Following pharmacological treatments at 37°C, cells were fixed with 4% paraformaldehyde for 10 min then washed with PBS. Cells were then blocked for one hour at room temperature with blocking solution containing 1% bovine serum albumin and 0.075% Triton X-100 in PBS followed by incubation with primary antibodies in

blocking solution at 4°C overnight. After washing, cells were incubated with secondary antibodies and DAPI in blocking solution or with isolectin B4 (IB4) in IB4 buffer (100 µM each MgCl₂, CaCl₂, and MnCl₂ in PBS) at room temperature in the dark for one hour followed by three final PBS washes.

Plates were imaged using a Cellomics CX5 microscope (Thermo Scientific) with a 10x objective following modified protocols described by Isensee et al. (2018, 2017, 2014). Cellomics software package (Thermo Scientific) was used to analyze 1104x1104 pixel images. Neurons were identified by PGP 9.5 staining intensity. When appropriate, bleed through between channels was compensated with raw fluorescence data from fluorescence controls using the slope determined by linear regression (Prism, GraphPad) as described by Roederer, 2002.

One- and two-dimensional density plots were generated using FlowJo (Becton Dickinson). Gating of subpopulations, based on neuronal soma area, CGRP expression, and IB4 binding as established previously by Garza Carbajal et al. (2020), was performed by setting thresholds at local minima of probability in 2D plots and corroborated by 3D cluster analysis. Individual cells used to perform the cluster analysis were normalized between the minimal (0.001%) and maximal (0.999%) fluorescence levels per channel. Cluster analysis (k-medians) was performed using Cluster 3.0 software (de Hoon et al., 2004). Three-dimensional (3D) plots were constructed using Plotly (Chart Studio). Data analysis and graph plots were performed using Prism.

2.5. Ca²⁺ imaging

Overnight cultured DRG neurons were loaded with 2 µM Fura-2AM (TEFLabs.com) in DMEM in the cell culture incubator for 1 hour. Neurons on coverslips

were placed in a diamond-shaped RC-40 low profile bath chamber on a QE-1 quick exchange platform (both from Warner Instruments) and were constantly perfused with the same ECS used for electrophysiological recording. Images were acquired on a live cell fluorescence system, including Nikon Eclipse TE2000-U microscope with 40X oil objective lens and a Sutter Instrument Lambda DG-4 ultra-high-speed wavelength switching system controlled by SlideBook software v5.0. Fura-2 fluorescence signals were excited alternately at 340 nm and 380 nm every 3 seconds and detected at 510 nm emission. Serotonin (300 nM or 10 μ M) or capsaicin (500 nM, Sigma-Aldrich) diluted in ECS or KCl (60 mM, made by substituting 57 mM NaCl from ECS with equimolar KCl) was applied to neurons through whole chamber perfusion by a peristaltic pump at a flow rate of approximately 2 ml/min. Serotonin was applied 90-120 secs following 2 min baseline recording. Capsaicin was applied following 5-HT stimulation to identify capsaicin-sensitive nociceptors. KCl was applied at the end of each recording to confirm responses from live neurons. Fura-2 fluorescence ratios (F340/F380) were analyzed using SlideBook to estimate intracellular Ca^{2+} concentration ($[\text{Ca}^{2+}]_i$) changes.

2.6. Surgical procedures

Rats were anesthetized with isoflurane for plantar incision as described previously by Brennan, et al. (Brennan et al., 1995). Anesthesia was induced by placing the rat in a chamber filled with 4% isoflurane in air followed by 2% isoflurane via a nose cone maintained during surgery. The left hind paw was sterilized with alternating iodine swabs and alcohol pads. Beginning 0.5-1 cm from the proximal edge of the heel, a ~2 cm longitudinal incision was made through the skin and fascia. The flexor digitorum

brevis muscle was then elevated and incised longitudinally, leaving intact the muscle origin and insertion. The skin was closed with two absorbable sutures.

2.7. Measurement of guarding behavior

Rats were placed individually on an elevated metal mesh (grid 6 x 6 mm) and enclosed by a clear plastic cage top (20.5 x 20.5 x 13.5 cm). Both hind paws were closely observed for a 1-min period every 4 min for 48 min or every 3 min for 36 min, depending on the number of rats in each group. For each 1-min observation period a score of 0, 1, or 2 was given for each paw according to its position during the majority of the period. As described previously (Xu and Brennan, 2010), a score of 0 was given if the incised area was touching and being blanched or distorted by the mesh. A score of 1 was given if the incised area was touching the mesh without being blanched or distorted. A score of 2 was given if the incised area was completely off of the mesh. A sum score was obtained for each hind paw by adding the 12 scores observed during the 48-min or 36-min testing period. The guarding score was obtained by subtracting the score of the uninjured paw from that of the injured paw.

2.8. Statistical analysis

All data sets were tested for normality with the Shapiro-Wilk and D'Agostino and Pearson tests. Normally distributed data were analyzed by parametric tests: t-test or 1- or 2-way ANOVA followed by Dunnett's or Tukey's multiple comparisons tests using Prism v8 (GraphPad Software, Inc). Non-normally distributed data were analyzed by non-parametric tests: Mann-Whitney or Kruskal-Wallis (GraphPad Software, Inc). If any data set within an analysis failed to pass either normality test, non-parametric statistics

were performed. Comparisons of incidences were made with Fisher's exact test. All tests were two-tailed, with one exception. The dose-response relationship for 5-HT and OA was tested with a one-tailed Fisher's exact test on the basis of prior observations indicating that the incidence of OA, which is low under our control conditions, would be increased but not decreased by 5-HT treatment. All t-tests were unpaired unless otherwise stated. Dose-response curves were fitted using Prism v8.

2.9. RNA sequencing

Seven days after deep tissue plantar incision surgery, the L4-6 DRG were collected from naïve and incised rats, keeping the left (ipsilateral) and right (contralateral) sides separate. All surgeries took place in the morning, and tissue collection was carried out in the afternoon on postoperative day 7. To ensure an adequate amount of tissue for RNA extraction, DRG were pooled from 2 rats for each sample. Thus, each sample contained 6 DRG – unilateral L4-6 from 2 rats. Each condition had 4 replicates, so each condition was represented by 8 rats. Total RNA was extracted and purified using the RNeasy Mini Kit (Qiagen).

RNA quantification and qualification, library preparation, sequencing, and bioinformatics analysis were performed by Novogene Co., Ltd in Sacramento, CA. Briefly, RNA degradation and contamination was monitored on 1% agarose gels. RNA purity was checked using the NanoPhotometer spectrophotometer (IMPLEN), and integrity and quantification were assessed using the RNA Nano 600 Assay Kit of the Bioanalyzer 2100 system (Agilent Technologies). A total of 1 µg RNA per sample was used as input materials for the RNA sample preparations. Sequencing libraries were generated using NEBNext Ultra RNA Library Prep Kit for Illumina (NEB). Library quality

was assessed on the Agilent Bioanalyzer 2100 system. Clustering of the index-coded samples was performed on a cBot Cluster Generation System using PE Cluster Kit cBot-HS (Illumina), then library preparations were sequenced on an Illumina platform and paired-end reads were generated. Raw reads (FASTQ format) were processed through fastp to obtain clean reads by removing reads containing adapter and poly-N sequences and reads with low quality. Downstream analyses were based on the clean data with high quality. Paired-end clean reads were mapped to the reference genome (*Rattus norvegicus*) using HISAT2 software. Featurecounts was used to count the read numbers mapped of each gene, including known and novel genes, and FPKM of each gene was calculated based on the length of the gene and reads count mapped to the gene. Differential expression analysis between two groups was performed using DESeq2 R package. The resulting p values were adjusted using the Benjamini and Hochberg's approach for controlling the False Discovery Rate.

Chapter 3

5-HT enhances DSFs, excitability, and OA in isolated rat DRG neurons

Note: Figures and text are partially reprinted from E. R. Lopez, A. Garza Carbajal, J. B. Tian, A. Bavencoffe, M. X. Zhu, C. W. Dessauer, and E. T. Walters. 2021. Serotonin enhances depolarizing spontaneous fluctuations, excitability, and ongoing activity in isolated rat DRG neurons via 5-HT₄ receptors and cAMP-dependent mechanisms. *Neuropharmacology* 184: 108408 and M. A. Odem, A. G. Bavencoffe, R. M. Cassidy, E. R. Lopez, J. Tian, C. W. Dessauer, and E. T. Walters. 2018. Isolated nociceptors reveal multiple specializations for generating irregular ongoing activity associated with ongoing pain. *Pain* 159 (11): 2347. Use of the text and figures are granted for use in a dissertation by an author without formal licensing from Wolters Kluwer Health, Inc. and Elsevier Ltd.

3.1. Introduction

As described in Chapter 1, pro-inflammatory mediators contribute to pain sensitization during injury and inflammation. One such mediator of interest is serotonin (5-hydroxytryptamine, 5-HT). Serotonin is well known for its important role as a neurotransmitter in the central nervous system in regulating mood and behavior. However, 5-HT mediates a wide variety of physiological functions both in the central nervous system and in the periphery, including gut motility, pain and inflammation, and other processes (Berger et al., 2009; Feldman, 2004; Sommer, 2004; Yadav, 2013). These two pools of 5-HT, one in the blood and periphery and one in the brain, function like two distinct molecules (Mann et al., 1992). Most of the 5-HT present in the periphery is synthesized in enterochromaffin cells of the gut (Gershon and Tack, 2007), where the rate-limiting step is the conversion of L-tryptophan to L-5OH-tryptophan by tryptophan hydroxylase (TPH). L-5OH-tryptophan is then converted to 5-HT by an aromatic L-amino acid decarboxylase (Mann et al., 1992; Walther et al., 2003). TPH1 carries out serotonin synthesis in the periphery, whereas TPH2 is responsible for serotonin synthesis in serotonergic neurons in the brain (Walther et al., 2003).

Serotonin was linked to pain and nociceptor hyperexcitability in a number of previous studies. Intradermal application of 5-HT produces hyperalgesia in mice and rats (Lin et al., 2011; Taiwo and Levine, 1992) and pain in humans (Schmelz et al., 2003). Serotonin application to dissociated DRG neurons can decrease the current needed to elicit an AP, increase the AP amplitude (Cardenas et al., 2001) and increase AP firing frequency during depolarizing current steps (Salzer et al., 2016). Several studies of 5-HT effects on nociceptor excitability have examined the effects of micromolar concentrations, often using relatively fast perfusion. Because exposure of

nociceptor somata to inflammatory mediators like serotonin may occur through prolonged exposure to low concentrations in the blood and/or cerebrospinal fluid (CSF), it is important to also examine the effects of relatively low concentrations over longer time periods.

3.2. Results

3.2.1. Dose-dependent relationship of the effects of 5-HT on hyperexcitability

To examine the dose-response relationship of 5-HT effects on DRG neurons under conditions of relatively prolonged exposure, I examined the effects of different concentrations (from 0.1 nM to 10 μ M) of 5-HT on functionally important excitability properties in probable nociceptors exposed to 5-HT for ~5-60 min. Consistent with earlier observations that low and high doses of 5-HT enhance a voltage-gated Na⁺ channel conductance (Cardenas et al., 1997; Gold et al., 1996), prolonged 5-HT treatment hyperpolarized the AP voltage threshold (Figure 3A; 1-way ANOVA, $F(6,76) = 2.28$, $p = 0.045$) at 10 nM and 100 nM compared to the vehicle control. Serotonin increased the incidence of medium- (3-5 mV) and large-amplitude (>5 mV) DSFs recorded while the membrane potential was held at approximately -45 mV under current clamp (Figure 3B; Kruskal-Wallis, $p = 0.0024$ and $p = 0.018$, respectively) at concentrations of 10 nM and 100 nM. The greatest increase in the incidence of OA at -45 mV occurred at 100 nM 5-HT (Figure 3C; 1-sided Fisher's exact test, $p = 0.005$). There were trends toward increased OA incidence with concentrations as low as 10 nM ($p = 0.065$) and as high as 10 μ M 5-HT ($p = 0.11$). Furthermore, there was an overall effect of 5-HT across all doses in reducing the rheobase during 2-s depolarizing test pulses, although individual doses showed no significant effects (Figure 3D; Kruskal-

Wallis, $p = 0.048$). None of the tested 5-HT concentrations produced significant effects on either RMP (Figure 3A; 1-way ANOVA, $F(6,76) = 1.61$, $p = 0.16$) or OA recorded at RMP (Figure 3C).




Figure 3. Dose-response effects of 5-HT on RMP, AP threshold, DSFs, and OA. DRG neurons were treated with 5-HT or vehicle before and during recording. Each concentration is represented by a minimum of 8 cells from at least 2 rats. P values listed under overall significance indicate the result of ANOVA, Kruskal-Wallis, or Fisher's exact tests assessing the presence of an overall effect across all doses. **(A)** 5-HT effects on RMP and AP threshold. Mean \pm SEM. * $p < 0.05$. **(B)** 5-HT effects on the frequency of medium-amplitude (3-5 mV) and large-amplitude (>5 mV) DSFs during 30-s depolarization to -45 mV. Mean \pm SEM. * $p < 0.05$, ** $p < 0.01$. **(C)** 5-HT effects on the incidence of OA measured during a ≥ 60 -s recording at RMP and then during a 30-s depolarization to -45 mV. P values indicate the result of Fisher's exact tests comparing no 5-HT to all 5-HT concentrations combined. * $p < 0.0083$ (after Bonferroni correction for 6 comparisons). **(D)** 5-HT effects on rheobase. Mean \pm SEM. Kruskal-Wallis test revealed a significant overall difference, but Dunn's test did not reveal differences at individual doses.

3.2.2. Exposure to 100 nM 5-HT potentiates OA in probable nociceptors, in part by enhancing DSFs

The effect of 100 nM 5-HT, the dose that yielded the strongest potentiation of OA (Figures 3C, 4A), on DSFs was examined in detail. During 30-s depolarization to -45 mV both the frequency of large (>5 mV amplitude) DSFs and frequency of APs were strongly increased by 5-HT (Figure 4B; Mann-Whitney tests, $p < 0.0001$). The mean amplitude of all DSFs (at least 1.5 mV amplitude) was increased in neurons treated with 5-HT (Mann-Whitney, $p < 0.0001$), and DSFs were largest in cells that had OA at -45 mV (Figure 4C; Mann-Whitney, $p < 0.0001$). Representative traces illustrating DSFs and OA in probable nociceptors held at -45 mV are shown in Figure 4D. As illustrated by raster plots (Figure 5A1,B1), DSFs occurred randomly in the control and 5-HT-treated conditions, and 5-HT increased the frequency of medium-amplitude DSFs (Mann-Whitney, $p < 0.001$), which rarely triggered APs (Figure 5A2), as well as the frequency of large-amplitude DSFs (Mann-Whitney, $p < 0.0001$), which frequently reach AP threshold (Figure 5B2; Fisher's exact test, $p < 0.05$).




Figure 4. Potentiation by 5-HT of OA in probable nociceptors. Dorsal root ganglion neurons from naive rats ($n = 4$) were treated with vehicle or 100-nM 5-HT for 10 to 30 minutes before and during each recording. After measurement of any SA, extrinsically driven OA was modeled by depolarization to -45 mV under current clamp for 30 to 60 seconds. (A) Pretreatment with 5-HT did not induce OA at RMP but significantly increased OA at -45 mV (the Fisher exact test). (B) In neurons tested at -45 mV, 5-HT significantly increased AP frequency during OA and large DSF frequency. Black lines-medians. (C) 5-HT increased the amplitude of DSFs measured at -45 mV, and the neurons with OA showed larger DSFs than silent neurons. Depolarizing spontaneous fluctuation sample sizes left to right: 1360, 2113, 1256, and 2217. Data are shown as mean \pm SEM. *** $p < 0.001$ **** $p < 0.0001$. (D) Representative recordings SFs and OA at -45 mV after treatment with vehicle or 5-HT. Insets: enlarged sections from each trace. AP, action potential; DSF, depolarizing spontaneous fluctuation; MP, membrane potential; OA, ongoing activity; RMP, resting membrane potential; SA, spontaneous activity. Data collected by Elia R. Lopez, DSF analysis and figure by Max A. Odem.




Figure 5. Treatment with 5-HT before and during recording at -45 mV increases the number of medium amplitude and large DSFs in probable nociceptors from naive rats. (A1, B1) Raster plots of medium amplitude and large DSFs during depolarization to -45 mV. Each row represents one neuron and each point a single DSF. (A2, B2) At -45 mV, 5-HT increased the number of medium amplitude and large DSFs, and the percentage of DSFs evoking APs. Bars represent the mean +/- SEM or fraction in total sample, and significance was tested using Mann-Whitney U or Fisher exact tests. * $p < 0.05$, *** $p < 0.001$, **** $p < 0.0001$. Neurons are from the naive rats ($n = 4$) used in Figure 6. AP, action potential; DSF, depolarizing spontaneous fluctuation. Data collected by Elia R. Lopez, DSF analysis and figure by Max A. Odem.

3.3. Conclusions

These results show that OA and two of its major electrophysiological mechanisms (increased DSF amplitude and decreased AP voltage threshold) in probable nociceptors are sensitive to relatively low concentrations of 5-HT. In addition, the results confirm

that, while these 5-HT concentrations enhance AP generation by at least two general electrophysiological alterations, this enhancement is only expressed when the membrane potential is maintained at a relatively depolarized level within the physiological range. Thus, prolonged (5-60 min) application of 100 nM 5-HT combined with an extrinsic source of depolarization (to -45 mV) for 30-60 sec provides a useful model for defining cell signaling mechanisms by which OA in nociceptors is enhanced acutely.

Chapter 4

5-HT potentiates OA in DRG neurons via 5-HT₄ receptors

Note: Figures and text are partially reprinted from E. R. Lopez, A. Garza Carbajal, J. B. Tian, A. Bavencoffe, M. X. Zhu, C. W. Dessauer, and E. T. Walters. 2021. Serotonin enhances depolarizing spontaneous fluctuations, excitability, and ongoing activity in isolated rat DRG neurons via 5-HT₄ receptors and cAMP-dependent mechanisms. *Neuropharmacology* 184: 108408. Use of the text and figures are granted for use in a dissertation by an author without formal licensing from Elsevier Ltd.

4.1. Introduction

While 5-HT-stimulated cell signaling that may lower AP threshold in nociceptors has been explored (Cardenas et al., 2001; Gold et al., 1996), cell signaling pathways that enhance DSFs and OA acutely have not been described. Multiple signaling pathways have been implicated in 5-HT effects on nociceptor excitability and pain, potentially linked to numerous 5-HT receptors expressed in the DRG, including those coupled to G_s , G_i , and G_q , as well as 5-HT-gated cation channels (Chen et al., 1998; Lin et al., 2011; Nicholson et al., 2003; Ohta et al., 2006). My objective was to define the predominant cell signaling mechanism by which 5-HT enhances DSFs and associated OA. Because 5-HT is known to strongly activate PKA in nociceptors (Isensee et al., 2017) and our previous studies linked PKA and EPAC activity to chronic pain-related OA (Bavencoffe et al., 2016; Berkey et al., 2020), I hypothesized that G_s -coupled 5-HT receptors (5-HTR) mediate the enhancement of DSFs, reduction of AP threshold, and consequent potentiation of OA by 5-HT.

4.2. Results

4.2.1. 5-HT₄ receptors are required for potentiation of DSFs and OA induced by 5-HT

To begin to elucidate the cell signaling pathways by which 5-HT modulates DSFs and AP threshold, and their effects on OA, I asked which 5-HT receptors are required. Selective antagonists of 5-HT receptors known to be expressed in the DRG were added to the 5-HT solution. The incidence of OA recorded at -45 mV in the presence of 100-300 nM 5-HT was blocked by the selective 5-HT₄ receptor antagonist GR113808 (Figure 6A, B; Fisher's exact test, $p = 0.0002$) but not by the other 5-HT receptor antagonists

tested. GR113808 reduced the frequencies of medium-amplitude (3-5 mV; Kruskal-Wallis, $p = 0.01$) and large-amplitude (>5 mV; Kruskal-Wallis, $p = 0.0007$) DSFs at -45 mV during exposure to 5-HT (Figure 6C). Additionally, treatment with GR113808 resulted in a more depolarized AP threshold in the presence of 5-HT compared to vehicle/5-HT (Figure 6D; Kruskal-Wallis, $p = 0.024$). Moreover, GR113808 prevented reduction of the rheobase by 5-HT (Figure 6E; Kruskal-Wallis, $p = 0.0099$). Selective antagonists of 5-HT_{2A/2C} (ketanserin), 5-HT_{2B} (RS127445) or 5-HT₃ (granisetron) had no effect on any of these measures (Figure 6A, C, D), and there was no significant effect on RMP by any of the agents tested (Figure 6F; Kruskal-Wallis, $p = 0.1963$).




Figure 6. 5-HT₄ receptor is required for potentiation of DSFs and OA by 5-HT.

Cells were pre-treated for 5-15 min with 1 μ M of the 5-HTR antagonist or vehicle control before cells were patched in the presence of the antagonist plus 100-300 nM 5-HT. **(A)** Representative recordings at -45 mV in different neurons exposed to vehicle/5-HT or GR113808/5-HT. Note the two APs (OA) and large DSFs in the left panel. MP = membrane potential. **(B)** 5-HTR antagonist effects on the incidence of OA during exposure to 5-HT. OA was measured at RMP for ≥ 60 s then during depolarization to -45 mV for 30 s. *** $p < 0.00025$ (after Bonferroni correction for 4 comparisons). **(C-E)** 5-HTR antagonist effects on the frequency of medium- (3-5 mV) and large-amplitude (> 5 mV) DSFs during 30-s depolarization to -45 mV **(C)**, AP threshold **(D)**, rheobase **(E)**, and RMP **(F)** in the presence of 5-HT. Mean \pm SEM. * $p < 0.05$. ** $p < 0.01$.

In high-content imaging studies using PKA-pR11 as a surrogate readout of PKA activation (Isensee et al., 2014), the selective 5-HT₄ antagonist GR113808 blocked PKA activation in response to 100 nM 5-HT in a dose-dependent manner (Figure 7; IC₅₀ = 5.55 nM; 2-way ANOVA, $F(16,63) = 3.18$, $p = 0.0005$), confirming a previous report (Isensee et al., 2017). Surprisingly, although there is evidence for expression of the G_s-coupled 5-HT₇ receptor in rodent and human DRG neurons (Chen et al., 1998; Lin et al., 2011; Morita et al., 2015; Ohta et al., 2006), and the selective 5-HT₇ agonist LP44 can evoke AP firing, albeit at a high concentration (Morita et al., 2015), I found that a selective antagonist of 5-HT₇ (SB269970) had no appreciable effect on PKA activation by 5-HT (Figure 7). As expected, 5-HT_{2A/2C} (ketanserin), 5-HT_{2B} (RS127445) and 5-HT₃ (granisetron) antagonists had no significant effect on PKA activation (Figure 7). These results suggest that, at these 5-HT concentrations, the G_s-coupled 5-HT₇ receptor does not play a role in PKA activation in primary DRG neurons, and the G_q-coupled receptors (5-HT₂) and 5-HT-gated cation channels (5-HT₃) do not alter PKA activation produced by activation of the 5-HT₄ receptor.




Figure 7. PKA activation measured by PKA-pR11 staining in rat DRG neurons. Different concentrations of antagonists were applied 30 min prior to 5-min co-application of the antagonist and 100 nM 5-HT. Each data point represents the mean \pm SEM of 3-5 separate experiments. **** $p < 0.0001$.

To further address whether G_q -coupled 5-HT₂ receptors might contribute to nociceptor responses to 5-HT under these potentially desensitizing electrophysiological testing conditions (relatively slow delivery and continuing exposure to 5-HT for at least several minutes), we measured Ca^{2+} responses to 5-HT in probable nociceptors using Fura-2. Example recordings from a neuron that failed to respond to 90-120 s superfusion with either 300 nM or 10 μ M 5-HT and another neuron that showed a weak response to the higher concentration are shown in Figure 8A. Only 5.6% (2/36) and 9.7% (3/31) of neurons responsive to capsaicin (i.e. probable nociceptors) showed detectable increases in $[Ca^{2+}]_i$ during superfusion with 300 nM or 10 μ M 5-HT, respectively (Figure 8B). Among the capsaicin-insensitive neurons, 0% (0/11) and 33.3% (2/6) showed an increase in $[Ca^{2+}]_i$ in response to 300 nM or 10 μ M 5-HT, respectively. These observations indicate that increasing 5-HT concentration relatively slowly (over tens of

seconds under our superfusion conditions) elicits Ca^{2+} responses in only a small subset of DRG neurons (4.3 and 13% of all neurons tested in 0.3 and 10 μM 5-HT, respectively). Taken together, these data indicate that DSFs and associated OA are enhanced in a sustained manner by relatively low concentrations of 5-HT that fail to evoke Ca^{2+} responses in most of the neurons sampled, and these effects are mediated primarily by the G_s -coupled 5-HT₄ receptor.




Figure 8. Ca^{2+} responses to 5-HT measured by Fura-2. (A) Representative traces of Fura-2 ratio changes used to indicate increases in $[\text{Ca}^{2+}]_i$ during superfusion of 300 nM or 10 μM 5-HT in single capsaicin-sensitive neurons. (B) Incidence of 5-HT-associated increases in $[\text{Ca}^{2+}]_i$ as measured with Fura-2. Cap-sens = capsaicin sensitive. Cap-insens = capsaicin-insensitive. Lo 5-HT = 300 nM 5-HT. Hi 5-HT = 10 μM 5-HT. Cap = 500 nM capsaicin. Hi KCl = 60 mM KCl. Data collected by Jin Bin Tian.

4.2.2. Selective 5-HT₄ activation can induce hyperexcitability in DRG neurons

Is selective activation of the 5-HT₄ receptor sufficient to enhance DSFs and promote OA in small DRG neurons? To answer this question, I used a selective 5-HT₄ agonist, prucalopride, and compared the dose dependence of its activation of PKA to the activation of PKA by 5-HT, along with the inhibition of these effects by an effective

dose of the 5-HT₄ receptor antagonist GR113808 (Figure 9). Activation of PKA by prucalopride and 5-HT exhibited a similar dose dependence, with an EC₅₀ of 4.53 (95% confidence interval (CI) = 1.78 – 11.45, R₂ = 0.89) for 5-HT and 10.23 nM (95% CI = 4.06 – 25.61, R₂ = 0.89) for prucalopride. A 2-way ANOVA revealed significant overall effects of dose (F(5,48) = 38.83, p < 0.0001) and drug (F(3,48) = 56.32, p < 0.0001). Importantly, GR113808 (1 μM) significantly reduced PKA activation by both 5-HT and prucalopride at all doses ≥ 10 nM and ≥ 100 nM, respectively (Figure 9).




Figure 9. Dose-dependent PKA activation by 5-HT and the 5-HT₄ agonist prucalopride. Vehicle (DMSO) or 1 μM GR113808 was co-applied with 5-HT or prucalopride for 5 min. Each data point represents the mean ± SEM of 3 separate experiments. Asterisks indicate significant difference of the agonist dose compared to no agonist. Hash marks indicate significant difference in the presence of antagonist compared to no antagonist. ** p < 0.01, ### p < 0.001, ****/##### p < 0.0001. Ppr, prucalopride; GR, GR113808.

Exposure to prucalopride (300 nM, ~5-60 minutes), like 5-HT, had no effect on RMP (Figure 10A; Mann-Whitney, $p = 0.79$) and did not induce OA at rest (Figure 10B). Prucalopride strongly increased the incidence of OA upon depolarization to -45 mV (Figure 10B, C; Fisher's exact test, $p = 0.0002$). The modest experimental depolarization also revealed increases in mean DSF amplitude (Figure 10C, D; Mann-Whitney, $p = 0.0006$) and increased frequencies of medium- and large-amplitude DSFs (Figure 10E; Mann-Whitney, $p = 0.0022$ and $p = 0.0014$, respectively), similar to that observed with comparable concentrations of 5-HT (Figure 3, Figure 5). Prucalopride significantly hyperpolarized AP voltage threshold (Figure 10F; Mann-Whitney, $p = 0.0036$) and markedly reduced rheobase (Figure 10G; Mann-Whitney, $p = 0.0024$).




Figure 10. Effects of prucalopride on hyperexcitability of probable nociceptors.

(A) Lack of effect of prucalopride on RMP measured during electrophysiological recordings from cells continuously exposed to 300 nM prucalopride before and during recording. Mean \pm SEM. (B) Effect of prucalopride on the incidence of OA determined from ≥ 60 -s recordings at RMP then 30-s recordings at ~ -45 mV. *** $p < 0.001$. (C) Representative traces of neurons treated with vehicle (DMSO) or prucalopride and depolarized to -45 mV. (D, E) Effects of prucalopride on the mean DSF amplitude and the frequency of medium- (3-5 mV) and large-amplitude (> 5 mV) DSFs during 30-s depolarization to -45 mV. Mean \pm SEM. ** $p < 0.01$ *** $p < 0.001$. (F) Effect of prucalopride on the AP voltage threshold. Mean \pm SEM. * $p < 0.05$. (G) Effect of prucalopride on the rheobase. Mean \pm SEM. ** $p < 0.01$.

DRG neurons comprise several distinct subpopulations, even when excluding large cells as done in our patch clamp experiments. Therefore, I used a high-content microscopy approach to examine 5-HT₄-induced PKA responses in DRG neuron subpopulations, as distinguished by the markers CGRP (for peptidergic nociceptors) and IB4-binding (for non-peptidergic nociceptors), as well as soma size (Garza Carbajal et al., 2020). The strongest PKA activation by prucalopride occurred in the nonpeptidergic nociceptors (IB4, 2.2-fold increase, paired t test, $p = 0.0042$), followed by an apparently weaker but still significant response in neurons positive for both IB4 binding and CGRP (IB-CG, 1.5-fold increase, paired t test, $p = 0.011$); no response was observed in the peptidergic nociceptors (CGRP), small- to medium-sized neurons negative for both markers (N), or large neurons (L, XL) (Figure 11).




Figure 11. Selective 5-HT₄ receptor activation of PKA in DRG neuron subpopulations. (A) Examples of cell staining for PKA-pRII. Scale bar = 25 μ m. (B) PKA-RII phosphorylation in controls, 300 nM 5-HT and 300 nM prucalopride, shown as coordinates of soma area (X-axis), CGRP staining intensity (Y-axis), and IB4 staining intensity (Z-axis). $n > 15,000$ neurons. (C) Prucalopride responses measured by PKA-pRII levels in specific neuronal subpopulations: N (negative for IB4 and CGRP and small somata), CGRP, IB-CG (weak staining for both IB4 and CGRP), L,XL (large and extra-large somata), and IB4. Each point represents the mean from one experiment normalized to the subpopulation baseline from the same experiment ($n = 4$ rats). * $p < 0.05$ ** $p < 0.01$. Figures in panels A and B made by Anibal Garza Carbajal.

4.3. Conclusions

These results indicate that activation of 5-HT₄ receptors is both necessary and sufficient to activate PKA and to promote larger DSFs, reduce AP threshold, and

increase the incidence of OA under depolarized conditions in response to 5-HT, and that this modulation is specific to IB4⁺ and IB4⁺/CGRP⁺ nociceptors.

Numerous 5-HT receptors are expressed in primary somatosensory neurons and several have been implicated in peripheral sensitization (Lloyd et al., 2013). For example, the 5-HT_{2A} antagonist ketanserin can attenuate 5-HT-induced thermal hyperalgesia (Tokunaga et al., 1998), and a 5-HT_{2B/C} antagonist can inhibit 5-HT-induced mechanical allodynia but not 5-HT-induced thermal hyperalgesia in rodents (Lin et al., 2011). It is known from overexpression studies in HEK293T cells that 5-HT can produce robust Ca²⁺ transients via 5-HT₂ receptors (Lin et al., 2011). Fast superfusion of 10 μM 5-HT produced rapidly activating and inactivating [Ca²⁺]_i responses in 67% of capsaicin-sensitive neurons tested in rats (Linhart et al., 2003), in contrast to the lack of effect we found with the 5-HT₂ antagonist on effects of 5-60 min bath application of 100-300 nM 5-HT. Similarly, only 3.4% of mouse DRG neurons responded to 1 μM 5-HT with an increase in [Ca²⁺]_i (Lin et al., 2011). However, significant [Ca²⁺]_i responses to 5-HT were reported in capsaicin-sensitive rat trigeminal ganglion neurons, which were attenuated by antagonists of 5-HT_{2A} receptors and 5-HT₃ receptors (Lloyd et al., 2011). Ionotropic 5-HT₃ receptors typically activate and desensitize rapidly. In rat DRG neurons, a 5-HT₂ antagonist abolished increased AP discharge during depolarizing steps produced by rapid perfusion of 10 μM 5-HT (Salzer et al., 2016).

Different results among these and other studies might be explained by procedural, species, and sex differences, but it seems likely that a major factor contributing to the lack of action potentials or calcium responses evoked by 5-HT at RMP in our experiments arose from our attempt to mimic sustained exposure to 5-HT

likely to occur during *in vivo* inflammation. Slow, prolonged administration of 5-HT is likely to substantially desensitize many 5-HT receptors in nociceptors. In addition, 5-HT₂ and 5-HT₄ receptors may function in partially separate nociceptor subpopulations, as 5-HT_{2A} receptors are mainly expressed in CGRP-synthesizing (peptidergic) small DRG neurons (Okamoto et al., 2002), while we found 5-HT₄-induced PKA-RII phosphorylation (used here as an indirect measurement of cAMP generation) to be largely restricted to IB4⁺ (nonpeptidergic) and IB4⁺/CGRP⁺ nociceptors. In mice, 5-HT₄ receptor expression was also shown by single-cell RNA-seq profiling to be restricted to nonpeptidergic DRG neurons (Linnarsson Lab, Mousebrain.org; Usoskin et al., 2015).

In addition to the 5-HT₄ family of G_s-coupled receptors, there is evidence for DRG neuron expression of G_s-coupled 5-HT₇ and 5-HT₆ receptors. 5-HT₇ activity can potentiate T-type Ca²⁺ current via PKA-dependent mechanisms in *Xenopus* oocytes co-expressing 5-HT₇ and Cav_{3.2} (Kim et al., 2006), and a 5-HT₇ agonist mimics potentiating effects of 5-HT on increases of [Ca²⁺]_i evoked by capsaicin in DRG neurons (Ohta et al., 2006). Functionally, 5-HT₇ is linked to acute and chronic itch but not pain behaviors in mice (Morita et al., 2015). We were unable to block 5-HT activation of PKA in DRG neurons with a selective 5-HT₇ antagonist (SB269970), suggesting 5-HT₇ activity in these neurons is not a major contributor to cAMP signaling evoked by low concentrations of 5-HT.

The evidence for expression of 5-HT₆ receptors in rat lumbar DRG is mixed. For example, 5-HT₆ receptor mRNA was reported to be increased after plantar injection of bee venom (Liu et al., 2005) and was detected above the noise level in my RNA sequencing study of rat DRG (see Chapter 6), but 5-HT₆ receptor mRNA was not

detected in rat DRG neurons by in situ hybridization (Nicholson et al., 2003) or in cultured DRG neurons by RT-PCR (Chen et al., 1998). Because of the close similarity of the effects of the 5-HT₄ receptor agonist prucalopride to those produced by 5-HT, and the complete blockade of 5-HT-induced OA, DSF enhancement, and PKA activation by the 5-HT₄ receptor antagonist GR113808, I conclude that other G_s-coupled 5-HT receptors are less important under conditions used in my experiments, although potential contributions of 5-HT₆ receptors have not been tested directly.

Besides G_s- and G_q-coupled receptors, DRG neurons express G_i-coupled 5-HT_{1/5} receptors. Any 5-HT_{1/5}-mediated effects on OA remain to be elucidated and they may be complex because G_i-coupled receptors usually decrease cAMP signaling, and they have been linked to inhibitory effects of 5-HT on nociceptors (Cardenas et al., 1997).

Chapter 5

5-HT potentiates OA in DRG neurons via cAMP-dependent mechanisms

Note: Figures and text are partially reprinted from E. R. Lopez, A. Garza Carbajal, J. B. Tian, A. Bavencoffe, M. X. Zhu, C. W. Dessauer, and E. T. Walters. 2021. Serotonin enhances depolarizing spontaneous fluctuations, excitability, and ongoing activity in isolated rat DRG neurons via 5-HT₄ receptors and cAMP-dependent mechanisms. *Neuropharmacology* 184: 108408. Use of the text and figures are granted for use in a dissertation by an author without formal licensing from Elsevier Ltd.

5.1. Introduction

Downstream of 5-HT₄ activation, cAMP production is increased, leading to activation of its effectors, among which PKA is best known (Isensee et al., 2017). The results I presented in Chapter 4 confirmed the activation of PKA by relatively low concentrations of 5-HT (Figure 9). PKA activity has previously been implicated in 5-HT effects on voltage-dependent Na⁺ current that should reduce AP voltage threshold and rheobase (Cardenas et al., 2001; Gold et al., 1996). Besides 5-HT, other injury- and inflammation-related signals, such as prostaglandins, also bind G_s-coupled receptors, leading to increased cAMP production and pain sensitization (Cui and Nicol, 1995; Ferreira et al., 1978; Hingtgen et al., 1995). In this study, a pharmacological approach was taken to examine the individual roles of the three major cAMP effectors - PKA, EPAC, and HCN - in 5-HT effects on nociceptor hyperexcitability and to examine the effects of general activation of cAMP signaling using a cAMP analog.

5.2. Results

5.2.1. PKA activity is required for potentiation of DSFs and OA by 5-HT

To test the necessity of PKA activity for 5-HT's effects on OA, DSFs, AP voltage threshold, and rheobase, I utilized two different types of PKA inhibitor: H-89, a small-molecule competitive inhibitor, and myr-PKI 14-22, a peptide that mimics endogenous PKA inhibitors. Both H-89 and PKI blocked 5-HT potentiation of OA at -45 mV (Figure 12A; Fisher's exact tests, $p = 0.01$ and $p = 0.0051$, respectively). Similarly, H-89 and PKI both attenuated the frequency of medium-amplitude DSFs (3-5 mV; Kruskal-Wallis, $p = 0.0008$) and large-amplitude DSFs (>5 mV; Kruskal-Wallis, $p = 0.0018$) at -45 mV (Figure 12B). PKI effectively blocked hyperpolarization of the AP voltage threshold by

5-HT (Figure 12C; Kruskal-Wallis, $p = 0.0036$). However, inhibition of PKA activity was not sufficient to significantly block the reduction of rheobase by 5-HT (Figure 12D; Kruskal-Wallis, $p = 0.11$). As anticipated, none of these treatments affected RMP (Figure 12C) or incidence of OA at RMP (Figure 12A). These results demonstrate that PKA plays a critical role in enhancement of DSFs, reduction of AP threshold, and associated potentiation of OA by 5-HT, but plays a lesser role in decreasing rheobase.




Figure 12. PKA activity is required for potentiation of DSFs and OA by 5-HT. Rat DRG neurons were treated with 10 μ M H-89, 1 μ M myr-PKI 14-22, or vehicle before and during exposure to 100-300 nM 5-HT. **(A)** Effects of H-89 and PKI on the incidence of OA during 5-HT exposure. The occurrence of OA was determined from ≥ 60 -s recordings at RMP then 30-s recordings at ~ -45 mV. * $p < 0.025$ (after Bonferroni correction for 2 comparisons). **(B-D)** Effects of H-89 and PKI on the frequency of medium- (3-5 mV) and large-amplitude (>5 mV) DSFs during 30-s depolarization to -45 mV **(B)**, AP voltage threshold **(C)**, and rheobase **(D)** in the presence of 5-HT. Mean \pm SEM. ** $p < 0.01$.

5.2.2. EPAC activity contributes to induction of hyperexcitability by 5-HT

While PKA is the cAMP effector best known for enhancing nociceptor activity and pain, important roles are also played by EPAC (Berkey et al., 2020; Fu et al., 2019; Huang and Gu, 2017; Pan et al., 2019; Singhmar et al., 2018). The relationship between 5-HT signaling and EPAC activity has begun to be elucidated in the brain and spinal cord (Cochet et al., 2013; Fields et al., 2015; Lin et al., 2003), but whether EPAC activity is involved in 5-HT effects on DRG neurons is unknown. To test this possibility, I employed an EPAC1 inhibitor, CE3F4, and EPAC2 inhibitor, ESI05, alone and in combination. Significant attenuation of OA generated at -45 mV in the presence of 5-HT was only observed with combined CE3F4/ESI05 treatment (Figure 13A; Fisher's exact test, $p = 0.002$), although there was a trend toward reduced OA incidence with ESI05 alone ($p = 0.032$, not significant after Bonferroni correction for multiple comparisons). Similarly, the frequency of large-amplitude (>5 mV) DSFs at -45 mV in the presence of 5-HT was significantly attenuated by the combination of CE3F4 and ESI05 (Figure 13B, right panel; Kruskal-Wallis, $p = 0.017$). No significant attenuation of medium-amplitude DSFs (Figure 13B, left; Kruskal-Wallis, $p = 0.24$) or AP threshold (Figure 13C) was observed, but possible trends toward more depolarized AP thresholds in the presence of 5-HT were observed with CE3F4 or ESI05 alone or in combination (1-way ANOVA, $F(3,87) = 2.23$, $p = 0.091$). Weak individual effects of EPAC1 and EPAC2 on AP threshold and DSFs might combine to produce significant effects on OA. No effect of EPAC inhibitors was found on 5-HT-induced reduction of rheobase (Figure 13D; Kruskal-Wallis, $p = 0.92$), and none of these treatments impacted RMP (Figure 13E; Kruskal-Wallis, $p = 0.89$). Taken together, these findings suggest that EPAC activity contributes

to the increases in DSF amplitude and incidence of OA caused by 5-HT under depolarized conditions.




Figure 13. EPAC activity contributes to hyperexcitability induced by 5-HT. Cells were treated with CE3F4 (10 μ M) or ESI-05 (5 μ M) alone or in combination or vehicle control before and during exposure to 100-300 nM 5-HT. **(A)** Effects of EPAC inhibitors on the incidence of OA was measured during ≥ 60 -sec recordings at RMP then during 30-sec depolarization to -45 mV in the presence of 5-HT. ** $p < 0.0033$ (Bonferroni correction for 3 comparisons). **(B)** Effects of EPAC inhibitors on the frequency of medium- (3-5 mV) and large-amplitude (>5 mV) DSFs during 30-sec depolarization to -45 mV in the presence of 5-HT. Mean \pm SEM. * $p < 0.05$. **(C)** Effects of EPAC inhibitors on the AP voltage threshold during exposure to 5-HT. Mean \pm SEM. **(D, E)** Effects of EPAC inhibitors on rheobase **(D)** and RMP **(E)** during exposure to 5-HT.

5.2.3. Nociceptor hyperexcitability induced by 5-HT does not require HCN activity

The other major cAMP effector known to impact neuronal activity is the HCN channel. HCN channels may contribute modestly to RMP in nociceptors (Du et al., 2014), and they are known to be important for some forms of pain (Emery et al., 2011; Weng et al., 2012). To examine whether HCN plays a role in enhancement of DSFs caused by 5-HT, I tested the effects of blocking this channel with a widely used HCN inhibitor, ZD7288 (e.g., Du et al., 2014), before and during exposure to 5-HT. ZD7288 had no significant effect on the incidence of OA at -45 mV (Figure 14A; Fisher's exact test, $p = 0.26$), frequency of medium- and large-amplitude DSFs at -45 mV (Figure 14B; Mann-Whitney, $p = 0.28$ and $p = 0.32$, respectively), firing frequency at -45 mV (Figure 14C; Mann-Whitney, $p = 0.13$), AP threshold (Figure 14D; t test, $p = 0.64$), or rheobase (Figure 14E; t test, $p = 0.39$), during exposure to 5-HT. These results suggest that HCN activity is not a major contributor to the effects of 5-HT on OA, DSFs, AP threshold, or rheobase in DRG neurons. Unexpectedly, the RMP was more depolarized in the presence of ZD7288 and 5-HT compared to 5-HT alone (mean = -60.9 mV and -67.8 mV, respectively; Mann-Whitney test, $p = 0.0012$; data not shown). This was surprising because ion current through HCN channels in this range of membrane potentials would be expected to be depolarizing, leading to the expectation that blocking the channels would hyperpolarize RMP. Although the significance of this unexpected depolarization of RMP is unknown, it adds to my evidence that 5-HT's effects on HCN signaling do not contribute to the nociceptor hyperexcitability I have investigated.




Figure 14. Nociceptor hyperexcitability induced by 5-HT does not require HCN activity. Rat DRG neurons were treated 100 μ M ZD7288 before and during exposure to 100 nM 5-HT. (A) Effect of ZD7288 on the incidence of OA during exposure to 5-HT. The occurrence of OA was measured during \geq 60-sec recordings at RMP then during 30-sec depolarization to -45 mV. (B-E) Effects of ZD7288 on the frequency of medium- (3-5 mV) and large-amplitude (>5 mV) DSFs during 30-sec depolarization to -45 mV (B), frequency of AP firing during 30-sec recordings at -45 mV (C), AP voltage threshold (D), and rheobase (E) in the presence of 5-HT. Mean \pm SEM.

5.2.4. Activation of cAMP signaling is sufficient to induce hyperexcitability in probable nociceptors

While we know that cAMP signaling is important for maintaining chronic nociceptor hyperactivity in vitro after spinal cord injury (Bavencoffe 2016; Berkey 2020),

and that 5-HT and PGE₂ stimulate cAMP signaling in nociceptors, it is not known whether an acute increase in cAMP, which can occur downstream of a number of receptors for various algogenic ligands, is sufficient to promote larger DSFs and OA. To answer this question, I applied the cAMP analog 8-Br-cAMP intracellularly via the patch pipette. Similar to extracellular application of 5-HT, intracellular dialysis of 8-Br-cAMP did not induce OA at rest, but it increased the incidence of OA when the neuron was experimentally depolarized to a holding potential of ~ -45 mV (Figure 15A; Fisher's exact test, $p = 0.028$) and reduced the rheobase (Figure 15D; t test, $p = 0.013$). Also similar to 5-HT, 8-Br-cAMP increased the frequency of medium- (3-5 mV) and large-amplitude (>5 mV) DSFs at -45 mV (Figure 15B; Mann-Whitney, $p = 0.0001$ and $p = 0.0024$, respectively) and hyperpolarized the AP voltage threshold (Figure 15C; Mann-Whitney, $p = 0.016$). Unlike 5-HT or the selective 5-HT₄ agonist prucalopride, 8-Br-cAMP significantly depolarized the RMP (Figure 15E; t test, $p = 0.0085$), indicating that activation of the cAMP signaling pathway can affect RMP (see also Momin and McNaughton, 2009), albeit not when cAMP signaling is stimulated by the 5-HT₄ receptor.




Figure 15. Activation of cAMP signaling by the cAMP analog 8-Br-cAMP is sufficient to potentiate DSFs and OA in isolated DRG neurons. Patch pipettes contained 100 μ M 8-Br-cAMP or vehicle in the ICS. (A) Effect of 8-Br-cAMP on the incidence of OA. The occurrence of OA was measured during ≥ 60 -sec recording at RMP then during 30-sec depolarization to -45 mV. * $p < 0.05$. (B-E) Effect of 8-Br-cAMP on the frequency of medium- (3-5 mV) and large-amplitude (>5 mV) DSFs during 30-sec depolarization to -45 mV (B), AP threshold (C), rheobase (D), and RMP (E). Mean \pm SEM. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

5.3. Conclusions

The inhibitors of effectors downstream of cAMP that produced the largest attenuation of 5-HT-induced hyperexcitability were inhibitors of PKA, which blocked enhancement of OA, DSFs, and excitability by 5-HT. PKA activity was previously linked to potentiation by 5-HT of transient receptor potential V1 (TRPV1) function (Ohta et al., 2006) and tetrodotoxin-resistant (TTX-R) Na⁺ current (Scroggs, 2011) in isolated DRG neurons, as well as to 5-HT-induced hyperalgesia in vivo (Aley and Levine, 1999). Whether enhanced TRPV1 or TTX-R Na⁺ currents are involved in 5-HT-induced OA, and the extent to which the mechanisms described in this study contribute to hyperalgesia in vivo, are not yet known. It is important to note that, while my measure of cAMP production in response to 5-HT and its analogs was type II PKA activity, this does not rule out the interesting possibility of significant contributions of type I PKAs to at least some of the 5-HT effects I observed.

While a number of studies demonstrated a role for EPAC in neuropathic and inflammatory pain (Berkey et al., 2020; Huang and Gu, 2017; Z.-H. Li et al., 2019; Singhmar et al., 2018), the link between 5-HT signaling and EPAC activity in nociceptors had not been explored. I found that EPAC1 and 2 activity (primarily in combination) contributed significantly to the hyperexcitable state induced by 5-HT. The need to block both EPAC isoforms to significantly attenuate the effects of 5-HT in rat DRG neurons is in contrast to the observation that inhibition of either EPAC1 or EPAC2 was sufficient to reverse spinal cord injury-induced nociceptor hyperactivity (Berkey et al., 2020), suggesting differences in the role of EPAC in persistent spinal cord injury-induced OA and acute 5-HT potentiation of OA.

Lastly, I found statistically insignificant trends for reduced excitability when inhibiting HCN channels during 5-HT treatment, suggesting that (at most) HCN channels are a minor contributor to the 5-HT-induced effects I measured. This is consistent with the enhancement of DSFs and OA occurring primarily at relatively depolarized membrane potentials where few HCN channels should be active. Inhibiting any one of the cAMP effectors tested (PKA, EPAC1/2, and HCN) failed to prevent 5-HT's reduction of rheobase (measured from a holding potential of -60 mV), suggesting that additive effects of these components of cAMP signaling, and perhaps other cell signaling pathways, drive this manifestation of 5-HT-induced hyperexcitability.

The promotion of OA by the cAMP analog 8-Br-cAMP showed that activation of cAMP signaling is sufficient to reduce AP threshold and enhance DSFs to increase nociceptor excitability. This suggests that other mediators, such as PGE₂, that activate G_s-coupled receptors on DRG neurons may enhance OA by similar mechanisms. While 8-Br-cAMP depolarized RMP (to ~-57 mV), further depolarization (experimentally, to ~-45 mV) was required to reveal effects on OA, as was also observed with 5-HT. Direct activation of adenylyl cyclase with forskolin produces effects similar to those of 8-Br-cAMP delivery (A. Bavencoffe, E.T. Walters, and C.W. Dessauer, unpublished observations). The lack of a significant increase in OA at RMP induced by 8-Br-cAMP despite the cAMP analog depolarizing RMP, reducing AP threshold, and enhancing DSFs can be explained by its insufficient alteration of some or all of the electrophysiological components that drive OA. Specifically, the hyperpolarization of AP threshold and increased incidence of large DSFs induced by 8-Br-cAMP were modest compared to what was observed with 5-HT, and the depolarization of RMP by 8-Br-cAMP to ~-57 mV is not close to the -45 mV holding potential used to enable OA during

5-HT treatment. The weaker effects of a relatively high concentration of 8-Br-cAMP compared to those of low doses of 5-HT are consistent with findings that OA generation in nociceptors involves interaction of cAMP signaling with at least one other signaling pathway. Interestingly, depolarization to -45 mV, where we see the marked effects on OA and DSFs with cAMP activation, also activates the extracellular signal-regulated kinase (ERK) pathway in IB4⁺ nociceptors (Garza Carbajal et al., 2020).

Chapter 6

**Effects in the DRG of deep tissue incision in a rat
model of post-surgical pain**

6.1. Introduction

The studies described thus far have provided detailed insight into cell signaling mechanisms that promote OA, in part by enhancing the underlying DSFs. To gain further insight into the contribution of DSFs and OA to different types of pain and the relevance of the mechanisms uncovered in previous chapters, it is important to examine pain and OA in a model that mimics a pain condition seen in humans. One such model is the deep tissue plantar incision rat model of postsurgical pain (Brennan et al., 1995). With 80% of surgical patients experiencing postoperative pain and 86% of these patients reporting the pain as moderate, severe, or extreme, it is clear that postsurgical pain is an important clinical problem for which new treatment options are needed (Apfelbaum et al., 2003; Gan et al., 2014; Gupta et al., 2010). It is estimated that 10-50% of surgical patients develop persistent pain that lasts for months, and 2-10% of patients describe this persistent postoperative pain as severe (Kehlet et al., 2006). There is evidence that more severe acute postsurgical pain increases the likelihood of developing chronic pain (Callesen et al., 1999; Katz et al., 1996; Perkins and Kehlet, 2000; Tasmuth et al., 1996). Thus, managing postsurgical pain early has the potential to prevent persistent postoperative pain.

In the common rat model of incisional pain (Brennan et al., 1995), a deep tissue incision (through skin, fascia, and muscle) on the plantar aspect of the hind paw induces pain and nociceptor ongoing activity (Xu and Brennan, 2010). Guarding behavior, a measure of non-evoked pain, and heat hyperalgesia were demonstrated to last up to five days post-incision in the incised paw (Xu and Brennan, 2010). Peripheral *in vivo* electrophysiological recordings showed ongoing activity in nociceptors one day post-

incision that correlated with guarding pain behavior and was resolved by seven days post-incision (Xu and Brennan, 2010).

Changes in pro-inflammatory cytokines, growth factors, cell signaling, or ion channel activation have been identified that contribute to pain after plantar incision. For example, p38 MAPK phosphorylation increases in the DRG following deep tissue incision and contributes to peripheral nerve sensitization (Mizukoshi et al., 2013), and this was linked to macrophage accumulation and increased TNF- α in the incised plantar tissue (Yamakita et al., 2017). TNF- α is also increased in the DRG and spinal cord post-incision (Chang et al., 2018), and phosphorylation of CREB, a transcription factor phosphorylated by PKA, is enhanced in the lumbar spinal cord following plantar incision (Cui et al., 2010). Upregulation of TRPV1 activity in nociceptor somata was linked to heat hypersensitivity after skin incision (Barabas and Stucky, 2013). A recent study examining the effects of sleep deprivation on post-surgical pain found no significant effect of incision alone on RMP or current threshold in large DRG neurons (which include relatively few nociceptors) 8-9 days post-incision (Q. Li et al., 2019). Electrophysiological changes that occur in nociceptor somata after deep tissue incision have not yet been defined.

While it is known that deep tissue plantar incision leads to OA in nociceptor peripheral fibers in vivo and changes in cell signaling pathways (e.g. p38 MAPK and ERK), inflammation (e.g. increased IL-1 β , TNF- α , and IL-6) and ion channel regulation (e.g. TRPV1 activity) in the DRG, whether OA occurs in isolated nociceptor somata and what specific electrophysiological alterations contribute to OA after deep tissue plantar incision have not been explored.

6.2. Results

6.2.1. OA persists in isolated nociceptors after deep tissue incision

To determine whether OA persists in isolated nociceptors after deep tissue incision, how long it persists, and what neurophysiological alterations contribute, I used whole-cell patch clamp recording of dissociated DRG neurons. Neurons were dissociated from the L4-L6 DRG as these contain the somata of sensory neurons that innervate the incised area of the hind paw. Neurons were dissociated on postoperative days (POD) 1, 7, and 14, and ipsilateral and contralateral sides were kept separate. Based on the correlation between OA in isolated DRG neurons and OA and/or behavioral alterations *in vivo* in other pain models, as well as the brief time course of electrophysiological and behavioral alterations previously described for the incision model (lasting less than 1 week), I expected to observe OA in DRG neurons isolated from the side ipsilateral to the incision on POD1 but not on POD7. Surprisingly, the largest increase in OA at rest (often referred to as spontaneous activity) occurred in the probable nociceptors isolated from the ipsilateral side on POD7 (Figure 16A, C; Fisher's exact test, $p = 0.0012$). Ongoing activity during artificial depolarization to -45 mV was significantly increased in ipsilateral neurons isolated on POD1 and POD7 compared to those isolated from naïve, uninjured rats (Figure 16C; Fisher's exact test, $p = 0.0031$ and $p = 0.0003$, respectively).




Figure 16. Hyperactivity persists in isolated DRG neurons after deep tissue incision. (A) Representative traces of naive and post-incision (isolated on postoperative day 7) neurons at rest. (B) Effect of incision on the rheobase. Mean \pm SEM. ** $p < 0.01$. (C) Effect of incision on the incidence of OA determined from ≥ 60 -s recordings at RMP then 30-s recordings at ~ -45 mV. * $p < 0.0083$ ** $p < 0.0017$ (Bonferroni corrections for 6 comparisons). (D) Effect of incision on RMP measured during ≥ 60 -s recordings. Mean \pm SEM. * $p < 0.05$. (E) Effect of incision on the AP voltage threshold. Mean \pm SEM. * $p < 0.05$. (F) Effects of incision on the frequency of medium- (3-5 mV) and large-amplitude (> 5 mV) DSFs during 30-s depolarization to -45 mV. Mean \pm SEM. * $p < 0.05$ *** $p < 0.001$. DSF data processed by Michael Zhu.

Deep tissue incision was associated with depolarization of the RMP (a hyperexcitable effect) in probable nociceptors isolated from the ipsilateral side on POD1, 7, and 14 (Figure 16D; Kruskal-Wallis, $p = 0.0443$, $p = 0.0234$, and $p = 0.0207$, respectively). The AP threshold was significantly hyperpolarized in ipsilateral neurons isolated on POD1 and 7 (Figure 16E; one-way ANOVA, $p = 0.0453$ and $p = 0.0106$, respectively). The frequency of medium-amplitude (3-5 mV) DSFs measured during depolarization to -45 mV was markedly increased in ipsilateral DRG neurons isolated on POD7 (Figure 16F; Kruskal-Wallis, $p = 0.0003$). Interestingly, DRG neurons isolated from the contralateral side at this timepoint also exhibited a significantly increased frequency of medium-amplitude DSFs (Figure 16F; Kruskal-Wallis, $p = 0.0142$). There was no statistically significant effect on large-amplitude (> 5 mV) DSFs (Figure 16F; Kruskal-Wallis, $p = 0.1234$). Additionally, the rheobase was significantly reduced in ipsilateral DRG neurons isolated on POD7 (Figure 16B; Kruskal-Wallis, $p = 0.0026$).

To determine whether this unexpected persistence of nociceptor hyperactivity was associated with more prolonged pain behavior than what has been shown

previously, I examined guarding behavior at 1, 7, and 14 days post-incision. A previous study (Xu and Brennan, 2010) correlated guarding behavior, a measure of non-evoked pain with *in vivo* spontaneous activity (equivalent to OA) in C-fiber nociceptors. They observed increased guarding behavior on POD1 but not on POD6 in rats with deep tissue incision, and guarding had resolved by POD1 in rats with incision through the skin only. Similarly, I found guarding behavior to be significantly increased on POD1 (Figure 17; Kruskal-Wallis, $p = 0.0035$) but absent on POD7. The apparent increase in guarding behavior in sham incised rats on POD1 was not statistically significant (Figure 17; Kruskal-Wallis, $p = 0.1851$). This suggests that our deep tissue incision condition is comparable in the time course of non-evoked pain resolution to published studies.




Figure 17. Guarding pain behavior is resolved by POD7. Guarding behavior measured during 12 one-minute observation periods every 3 or 4 minutes. Mean \pm SEM. 2-way ANOVA, $F(11,49) = 13.56$, $p < 0.0001$, followed by separate Kruskal-Wallis tests for each time point, ** $p < 0.01$. POD, postoperative day; Deep, incision through skin, fascia, and muscle (deep tissue incision); Sham, incision through skin and possibly fascia but not muscle; Naïve, no incision.

6.2.2. Global transcriptome analysis of rat DRG to identify genes involved in persistent nociceptor hyperexcitability after deep tissue incision

The unexpected findings of hyperexcitability persisting in isolated nociceptors for at least 7 to 14 days post-incision (Figure 16D) and of hyperexcitable effects in DRG neurons contralateral to the incision (Figure 16F) raise many questions, including whether alterations in gene expression might underlie this persistent hyperexcitability. To address the question of whether gene expression changes accompany hyperactivity of DRG neurons at 7 days post-incision, the timepoint where the greatest effect on OA at RMP was observed (Figure 16C), I turned to the unbiased approach of RNA sequencing. To detect potential changes in gene expression bilaterally, RNA was extracted separately from ipsilateral L4-6 DRG and contralateral L4-6 DRG and similarly from left (corresponding to the ipsilateral side of incised rats) and right (corresponding to the contralateral side) L4-6 DRG from naïve rats. Therefore, ipsilateral and contralateral sides each had their own control in case lateralized differences occur normally. All samples had similar levels of gene expression (Figure 18A), and replicates correlated well with each other (Figure 18B). For differential gene expression, cutoffs were set at 2-fold change and p value < 0.01.





Figure 18. Gene expression distribution and correlation between samples. (A) Box plots displaying the distribution of gene expression levels and FPKM among different samples. FPKM, number of fragments per kilobase length of gene per million fragments. (B) Correlation coefficient matrix. R^2 , square of Pearson correlation coefficient (R). INJ_CON, incised (injured) contralateral group; NV_CON, naïve contralateral group; INJ_IPS, incised ipsilateral group; NV_IPS, naïve ipsilateral group; IR, incised contralateral sample; NR, naïve contralateral sample; IL, incised ipsilateral sample; NL, naïve ipsilateral sample.

In ipsilateral DRG, 6 genes, *Vip*, *Fam131a*, *RragB*, *Stac2*, *Ecel1*, and *Yif1b* were significantly upregulated compared with naïve controls, and 1 gene, *Zfp622*, was downregulated (Figure 19; Table 1). In contralateral DRG, only one gene was differentially expressed; *AC115341.1* was downregulated compared to naïve controls (Figure 20; Table 2). The differentially expressed genes are discussed in section 6.3.




Figure 19. Volcano plot of ipsilateral differentially expressed genes 7 days post-incision. Expression in L4-6 DRG from the ipsilateral side of incised rats compared to L4-6 DRG from the same side of naïve rats. Points represent genes labeled with the gene name. Dashed lines represent cutoffs of 2-fold change and p value < 0.01.

Table 1. Genes differentially expressed in ipsilateral DRG at 7 days post-incision compared to naïve controls.

Gene Name	Description	Log2 Fold Change	padj	Chromosome
Vip	Vasoactive intestinal peptide	4.8922	0.0000	1
Zfp622	Zinc finger protein	-3.9261	0.0000	2
Fam131a	Family w/ sequence similarity 131, member A	2.6137	0.0003	11
RragB	Ras-related GTP binding B	2.4283	0.0004	X
Stac2	SH3 & cysteine rich domain 2	1.8303	0.0015	10
Ecel1	Endothelin converting enzyme-like 1	1.3285	0.0036	9
Yif1b	Yip1 interacting factor homolog B	3.8085	0.0081	1




Figure 20. Volcano plot of contralateral differentially expressed genes 7 days post-incision. Expression in L4-6 DRG from the contralateral side of incised rats compared to L4-6 DRG from the same side of naïve rats. Points represent genes labeled with the gene name. Dashed lines represent cutoffs of 2-fold change and $p < 0.01$.

Table 2. Genes differentially expressed in contralateral DRG at 7 days post-incision compared to naïve controls.

Gene Name	Description	Log2 Fold Change	padj	Chromosome
AC115341.1	Serine-threonine protein phosphatase 2A activator	-1.0558	0.0000	3

To establish the noise threshold, I used an approach that takes into account sample-to-sample variation, as described recently by Koch, et al. (Koch et al., 2018). Variability between samples was visualized for this purpose by comparing the number of genes expressed at different cutoffs across all samples. The samples did not become indistinguishable until an FPKM cutoff of 0.5 was reached, permitting a low counts threshold of FPKM = 0.5 (Figure 21). All differentially expressed genes were above this determined noise level in at least 3 out of 4 replicates in at least one condition (incised or naïve) (Table 3).




Figure 21. Quantification of genes with expression above different FPKM cutoff values. The gene expression distributions across different samples align quickly, leading to a threshold of FPKM = 0.5. IL, incised ipsilateral; NL, naïve ipsilateral; 1-4, biological replicates.

Table 3. FPKM values of genes differentially expressed in ipsilateral and contralateral DRG at 7 days post-incision. IL, incised ipsilateral; NL, naïve ipsilateral; IR, incised contralateral; NR, naïve contralateral; 1-4, biological replicates.

gene_id	IL1	IL2	IL3	IL4	NL1	NL2	NL3	NL4	gene_name
ENSRNOG00000018808	2.28268558	3.83441997	0.91657168	1.35470858	0.07987836	0.04286206	0.03690832	0.12633287	Vip
ENSRNOG00000059443	0.20308313	0.07354765	0.03832587	0.13704748	2.58854943	1.65783152	1.00314401	1.27661141	Zfp622
ENSRNOG00000045653	1.85310546	0.27719848	0.74505199	0.94243543	0.11594747	0.19553739	0.16837634	0.13971697	Fam131a
ENSRNOG00000050535	0.62671753	0.92122763	1.32188818	0.24878267	0.16673874	0.16267385	0.12606993	0.12785855	RragB
ENSRNOG0000004805	1.63573239	2.42106928	0.80529289	1.59978041	0.52635389	0.60671673	0.16213686	0.53442082	Stac2
ENSRNOG00000019447	0.68393225	0.68922364	0.45642772	0.55295734	0.22823011	0.32366111	0.13558529	0.26642351	Ecel1
ENSRNOG00000020616	11.7440057	13.6040629	1.19461767	21.6211559	0.95890612	0.44103515	0.37977333	1.66100844	Yif1b
gene_id	IR1	IR2	IR3	IR4	NR1	NR2	NR3	NR4	gene_name
ENSRNOG00000022490	36.27219	29.65835	34.10362	36.57926	62.69084	65.93988	84.64073	70.25088	AC115341.1

6.3. Conclusions

With the plantar incision model of post-surgical pain, I have shown thus far that deep tissue incision potentiates OA, depolarizes RMP, and hyperpolarizes AP threshold in DRG neurons isolated from the ipsilateral side 1 day post-incision. Unexpectedly, the largest changes in ipsilateral DRG neurons compared with naïve controls were observed in probable nociceptors isolated 7 days post-incision, with an increased incidence of OA at RMP and at -45 mV, depolarized RMP, hyperpolarized AP threshold, and enhanced DSFs. Depolarization of RMP was also present in DRG neurons isolated 14 days post-incision. Additionally, enhanced DSFs were detected in DRG neurons isolated from the contralateral side 7 days post-incision. These results suggest that hyperexcitable effects of deep tissue incision on nociceptors persist longer than what has been revealed by *in vivo* behavioral tests and that some effects occur bilaterally. This persistent hyperexcitability observed in isolated nociceptors may be the result of a “primed” state induced by the incision that is revealed by the stress of the dissociation procedure. Alternatively, nociceptor hyperexcitability may be actively suppressed *in vivo*, such as by endogenous opioid pathways, and thus is only revealed when the nociceptors are

removed from such suppressive mechanisms, which would be consistent with the recent finding that hyperalgesia can be reinstated by opioid receptor antagonists 21 days post-incision (Custodio-Patsey et al., 2020). Hypotheses and future directions regarding the mechanisms underlying the hyperexcitability in isolated nociceptors lasting longer than *in vivo* pain will be discussed in Chapter 7.

In contrast to a recent study that found 126 genes differentially expressed in DRG 1 day post-incision compared with controls (Tran et al., 2020), my RNA sequencing revealed few transcriptional changes in DRG 7 days post-incision compared to naïve controls, suggesting that alterations at the level of gene expression may not account for the observed effects on nociceptor excitability at this time point. Given the ability of 5-HT to produce covert hyperexcitability (revealed only when membrane potential is depolarized) shown in Chapter 3, an important question was whether the mRNAs for any 5-HT receptors changed in expression after incision. Several 5-HT receptor mRNAs were present in my DRG samples— in descending order of abundance, *Htr3b*, *Htr3a*, *Htr1d*, *Htr1b*, *Htr4*, *Htr1a*, *Htr2a*, *Htr5b*, and *Htr2c*. However, there was no significant differential expression of any 5-HT receptors 7 days post-injury. The only differentially expressed genes identified are described briefly below.

Vip: The upregulated gene showing the most statistical significance (Figure 19, Table 1) on POD7 in ipsilateral DRG, albeit still at a low level of expression (Table 3), was *Vip*, which encodes vasoactive intestinal peptide (VIP). VIP is a neuropeptide that was originally reported as a vasodilator (Said and Mutt, 1970) and has since been found to have a wide array of physiological and pathological effects, including but not limited to gastrointestinal function and diseases (Iwasaki et al., 2019), cancer (Siddappa and Vege, 2019), and pain (Bourlev et al., 2018; McDougall et al., 2006). VIP carries out its

activities by binding the G_s-coupled receptors VPAC1/2 (Moody and Jensen, 2013) and is widely distributed in the CNS and PNS (Lorén et al., 1979; Said, 1984).

Fam131a: This gene encodes a FAM131 family member. Little is known about the function of these proteins other than their ability to be myristoylated (Suzuki et al., 2010), suggesting a putative role in cell signaling.

RragB: RAS-related GTP-binding protein B (RRAGB), as the name suggests, is a GTPase that is homologous to RAS, a GTPase that is well-known for its role in cancer. GTPases are cellular switches that alternate between an active GTP-bound state and an inactive GDP-bound state. RRAG family GTPases are known to be involved in cellular responses to amino acid availability by regulating signaling through mammalian target of rapamycin complex 1 (mTORC1) (Takahara et al., 2020). The function of RRAGB in the DRG has not been studied. Interestingly, the activity of its homolog, RAS, appears to be involved in nociceptor hyperexcitability stimulated by membrane depolarization (Garza Carbajal et al., 2020).

Stac2: Another gene of interest that was significantly upregulated was *Stac2*, which encodes SH3 and cysteine-rich domain-containing protein 2 (STAC2). About a decade ago, STAC1 and STAC2, of unknown function at the time, were shown to be expressed in distinct subsets of DRG neurons (Legha et al., 2010). Since then, studies in neurons of the brain have uncovered a role for STAC2 in the regulation of voltage-gated Ca²⁺ channel activity (Campiglio et al., 2018; Polster et al., 2018, 2015).

Ecel1: Endothelin converting enzyme like 1 (ECE1), also known as damage-induced neuronal endopeptidase (DINE) is a neuron-specific membrane-bound

metalloprotease that shares homology with neprilysin and endothelin-converting enzyme, which degrade or process neuropeptides (Benoit et al., 2004; Kiryu-Seo et al., 2000). Transcriptional responses of this gene have been observed with various types of nerve injuries (Kaneko et al., 2017; Kiryu-Seo, 2006). For example, *Ecel1* expression was observed in small sized DRG neurons after sciatic nerve injury. The function and substrate(s) of ECEL1 are largely unknown, but some evidence suggests it has neuroprotective effects (Kaneko et al., 2017; Matsumoto et al., 2016).

Yif1b: YIP1 interacting factor homology B (YIF1B) is involved in anterograde trafficking from the endoplasmic reticulum to the plasma membrane and in the organization of Golgi architecture (Alterio et al., 2015; Matern et al., 2000). YIF1B plays a key role in targeting the 5-HT_{1A} receptor to neuronal dendrites in the brain (Carrel et al., 2008). It is known that YIF1B does not interact with the 5-HT_{1B} receptor (Carrel et al., 2008), but whether or not YIF1B has affinity for other 5-HT receptors, or receptors for other neuromodulators, and what its function is in the DRG are not known.

Zfp622: The only gene found to be downregulated in ipsilateral DRG 7 days post-incision encodes zinc finger protein 622 (ZFP622), also known as zinc finger-like protein 9 (ZPR9), which was originally identified as a substrate of murine protein serine/threonine kinase 38 (MPK38) (Seong et al., 2002). ZNF622 regulates apoptosis signal-regulating kinase 1 (ASK1), transforming growth factor β (TGF- β), and p53 signaling pathways (Seong et al., 2017), and a recent study suggests ZFP622 may act as a cellular antiviral protein in humans (Mun and Punga, 2018). The function of ZFP622 in the DRG has not been studied.

AC115341.1: The only gene found to be differentially expressed in contralateral DRG 7 days post-incision was a pseudogene of *Ptpa*, a gene encoding a serine/threonine protein phosphatase 2A activator. PTPAs accelerate protein folding and catalyze cis-trans isomerization of proline imidic peptide bonds in oligopeptides (www.uniprot.org).

It is important to note that differential expression studies were conducted from RNA extracted from whole DRG tissue, so while predictions can be made based on what is known about the expression of these genes, it is uncertain whether the genes of interest were expressed in nociceptors, other sensory neurons, or non-neuronal cell types. Furthermore, a relatively low expression in the whole DRG does not mean that a given gene could not be expressed to a much greater degree in a subpopulation of DRG neurons of a subset of nociceptors. Finally, increasing evidence indicates that translational modifications of DRG neurons are important for driving pain, perhaps even more important than transcriptional alterations (Megat et al., 2019). Predictions and future directions regarding the potential roles of the differentially expressed genes detected in this study are discussed in Chapter 7.

Chapter 7

Concluding remarks and future directions

7.1. Summary of conclusions

The major findings of this study are (1) that low concentrations of 5-HT promote acute OA through the G_s -coupled 5-HT₄ receptor and downstream cAMP signaling, predominantly via activation of PKA, with some contributions from EPAC (Figure 22), and (2) that OA persists in isolated nociceptors for weeks after deep tissue plantar incision, with effects on RMP, AP threshold, and DSFs but with few transcriptional changes associated with this persistent OA.

7.2. Functional implications of 5-HT₄-dependent cAMP signaling in nociceptors

Nociceptor OA induced by injury or inflammation may be generated in peripheral terminals, axonal neuromas, and/or the soma, with each site potentially exposed persistently to inflammatory mediators, including 5-HT (discussed by Walters, 2019). Our findings set the stage for multidisciplinary approaches to define potentially important contributions of 5-HT-stimulated cAMP signaling in nociceptors – within the DRG and at sites of injury – to behaviorally expressed ongoing pain.




Figure 22. Graphical summary of 5-HT₄-mediated potentiation of OA in nociceptors. In isolated nociceptors exposed to 5-HT for 5-60 min, the G_s-coupled 5-HT₄ receptor stimulates cAMP signaling, with the effectors PKA and EPAC causing hyperpolarized AP threshold and enhanced DSFs, thereby potentiating OA in the presence of a depolarizing stimulus. reprinted from E. R. Lopez, A. Garza Carbajal, J. B. Tian, A. Bavencoffe, M. X. Zhu, C. W. Dessauer, and E. T. Walters. 2021. Serotonin enhances depolarizing spontaneous fluctuations, excitability, and ongoing activity in isolated rat DRG neurons via 5-HT₄ receptors and cAMP-dependent mechanisms. *Neuropharmacology* 184: 108408. Use of the text and figures are granted for use in a dissertation by an author without formal licensing from Elsevier Ltd.

The nociceptor hyperexcitability mechanisms described in Chapters 3-5 may contribute to pain associated with peripheral tissue injury, such as incisional pain. As described in Chapter 1, 5-HT is one of several mediators released by activated mast cells. Mast cells release 5-HT when activated by injuries such as plantar incision (Oliveira et al., 2011). Serotonin-cAMP signaling promotes OA by reducing AP threshold and enhancing DSFs, with the OA generated in the periphery and/or soma likely to contribute to ongoing pain and central sensitization. The effects of 5-HT-cAMP signaling

on rheobase may be particularly relevant in the periphery, where increased 5-HT₄ activity in nociceptors may render their peripheral terminals more sensitive to sensory generator potentials and thereby contribute to hyperalgesia.

As my studies were conducted in isolated DRG neurons, the mechanisms of nociceptor hyperexcitability defined by these studies may be especially relevant in the DRG. Besides mast cells, 5-HT is also stored in platelets and released upon platelet activation. Interestingly, 5-HT is elevated in the plasma as well as in the CSF acutely following spinal cord injury (Brodner et al., 1980; Sharma et al., 1993). A study also found significantly elevated plasma 5-HT levels in patients with primary fibromyalgia syndrome (PFS), a condition characterized by diffuse chronic pain, compared to controls (Legangneux et al., 2001). Because DRG are perfused by blood in addition to CSF (Abram et al., 2006; Godel et al., 2016), the contribution of circulating and intrathecal 5-HT to the early C-fiber OA generated within the DRG in vivo after spinal cord injury (Bedi et al., 2010) or to PFS pain warrants further investigation.

7.3. Advantages and potential pitfalls of a pharmacological approach to studying molecular mechanisms

The necessity and relative contribution of a given pathway or protein to a physiological outcome of interest can be determined experimentally by examining the effects of functionally removing the pathway or protein. Functional removal can be achieved by genetic deletion or suppression or by pharmacological inhibition. Pharmacological approaches to studying molecular mechanisms include antibody-based, peptide-based, and (most commonly) small-molecule based treatments to inhibit,

or in some cases activate, a protein of interest. Compared to genetic approaches, pharmacological inhibition typically takes place on a significantly shorter time scale. On the one hand, creating a knockout mouse when one is not already available can take about a year from start to finish (www.med.umich.edu/tamc), and effective knockdown of a gene may involve a slow turnover rate of already existing gene products. On the other hand, the effects of pharmacologically inhibiting a protein typically occur within seconds to hours, depending on the mode of delivery and the outcome being measured. Pharmacological tools also provide the power to observe the effects of inhibiting the target of interest in real time (avoiding compensatory effects that often occur with transgenic approaches) and the ability to compare functional outcomes before and after inhibition of the target within the same animal or the same cell. Pharmacological studies also provide an additional degree of translatability since, in many cases, it is more feasible to treat a human with a drug than to knock out or knock down a gene in a patient.

Nonetheless, there are a number of major weaknesses to keep in mind when employing a pharmacological approach. Notably, it is common for drugs to exhibit significant off-target effects, especially in the case of kinase inhibitors (Davis et al., 2011; Michel and Seifert, 2015). Cell permeability is also a common issue for drugs with intracellular targets. Different drugs differ in their ability to cross the plasma membrane, and the extracellular concentration of drug is often a poor predictor of its intracellular concentration. Even if a drug is applied intracellularly, such as via a micropipette in an electrophysiological assay, it can be difficult to know the local concentration at the target. Thus, the effective concentration of a drug against its target as determined in a cell-free assay, may have limited translation to a cell, tissue, or intact animal. This could lead to under-dosing and result in false negative data. However, higher doses are more likely

to lead to off-target effects that may result in false positive data. Additionally, known off-target effects are often overlooked. Furthermore, high doses of some drugs may lead to negative effects of the drug or its solvent on membrane properties or cell integrity, complicating the interpretation of effects in intact cells, and some compounds may interfere with the assay itself rather than the pathway under study, making the results uninterpretable.

I have attempted to minimize these pitfalls by reviewing the primary literature on the use of each drug, as information provided by a supplier may be biased. Instead of relying on doses reported in other studies, for the most important drugs, I determined dose-response relationships before choosing my experimental drug concentration. To control for solvent effects, vehicle controls were used where appropriate. Furthermore, I substantiated the role of PKA by including two structurally distinct drugs that work by different modes of action.

7.4. Future directions

While I was able to define a 5-HT-dependent mechanism that potentiates OA in nociceptors as well as uncover an unexpected time course of OA in DRG neurons isolated after plantar incision, there are many questions left to explore. Future directions of greatest interest are discussed below.

7.4.1. cAMP signaling in nociceptors – what about POPDC?

POPDC is the most recently discovered cAMP effector. The *Popdc* gene family consists of *Popdc 1*, *Popdc2*, and *Popdc3*. My RNA sequencing data indicates that *Popdc3* and *Popdc2* are expressed in rat DRG, and previous studies showed expression

of *Popdc1* in the DRG and neurons of the spinal cord in embryonic mice (Andrée et al., 2002a, 2002b). Major advances in understanding POPDC function thus far established its important role in regulating heart rate and skeletal muscle regeneration. Importantly, POPDCs are known to interact with ion channels (Schindler and Brand, 2016). For example, in the heart, cAMP modulates the direct interaction of POPDC with the two-pore K⁺ channel TREK-1; binding of cAMP to POPDC disrupts its interaction with TREK-1, thereby reducing the plasma membrane localization of TREK-1 and impacting heart rate dynamics (Froese et al., 2012). The potential role of POPDC in neurons remains to be explored and will be an important avenue for future research to further our understanding of cAMP signaling in the peripheral nervous system and whether cAMP-POPDC signaling plays a role in ion channel regulation in sensory neurons.

7.4.2. Role of 5-HT/cAMP signaling in postsurgical pain

A study by Oliveira and colleagues demonstrated that 5-HT levels increased in the paw after plantar incision in mice, and reduction of 5-HT levels in the paw by mast cell depletion was associated with decreased mechanical allodynia post-incision (Oliveira et al., 2011). Oliveira et al. (2011) found that pretreatment with selective 5-HT₃ or 5-HT_{2A} receptor antagonists partially attenuated mechanical allodynia 0.5, 1, and 2 hours after incision, and they were able to achieve complete reversal of mechanical allodynia by coadministration of 5-HT₃ and 5-HT_{2A} antagonists along with a histamine (another mast cell mediator) receptor antagonist. However, this study did not exclude potential roles for 5-HT₄ receptors in other painful effects of incision, notably hyperalgesia and spontaneous pain, which were not examined. Hyperexcitability and OA in nociceptors are implicated in hyperalgesia and spontaneous pain, whereas

mechanical allodynia is thought to be expressed by the activation of A-fiber LTMRs (C. N. Liu et al., 2000; C.-N. Liu et al., 2000; Walters, 2021), which are likely excluded from our electrophysiological studies due to their larger size. Thermal hyperalgesia and spontaneous guarding pain behavior occur after plantar incision, so future studies should examine the contribution of mast cells, 5-HT, and 5-HT₄ receptors to these types of post-incisional pain that are likely driven by hyperexcitability and OA in C-fibers (Djoughri et al., 2006; Wu et al., 2002; Xu and Brennan, 2010). Furthermore, Oliveira and colleagues (2011) showed 5-HT was increased in the paw within one hour post-incision, and levels dropped back down by 48 hours compared to sham-operated animals, but it is not clear how the 5-HT level at 48 hours compares to baseline/naive levels. It will be of interest in future studies to determine whether changes in 5-HT levels only occur locally or if increases can be detected in the blood or CSF as well as how long 5-HT levels remain elevated post-incision compared to baseline.

7.4.3. Why does hyperactivity persist in isolated nociceptors longer than *in vivo* pain and OA?

Studying longer-lasting effects of incision could provide clues to what is involved in the transition from acute to chronic postsurgical pain. One attractive hypothesis that could explain the hyperexcitability observed in isolated nociceptors at 7 and 14 days post-incision when pain behavior is no longer present is that it is a manifestation of hyperalgesic priming. Hyperalgesic priming is a model of pain plasticity in which an initial priming stimulus that sensitizes nociceptors, such as acute tissue damage or inflammation, leads to a primed state after the initial sensitization has apparently

resolved, resulting in an exaggerated nociceptive response to subsequent exposure to an inflammatory test stimulus (Kandasamy and Price, 2015; Price and Inyang, 2015).

Plantar incision has been shown to act as a priming stimulus, resulting in exaggerated allodynia in response to a test intraplantar injection of PGE₂ on postoperative day 14 (Baptista-de-Souza et al., 2020; Burton et al., 2017; Tillu et al., 2012). While a modest dose of an inflammatory mediator such as PGE₂ is typically used experimentally to precipitate primed behavioral responses long after the priming event (e.g. Burton et al., 2017; Khomula et al., 2017; Wang et al., 2018), it is conceivable that the DRG neuron isolation procedure, which involves severing the axons from the cell bodies in the process of DRG removal followed by chemical and physical disruption to dissociate the cells, could also precipitate primed responses, revealing a primed state induced by the incision that is manifested as nociceptor hyperexcitability. This hypothesis can be tested by seeing whether inhibitors of key players known to mediate hyperalgesic priming, such as PKC ϵ (Aley et al., 2000) attenuate signs of hyperexcitability at 7 or 14 days post-incision.

A related hypothesis involves the role of endogenous opioid receptor analgesia that suppresses latent pain sensitization and promotes the return to normal pain thresholds following tissue injury (Campillo et al., 2011; Corder et al., 2013). Inhibition of spinal μ - or κ -opioid receptors (MOR and KOR, respectively) reinstates mechanical allodynia 21 days after plantar incision (Custodio-Patsey et al., 2020). One way to relate the role of endogenous opioids to suppression of nociceptor OA is to test whether MOR or KOR antagonists can reinstate OA in nociceptors *in vivo* at a chronic post-incisional timepoint.

7.4.4. Potential new molecular contributors to postsurgical pain suggested by transcriptional analysis

Of the eight genes I found to be differentially expressed in DRG one week after plantar incision compared to naïve controls, two with functions that plausibly could contribute to nociceptor OA and postsurgical pain are discussed below.

Vip: Vasoactive intestinal peptide (VIP) is a neuropeptide that activates G_s-coupled VPAC receptors and is known to be present in subpopulations of trigeminal ganglion and DRG neurons (Kummer and Heym, 1986; Lazarov, 1994; Xie et al., 2020). Besides neurons, VIP is produced by other cell types, notably immune cells such as mast cells, T cells, and macrophages (Cutz et al., 1978; Delgado and Ganea, 2001; Leceta et al., 1994; Metwali et al., 2002; Wershil et al., 1993). Moreover, macrophages are present in DRG and have been shown to contribute to the initiation and maintenance of pain after spared nerve injury in mice (Yu et al., 2020). However, preliminary data revealed no significant activation of PKA by VIP in primary DRG neurons from naïve rats (A. Garza Carbajal, unpublished observations), suggesting that these cells may exhibit little to no response to this neuropeptide under normal conditions. Rather, the sensory neurons may be producing VIP for release at central terminals, which is in line with early studies showing that VIP is present in Lissauer's tract and Lamina I of the dorsal horn of the spinal cord, where the central axons of nociceptors reach the spinal cord (Purves et al., 2001), in humans, cats, and rats (Anand et al., 1983; Basbaum and Glazer, 1983). Basbaum and Glazer (1983) noted that the staining pattern of VIP was indicative of secretion from A δ -nociceptors, which represent an important but very small fraction of

DRG neurons. A later study demonstrated increased cAMP levels in the spinal cord linked to release of VIP from primary afferents (Liu and Gintzler, 2003).

In addition to producing VIP, immune cells can also respond to VIP. Accordingly, VIP has also been implicated in neurogenic inflammation, whereby primary afferents release pro-inflammatory neuropeptides into tissues, initiating an inflammatory reaction which can in turn produce painful symptoms. For example, VIP is one of several neuropeptides implicated in neurogenic inflammation that induces psoriasis flares (Al'Abadie et al., 1995; Chan et al., 1997; Kwon et al., 2018; Naukkarinen et al., 1993), which has been linked to VIP's ability to activate immune cells, such as mast cells, to release pro-inflammatory mediators (Choi and Di Nardo, 2018; Lowman et al., 1988; Scholzen et al., 1998). Interestingly, there is evidence that VIP and other neuropeptides can also have anti-inflammatory effects on immune cells. For example, VIP is able to inhibit macrophage production of pro-inflammatory cytokines such as TNF- α and IL-6 (Delgado et al., 2003; Martínez et al., 1998). Such opposing activities may depend upon the physiological context (Baral et al., 2019).

Increased VIP production by DRG neurons after plantar incision should be confirmed, such as by immunostaining or quantitative PCR. To rule out potential effects on DRG neurons of secretion of VIP from other cell types (e.g. macrophages) or possible interaction between DRG neurons via VIP secretion, a simple experiment would be to apply a VPAC receptor antagonist to DRG neurons isolated after incision to see if hyperactivity is attenuated. The contribution of VIP secretion from sensory neurons to post-incisional pain, either at the spinal cord or in peripheral tissue, can be tested by

intrathecal or intraplantar injection, respectively, of a VPAC receptor antagonist prior to behavioral tests.

Stac2: An early study found that genes for Src homology 3 and cysteine rich domain proteins (STAC1 and STAC2) are expressed in a mutually exclusive fashion in mouse DRG neurons, with STAC1 predominantly expressed in peptidergic nociceptors and STAC2 expressed in a subset of nonpeptidergic nociceptors and low threshold mechanoreceptors (Legha et al., 2010). Under the assumption that this expression pattern is similar in rat DRG neurons, we can predict the *Stac2* expression detected in my RNA sequencing study of whole DRG tissue occurred in a subset of nociceptors.

STAC2 has been shown to inhibit Ca²⁺-dependent inactivation of neuronal L-type Ca²⁺ channels, thereby increasing these voltage-dependent Ca²⁺ currents (Polster et al., 2018). While the neuronal function of STAC2 has only been reported in the brain (Polster et al., 2018, 2015), we can predict based on these findings that STAC2 similarly increases L-type Ca²⁺ currents in nociceptors. Unpublished data implicates L-type Ca²⁺ channels in increased ERK signaling in rat DRG neurons after spinal cord injury (A. Garza Carbajal, unpublished observations), which has been linked to persistent nociceptor hyperactivity (Garza Carbajal et al., 2020), and *Stac2* transcripts also appear to be upregulated after spinal cord injury (R. Cuevas-Diaz Duran, A. Garza Carbajal, Y. Li, E. T. Walters, C. W. Dessauer, and J. Wu, unpublished observations). Additionally, a recent study demonstrated L-type Ca²⁺ channel expression and activity in the DRG contributes to the effects of sleep deprivation on delayed recovery from postsurgical mechanical allodynia and heat hyperalgesia in rats (Li et al., 2019). Thus, an exciting

future direction is to investigate whether modulation of L-type Ca^{2+} channel activity by STAC2 contributes to nociceptor OA and spontaneous pain after plantar incision.

Bibliography

- Abram, S.E., Yi, J., Fuchs, A., Hogan, Q.H., 2006. Permeability of injured and intact peripheral nerves and dorsal root ganglia. *Anesthesiology* 105, 146–153.
<https://doi.org/10.1097/00000542-200607000-00024>
- Aich, A., Afrin, L.B., Gupta, K., 2015. Mast Cell-Mediated Mechanisms of Nociception. *Int J Mol Sci* 16, 29069–29092. <https://doi.org/10.3390/ijms161226151>
- Al'Abadie, M.S., Senior, H.J., Bleehen, S.S., Gawkrödger, D.J., 1995. Neuropeptides and general neuronal marker in psoriasis--an immunohistochemical study. *Clin Exp Dermatol* 20, 384–389. <https://doi.org/10.1111/j.1365-2230.1995.tb01354.x>
- Aley, K.O., Levine, J.D., 1999. Role of Protein Kinase A in the Maintenance of Inflammatory Pain. *J. Neurosci.* 19, 2181–2186.
<https://doi.org/10.1523/JNEUROSCI.19-06-02181.1999>
- Aley, K.O., Messing, R.O., Mochly-Rosen, D., Levine, J.D., 2000. Chronic Hypersensitivity For Inflammatory Nociceptor Sensitization Mediated by the ϵ Isozyme of Protein Kinase C. *J. Neurosci.* 20, 4680–4685.
<https://doi.org/10.1523/JNEUROSCI.20-12-04680.2000>
- Alterio, J., Masson, J., Diaz, J., Chachlaki, K., Salman, H., Areias, J., Al Awabdh, S., Emerit, M.B., Darmon, M., 2015. Yif1B Is Involved in the Anterograde Traffic Pathway and the Golgi Architecture. *Traffic* 16, 978–993.
<https://doi.org/10.1111/tra.12306>
- Anand, P., Gibson, S.J., McGregor, G.P., Blank, M.A., Ghatei, M.A., Bacarese-Hamilton, A.J., Polak, J.M., Bloom, S.R., 1983. A VIP-containing system concentrated in the lumbosacral region of human spinal cord. *Nature* 305, 143–145. <https://doi.org/10.1038/305143a0>

- Andrée, B., Fleige, A., Arnold, H.-H., Brand, T., 2002a. Mouse Pop1 is required for muscle regeneration in adult skeletal muscle. *Mol Cell Biol* 22, 1504–1512.
<https://doi.org/10.1128/mcb.22.5.1504-1512.2002>
- Andrée, B., Fleige, A., Hillemann, T., Arnold, H.-H., Kessler-Icekson, G., Brand, T., 2002b. Molecular and functional analysis of Popeye genes: A novel family of transmembrane proteins preferentially expressed in heart and skeletal muscle. *Exp Clin Cardiol* 7, 99–103.
- Apfelbaum, J.L., Chen, C., Mehta, S.S., Gan, T.J., 2003. Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. *Anesth Analg* 97, 534–540, table of contents.
<https://doi.org/10.1213/01.ane.0000068822.10113.9e>
- Austin, P.J., Moalem-Taylor, G., 2010. The neuro-immune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like glial cells and cytokines. *J Neuroimmunol* 229, 26–50.
<https://doi.org/10.1016/j.jneuroim.2010.08.013>
- Azimi, E., Xia, J., Lerner, E.A., 2016. Peripheral Mechanisms of Itch. *Curr Probl Dermatol* 50, 18–23. <https://doi.org/10.1159/000446012>
- Backonja, M.-M., Stacey, B., 2004. Neuropathic pain symptoms relative to overall pain rating. *The Journal of Pain* 5, 491–497.
<https://doi.org/10.1016/j.jpain.2004.09.001>
- Baptista-de-Souza, D., Tavares-Ferreira, D., Megat, S., Sankaranarayanan, I., Shiers, S., Flores, C.M., Ghosh, S., Luiz Nunes-de-Souza, R., Canto-de-Souza, A., Price, T.J., 2020. Sex differences in the role of atypical PKC within the

- basolateral nucleus of the amygdala in a mouse hyperalgesic priming model. *Neurobiology of Pain* 8, 100049. <https://doi.org/10.1016/j.ynpai.2020.100049>
- Barabas, M.E., Stucky, C.L., 2013. TRPV1, but not TRPA1, in primary sensory neurons contributes to cutaneous incision-mediated hypersensitivity. *Mol Pain* 9, 9. <https://doi.org/10.1186/1744-8069-9-9>
- Baral, P., Udit, S., Chiu, I.M., 2019. Pain and immunity: implications for host defence. *Nat Rev Immunol* 19, 433–447. <https://doi.org/10.1038/s41577-019-0147-2>
- Basbaum, A.I., Bautista, D.M., Scherrer, G., Julius, D., 2009. Cellular and Molecular Mechanisms of Pain. *Cell* 139, 267–284. <https://doi.org/10.1016/j.cell.2009.09.028>
- Basbaum, A.I., Glazer, E.J., 1983. Immunoreactive vasoactive intestinal polypeptide is concentrated in the sacral spinal cord: a possible marker for pelvic visceral afferent fibers. *Somatosens Res* 1, 69–82. <https://doi.org/10.3109/07367228309144541>
- Bavencoffe, A., Li, Y., Wu, Z., Yang, Q., Herrera, J., Kennedy, E.J., Walters, E.T., Dessauer, C.W., 2016. Persistent Electrical Activity in Primary Nociceptors after Spinal Cord Injury Is Maintained by Scaffolded Adenylyl Cyclase and Protein Kinase A and Is Associated with Altered Adenylyl Cyclase Regulation. *J. Neurosci.* 36, 1660–1668. <https://doi.org/10.1523/JNEUROSCI.0895-15.2016>
- Bedi, S.S., Yang, Q., Crook, R.J., Du, J., Wu, Z., Fishman, H.M., Grill, R.J., Carlton, S.M., Walters, E.T., 2010. Chronic spontaneous activity generated in the somata of primary nociceptors is associated with pain-related behavior after spinal cord injury. *J. Neurosci.* 30, 14870–14882. <https://doi.org/10.1523/JNEUROSCI.2428-10.2010>

- Bennett, G.J., 2012. What Is Spontaneous Pain and Who Has It? *The Journal of Pain* 13, 921–929. <https://doi.org/10.1016/j.jpain.2012.05.008>
- Benoit, A., Vargas, M.A., Desgroseillers, L., Boileau, G., 2004. Endothelin-converting enzyme-like 1 (ECE1) is present both in the plasma membrane and in the endoplasmic reticulum. *Biochem J* 380, 881–888. <https://doi.org/10.1042/BJ20040215>
- Berger, M., Gray, J.A., Roth, B.L., 2009. The expanded biology of serotonin. *Annu Rev Med* 60, 355–366. <https://doi.org/10.1146/annurev.med.60.042307.110802>
- Berkey, S.C., Herrera, J.J., Odem, M.A., Rahman, S., Cheruvu, S.S., Cheng, X., Walters, E.T., Dessauer, C.W., Bavencoffe, A.G., 2020. EPAC1 and EPAC2 promote nociceptor hyperactivity associated with chronic pain after spinal cord injury. *Neurobiol Pain* 7, 100040. <https://doi.org/10.1016/j.ynpai.2019.100040>
- Bolin, L.M., Verity, A.N., Silver, J.E., Shooter, E.M., Abrams, J.S., 1995. Interleukin-6 production by Schwann cells and induction in sciatic nerve injury. *J Neurochem* 64, 850–858. <https://doi.org/10.1046/j.1471-4159.1995.64020850.x>
- Bourlev, V., Moberg, C., Ilyasova, N., Davey, E., Kunovac Kallak, T., Olovsson, M., 2018. Vasoactive intestinal peptide is upregulated in women with endometriosis and chronic pelvic pain. *Am J Reprod Immunol* 80, e12857. <https://doi.org/10.1111/aji.12857>
- Brennan, T.J., Vandermeulen, Erk P., Gebhart, G. F., 1995. Characterization of a Rat Model of Incisional Pain. *Pain* 64, 493–501. [https://doi.org/10.1016/0304-3959\(95\)01441-1](https://doi.org/10.1016/0304-3959(95)01441-1)
- Breser, M.L., Salazar, F.C., Rivero, V.E., Motrich, R.D., 2017. Immunological Mechanisms Underlying Chronic Pelvic Pain and Prostate Inflammation in

Chronic Pelvic Pain Syndrome. *Front Immunol* 8, 898.

<https://doi.org/10.3389/fimmu.2017.00898>

Brodner, R.A., Dohrmann, G.J., Roth, R.H., Rubin, R.A., 1980. Correlation of cerebrospinal fluid serotonin and altered spinal cord blood flow in experimental trauma. *Surg Neurol* 13, 337–343.

Burton, M.D., Tillu, D.V., Mazhar, K., Mejia, G.L., Asiedu, M.N., Inyang, K., Hughes, T., Lian, B., Dussor, G., Price, T.J., 2017. Pharmacological activation of AMPK inhibits incision-evoked mechanical hypersensitivity and the development of hyperalgesic priming in mice. *Neuroscience* 359, 119–129.

<https://doi.org/10.1016/j.neuroscience.2017.07.020>

Bushnell, M., Apkarian, A., 2005. Representation of pain in the brain, in: *Textbook of Pain*. Elsevier Churchill Livingstone, Philadelphia, Pennsylvania, pp. 107–124.

Callesen, T., Bech, K., Kehlet, H., 1999. Prospective study of chronic pain after groin hernia repair. *Br J Surg* 86, 1528–1531. <https://doi.org/10.1046/j.1365-2168.1999.01320.x>

Campiglio, M., Costé de Bagneaux, P., Ortner, N.J., Tuluc, P., Van Petegem, F., Flucher, B.E., 2018. STAC proteins associate to the IQ domain of CaV1.2 and inhibit calcium-dependent inactivation. *Proc Natl Acad Sci U S A* 115, 1376–1381. <https://doi.org/10.1073/pnas.1715997115>

Campillo, A., Cabañero, D., Romero, A., García-Nogales, P., Puig, M.M., 2011. Delayed postoperative latent pain sensitization revealed by the systemic administration of opioid antagonists in mice. *Eur J Pharmacol* 657, 89–96. <https://doi.org/10.1016/j.ejphar.2011.01.059>

- Cardenas, C.G., Mar, L.P.D., Scroggs, R.S., 1997. Two Parallel Signaling Pathways Couple 5HT_{1A} Receptors to N- and L-Type Calcium Channels in C-Like Rat Dorsal Root Ganglion Cells. *Journal of Neurophysiology* 77, 3284–3296.
<https://doi.org/10.1152/jn.1997.77.6.3284>
- Cardenas, L.M., Cardenas, C.G., Scroggs, R.S., 2001. 5HT increases excitability of nociceptor-like rat dorsal root ganglion neurons via cAMP-coupled TTX-resistant Na(+) channels. *Journal of Neurophysiology* 86, 241–248.
<https://doi.org/10.1152/jn.2001.86.1.241>
- Carrel, D., Masson, J., Al Awabdh, S., Capra, C.B., Lenkei, Z., Hamon, M., Emerit, M.B., Darmon, M., 2008. Targeting of the 5-HT_{1A} serotonin receptor to neuronal dendrites is mediated by Yif1B. *J Neurosci* 28, 8063–8073.
<https://doi.org/10.1523/JNEUROSCI.4487-07.2008>
- Chan, J., Smoller, B.R., Raychauduri, S.P., Jiang, W.Y., Farber, E.M., 1997. Intraepidermal nerve fiber expression of calcitonin gene-related peptide, vasoactive intestinal peptide and substance P in psoriasis. *Arch Dermatol Res* 289, 611–616. <https://doi.org/10.1007/s004030050249>
- Chang, L., Ye, F., Luo, Q., Tao, Y., Shu, H., 2018. Increased Hyperalgesia and Proinflammatory Cytokines in the Spinal Cord and Dorsal Root Ganglion After Surgery and/or Fentanyl Administration in Rats. *Anesth Analg* 126, 289–297.
<https://doi.org/10.1213/ANE.0000000000002601>
- Chen, J.J., Vasko, M.R., Wu, X., Staeva, T.P., Baez, M., Zgombick, J.M., Nelson, D.L., 1998. Multiple Subtypes of Serotonin Receptors Are Expressed in Rat Sensory Neurons in Culture. *J Pharmacol Exp Ther* 287, 1119–1127.

- Choi, J.E., Di Nardo, A., 2018. Skin neurogenic inflammation. *Semin Immunopathol* 40, 249–259. <https://doi.org/10.1007/s00281-018-0675-z>
- Cochet, M., Donneger, R., Cassier, E., Gaven, F., Lichtenthaler, S.F., Marin, P., Bockaert, J., Dumuis, A., Claeysen, S., 2013. 5-HT₄ receptors constitutively promote the non-amyloidogenic pathway of APP cleavage and interact with ADAM10. *ACS Chem Neurosci* 4, 130–140. <https://doi.org/10.1021/cn300095t>
- Comitato, A., Bardoni, R., 2021. Presynaptic Inhibition of Pain and Touch in the Spinal Cord: From Receptors to Circuits. *Int J Mol Sci* 22. <https://doi.org/10.3390/ijms22010414>
- Corder, G., Doolen, S., Donahue, R.R., Winter, M.K., Jutras, B.L., He, Y., Hu, X., Wieskopf, J.S., Mogil, J.S., Storm, D.R., Wang, Z.J., McCarson, K.E., Taylor, B.K., 2013. Constitutive μ -opioid receptor activity leads to long-term endogenous analgesia and dependence. *Science* 341, 1394–1399. <https://doi.org/10.1126/science.1239403>
- Cui, M., Nicol, G.D., 1995. Cyclic AMP mediates the prostaglandin E₂-induced potentiation of bradykinin excitation in rat sensory neurons. *Neuroscience* 66, 459–466. [https://doi.org/10.1016/0306-4522\(94\)00567-o](https://doi.org/10.1016/0306-4522(94)00567-o)
- Cui, Y., Xu, J., Dai, R., Li, C., Liu, D., Yang, L., Wang, J., 2010. [Change of p-CREB after surgical incisional pain in rat spinal cord]. *Zhong Nan Da Xue Xue Bao Yi Xue Ban* 35, 833–839. <https://doi.org/10.3969/j.issn.1672-7347.2010.08.010>
- Custodio-Patsey, L., Donahue, R.R., Fu, W., Lambert, J., Smith, B.N., Taylor, B.K., 2020. Sex differences in kappa opioid receptor inhibition of latent postoperative pain sensitization in dorsal horn. *Neuropharmacology* 163, 107726. <https://doi.org/10.1016/j.neuropharm.2019.107726>

- Cutz, E., Chan, W., Track, N.S., Goth, A., Said, S.I., 1978. Release of vasoactive intestinal polypeptide in mast cells by histamine liberators. *Nature* 275, 661–662. <https://doi.org/10.1038/275661a0>
- Dahlhamer, J., Lucas, J., Zelaya, C., Nahin, R., Mackey, S., DeBar, L., Kerns, R., Von Korff, M., Porter, L., Helmick, C., 2018. Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults - United States, 2016. *MMWR Morb Mortal Wkly Rep* 67, 1001–1006. <https://doi.org/10.15585/mmwr.mm6736a2>
- Daneshjou, K., Jafarih, H., Raaeskarami, S.-R., 2012. Congenital Insensitivity to Pain and Anhydrosis (CIPA) Syndrome; A Report of 4 Cases. *Iran J Pediatr* 22, 412–416.
- Das, V., 2015. An Introduction to Pain Pathways and Pain “Targets,” in: *Progress in Molecular Biology and Translational Science*. Elsevier, pp. 1–30. <https://doi.org/10.1016/bs.pmbts.2015.01.003>
- Davis, M.I., Hunt, J.P., Herrgard, S., Ciceri, P., Wodicka, L.M., Pallares, G., Hocker, M., Treiber, D.K., Zarrinkar, P.P., 2011. Comprehensive analysis of kinase inhibitor selectivity. *Nat Biotechnol* 29, 1046–1051. <https://doi.org/10.1038/nbt.1990>
- Delgado, M., Ganea, D., 2001. Cutting edge: is vasoactive intestinal peptide a type 2 cytokine? *J Immunol* 166, 2907–2912. <https://doi.org/10.4049/jimmunol.166.5.2907>
- Delgado, M., Leceta, J., Ganea, D., 2003. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia. *J Leukoc Biol* 73, 155–164. <https://doi.org/10.1189/jlb.0702372>

- Dessauer, C.W., Watts, V.J., Ostrom, R.S., Conti, M., Dove, S., Seifert, R., 2017. International Union of Basic and Clinical Pharmacology. CI. Structures and Small Molecule Modulators of Mammalian Adenylyl Cyclases. *Pharmacol Rev* 69, 93–139. <https://doi.org/10.1124/pr.116.013078>
- Dhaka, A., Earley, T.J., Watson, J., Patapoutian, A., 2008. Visualizing cold spots: TRPM8-expressing sensory neurons and their projections. *J Neurosci* 28, 566–575. <https://doi.org/10.1523/JNEUROSCI.3976-07.2008>
- Dina, O.A., Barletta, J., Chen, X., Mutero, A., Martin, A., Messing, R.O., Levine, J.D., 2000. Key role for the epsilon isoform of protein kinase C in painful alcoholic neuropathy in the rat. *J Neurosci* 20, 8614–8619.
- Dina, O.A., Chen, X., Reichling, D., Levine, J.D., 2001. Role of protein kinase Cepsilon and protein kinase A in a model of paclitaxel-induced painful peripheral neuropathy in the rat. *Neuroscience* 108, 507–515. [https://doi.org/10.1016/s0306-4522\(01\)00425-0](https://doi.org/10.1016/s0306-4522(01)00425-0)
- Djoughri, L., Koutsikou, S., Fang, X., McMullan, S., Lawson, S.N., 2006. Spontaneous pain, both neuropathic and inflammatory, is related to frequency of spontaneous firing in intact C-fiber nociceptors. *J. Neurosci.* 26, 1281–1292. <https://doi.org/10.1523/JNEUROSCI.3388-05.2006>
- D’Mello, R., Dickenson, A.H., 2008. Spinal cord mechanisms of pain. *British Journal of Anaesthesia* 101, 8–16. <https://doi.org/10.1093/bja/aen088>
- Du, X., Hao, H., Gigout, S., Huang, D., Yang, Y., Li, L., Wang, C., Sundt, D., Jaffe, D.B., Zhang, H., Gamper, N., 2014. Control of somatic membrane potential in nociceptive neurons and its implications for peripheral nociceptive transmission. *Pain* 155, 2306–2322. <https://doi.org/10.1016/j.pain.2014.08.025>

- Dubin, A.E., Patapoutian, A., 2010. Nociceptors: the sensors of the pain pathway. *J Clin Invest* 120, 3760–3772. <https://doi.org/10.1172/JCI42843>
- Eijkelkamp, N., Wang, H., Garza-Carbajal, A., Willemen, H.L.D.M., Zwartkruis, F.J., Wood, J.N., Dantzer, R., Kelley, K.W., Heijnen, C.J., Kavelaars, A., 2010. Low nociceptor GRK2 prolongs prostaglandin E2 hyperalgesia via biased cAMP signaling to Epac/Rap1, protein kinase Cepsilon, and MEK/ERK. *J Neurosci* 30, 12806–12815. <https://doi.org/10.1523/JNEUROSCI.3142-10.2010>
- Emery, E.C., Young, G.T., Berrococo, E.M., Chen, L., McNaughton, P.A., 2011. HCN2 ion channels play a central role in inflammatory and neuropathic pain. *Science* 333, 1462–1466. <https://doi.org/10.1126/science.1206243>
- Feldman, J.M., 2004. Serotonin, in: *Encyclopedia of Gastroenterology*. Elsevier, pp. 346–351. <https://doi.org/10.1016/B0-12-386860-2/00638-9>
- Ferreira, S.H., Nakamura, M., de Abreu Castro, M.S., 1978. The hyperalgesic effects of prostacyclin and prostaglandin E2. *Prostaglandins* 16, 31–37. [https://doi.org/10.1016/0090-6980\(78\)90199-5](https://doi.org/10.1016/0090-6980(78)90199-5)
- Fields, D.P., Springborn, S.R., Mitchell, G.S., 2015. Spinal 5-HT7 receptors induce phrenic motor facilitation via EPAC-mTORC1 signaling. *J. Neurophysiol.* 114, 2015–2022. <https://doi.org/10.1152/jn.00374.2015>
- Forsythe, P., Bienenstock, J., 2012. The mast cell-nerve functional unit: a key component of physiologic and pathophysiologic responses. *Chem Immunol Allergy* 98, 196–221. <https://doi.org/10.1159/000336523>
- Froese, A., Breher, S.S., Waldeyer, C., Schindler, R.F.R., Nikolaev, V.O., Rinné, S., Wischmeyer, E., Schlueter, J., Becher, J., Simrick, S., Vauti, F., Kutzt, J., Meister, P., Kreissl, S., Torlopp, A., Liebig, S.K., Laakmann, S., Müller, T.D.,

- Neumann, J., Stieber, J., Ludwig, A., Maier, S.K., Decher, N., Arnold, H.-H., Kirchhof, P., Fabritz, L., Brand, T., 2012. Popeye domain containing proteins are essential for stress-mediated modulation of cardiac pacemaking in mice. *J Clin Invest* 122, 1119–1130. <https://doi.org/10.1172/JCI59410>
- Fu, W. a, Nelson, T.S. b, Santos, D.F. b, Doolen, S. b, Gutierrez, J.J.P. b, Ye, N. e, Zhou, J. e, K. Taylor, B. a, 2019. An NPY Y1 receptor antagonist unmasks latent sensitization and reveals the contribution of protein kinase A and Epac to chronic inflammatory pain. *Pain* 160, 1754–1765. <https://doi.org/10.1097/j.pain.0000000000001557>
- Gan, T.J., Habib, A.S., Miller, T.E., White, W., Apfelbaum, J.L., 2014. Incidence, patient satisfaction, and perceptions of post-surgical pain: results from a US national survey. *Curr Med Res Opin* 30, 149–160. <https://doi.org/10.1185/03007995.2013.860019>
- Gao, W., Zan, Y., Wang, Z.-J.J., Hu, X.-Y., Huang, F., 2016. Quercetin ameliorates paclitaxel-induced neuropathic pain by stabilizing mast cells, and subsequently blocking PKC ϵ -dependent activation of TRPV1. *Acta Pharmacol Sin* 37, 1166–1177. <https://doi.org/10.1038/aps.2016.58>
- Garza Carbajal, A., Bavencoffe, A., Walters, E.T., Dessauer, C.W., 2020. Depolarization-dependent C-Raf signaling promotes hyperexcitability and reduces opioid sensitivity of isolated nociceptors after spinal cord injury. *J. Neurosci.* <https://doi.org/10.1523/JNEUROSCI.0810-20.2020>
- Gershon, M.D., Tack, J., 2007. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. *Gastroenterology* 132, 397–414. <https://doi.org/10.1053/j.gastro.2006.11.002>

- Godel, T., Pham, M., Heiland, S., Bendszus, M., Bäumer, P., 2016. Human dorsal-root-ganglion perfusion measured in-vivo by MRI. *Neuroimage* 141, 81–87. <https://doi.org/10.1016/j.neuroimage.2016.07.030>
- Gold, M.S., Reichling, D.B., Shuster, M.J., Levine, J.D., 1996. Hyperalgesic agents increase a tetrodotoxin-resistant Na⁺ current in nociceptors. *Proc. Natl. Acad. Sci. U.S.A.* 93, 1108–1112. <https://doi.org/10.1073/pnas.93.3.1108>
- Goode, D.J., Molliver, D.C., 2021. Regulation of mitochondrial function by Epac2 contributes to acute inflammatory hyperalgesia. *J Neurosci.* <https://doi.org/10.1523/JNEUROSCI.2368-20.2021>
- Gradwell, M.A., Callister, R.J., Graham, B.A., 2020. Reviewing the case for compromised spinal inhibition in neuropathic pain. *J Neural Transm (Vienna)* 127, 481–503. <https://doi.org/10.1007/s00702-019-02090-0>
- Guan, Z., Kuhn, J.A., Wang, X., Colquitt, B., Solorzano, C., Vaman, S., Guan, A.K., Evans-Reinsch, Z., Braz, J., Devor, M., Abboud-Werner, S.L., Lanier, L.L., Lomvardas, S., Basbaum, A.I., 2016. Injured sensory neuron-derived CSF1 induces microglial proliferation and DAP12-dependent pain. *Nat Neurosci* 19, 94–101. <https://doi.org/10.1038/nn.4189>
- Guo, D., Hu, J., 2014. Spinal presynaptic inhibition in pain control. *Neuroscience* 283, 95–106. <https://doi.org/10.1016/j.neuroscience.2014.09.032>
- Gupta, A., Kaur, K., Sharma, S., Goyal, S., Arora, S., Murthy, R.S.R., 2010. Clinical aspects of acute post-operative pain management & its assessment. *J Adv Pharm Technol Res* 1, 97–108.
- Gupta, K., Harvima, I.T., 2018. Mast cell-neural interactions contribute to pain and itch. *Immunol Rev* 282, 168–187. <https://doi.org/10.1111/imr.12622>

- Hingtgen, C.M., Waite, K.J., Vasko, M.R., 1995. Prostaglandins facilitate peptide release from rat sensory neurons by activating the adenosine 3',5'-cyclic monophosphate transduction cascade. *J Neurosci* 15, 5411–5419.
- Huang, L.-Y., Gu, Y., 2017. Epac and Nociceptor Sensitization. *Mol Pain* 13, 1744806917716234. <https://doi.org/10.1177/1744806917716234>
- Hucho, T.B., Dina, O.A., Levine, J.D., 2005. Epac mediates a cAMP-to-PKC signaling in inflammatory pain: an isolectin B4(+) neuron-specific mechanism. *J Neurosci* 25, 6119–6126. <https://doi.org/10.1523/JNEUROSCI.0285-05.2005>
- Hughes, D.I., Todd, A.J., 2020. Central Nervous System Targets: Inhibitory Interneurons in the Spinal Cord. *Neurotherapeutics* 17, 874–885. <https://doi.org/10.1007/s13311-020-00936-0>
- Isensee, J., Diskar, M., Waldherr, S., Buschow, R., Hasenauer, J., Prinz, A., Allgower, F., Herberg, F.W., Hucho, T., 2014. Pain modulators regulate the dynamics of PKA-RII phosphorylation in subgroups of sensory neurons. *Journal of Cell Science* 127, 216–229. <https://doi.org/10.1242/jcs.136580>
- Isensee, J., Krahé, L., Moeller, K., Pereira, V., Sexton, J.E., Sun, X., Emery, E., Wood, J.N., Hucho, T., 2017. Synergistic regulation of serotonin and opioid signaling contributes to pain insensitivity in Nav1.7 knockout mice. *Sci. Signal.* 10, eaah4874. <https://doi.org/10.1126/scisignal.aah4874>
- Iwasaki, M., Akiba, Y., Kaunitz, J.D., 2019. Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system. *F1000Res* 8. <https://doi.org/10.12688/f1000research.18039.1>
- Jaggi, A.S., Kaur, G., Bali, A., Singh, N., 2017. Pharmacological investigations on mast cell stabilizer and histamine receptor antagonists in vincristine-induced

- neuropathic pain. *Naunyn Schmiedebergs Arch Pharmacol* 390, 1087–1096.
<https://doi.org/10.1007/s00210-017-1426-8>
- Jessen, K.R., Mirsky, R., 2019. The Success and Failure of the Schwann Cell Response to Nerve Injury. *Front Cell Neurosci* 13, 33.
<https://doi.org/10.3389/fncel.2019.00033>
- Joseph, E.K., Levine, J.D., 2003a. Sexual dimorphism in the contribution of protein kinase C isoforms to nociception in the streptozotocin diabetic rat. *Neuroscience* 120, 907–913. [https://doi.org/10.1016/s0306-4522\(03\)00400-7](https://doi.org/10.1016/s0306-4522(03)00400-7)
- Joseph, E.K., Levine, J.D., 2003b. Sexual dimorphism for protein kinase c epsilon signaling in a rat model of vincristine-induced painful peripheral neuropathy. *Neuroscience* 119, 831–838. [https://doi.org/10.1016/s0306-4522\(03\)00203-3](https://doi.org/10.1016/s0306-4522(03)00203-3)
- Kandasamy, R., Price, T.J., 2015. The Pharmacology of Nociceptor Priming. *Handb Exp Pharmacol* 227, 15–37. https://doi.org/10.1007/978-3-662-46450-2_2
- Kaneko, A., Kiryu-Seo, S., Matsumoto, S., Kiyama, H., 2017. Damage-induced neuronal endopeptidase (DINE) enhances axonal regeneration potential of retinal ganglion cells after optic nerve injury. *Cell Death Dis* 8, e2847.
<https://doi.org/10.1038/cddis.2017.212>
- Katz, J., Jackson, M., Kavanagh, B.P., Sandler, A.N., 1996. Acute pain after thoracic surgery predicts long-term post-thoracotomy pain. *Clin J Pain* 12, 50–55.
<https://doi.org/10.1097/00002508-199603000-00009>
- Kehlet, H., Jensen, T.S., Woolf, C.J., 2006. Persistent postsurgical pain: risk factors and prevention. *Lancet* 367, 1618–1625. [https://doi.org/10.1016/S0140-6736\(06\)68700-X](https://doi.org/10.1016/S0140-6736(06)68700-X)

- Khasar, S.G., Lin, Y.H., Martin, A., Dadgar, J., McMahon, T., Wang, D., Hundle, B., Aley, K.O., Isenberg, W., McCarter, G., Green, P.G., Hodge, C.W., Levine, J.D., Messing, R.O., 1999. A novel nociceptor signaling pathway revealed in protein kinase C epsilon mutant mice. *Neuron* 24, 253–260.
[https://doi.org/10.1016/s0896-6273\(00\)80837-5](https://doi.org/10.1016/s0896-6273(00)80837-5)
- Khomula, E.V., Ferrari, L.F., Araldi, D., Levine, J.D., 2017. Sexual Dimorphism in a Reciprocal Interaction of Ryanodine and IP3 Receptors in the Induction of Hyperalgesic Priming. *J. Neurosci.* 37, 2032–2044.
<https://doi.org/10.1523/JNEUROSCI.2911-16.2017>
- Kidd, G.J., Ohno, N., Trapp, B.D., 2013. Biology of Schwann cells. *Handb Clin Neurol* 115, 55–79. <https://doi.org/10.1016/B978-0-444-52902-2.00005-9>
- Kim, C.F., Moalem-Taylor, G., 2011. Interleukin-17 contributes to neuroinflammation and neuropathic pain following peripheral nerve injury in mice. *J Pain* 12, 370–383. <https://doi.org/10.1016/j.jpain.2010.08.003>
- Kim, J.-A., Park, J.-Y., Kang, H.-W., Huh, S.-U., Jeong, S.-W., Lee, J.-H., 2006. Augmentation of Cav3.2 T-type calcium channel activity by cAMP-dependent protein kinase A. *J. Pharmacol. Exp. Ther.* 318, 230–237.
<https://doi.org/10.1124/jpet.106.101402>
- Kim, J.-H., Yamamoto, T., Lee, J., Yashiro, T., Hamada, T., Hayashi, S., Kadowaki, M., 2014. CGRP, a neurotransmitter of enteric sensory neurons, contributes to the development of food allergy due to the augmentation of microtubule reorganization in mucosal mast cells. *Biomed Res* 35, 285–293.
<https://doi.org/10.2220/biomedres.35.285>

- Kiryu-Seo, S., 2006. Identification and functional analysis of damage-induced neuronal endopeptidase (DINE), a nerve injury associated molecule. *Anat Sci Int* 81, 1–6. <https://doi.org/10.1111/j.1447-073X.2006.00136.x>
- Kiryu-Seo, S., Sasaki, M., Yokohama, H., Nakagomi, S., Hirayama, T., Aoki, S., Wada, K., Kiyama, H., 2000. Damage-induced neuronal endopeptidase (DINE) is a unique metallopeptidase expressed in response to neuronal damage and activates superoxide scavengers. *Proceedings of the National Academy of Sciences* 97, 4345–4350. <https://doi.org/10.1073/pnas.070509897>
- Kleggetveit, I.P., Namer, B., Schmidt, R., Helås, T., Rückel, M., Ørstavik, K., Schmelz, M., Jørum, E., 2012. High spontaneous activity of C-nociceptors in painful polyneuropathy: *Pain* 153, 2040–2047. <https://doi.org/10.1016/j.pain.2012.05.017>
- Klein, T., Stahn, S., Magerl, W., Treede, R.-D., 2008. The role of heterosynaptic facilitation in long-term potentiation (LTP) of human pain sensation. *Pain* 139, 507–519. <https://doi.org/10.1016/j.pain.2008.06.001>
- Koch, C.M., Chiu, S.F., Akbarpour, M., Bharat, A., Ridge, K.M., Bartom, E.T., Winter, D.R., 2018. A Beginner’s Guide to Analysis of RNA Sequencing Data. *Am J Respir Cell Mol Biol* 59, 145–157. <https://doi.org/10.1165/rcmb.2017-0430TR>
- Kummer, W., Heym, C., 1986. Correlation of neuronal size and peptide immunoreactivity in the guinea-pig trigeminal ganglion. *Cell Tissue Res* 245, 657–665. <https://doi.org/10.1007/BF00218569>
- Kwon, C.W., Fried, R.G., Nousari, Y., Ritchlin, C., Tausk, F., 2018. Psoriasis: Psychosomatic, somatopsychic, or both? *Clin Dermatol* 36, 698–703. <https://doi.org/10.1016/j.clindermatol.2018.08.009>

- Laumet, G., Bavencoffe, A., Edralin, J.D., Huo, X.-J., Walters, E.T., Dantzer, R., Heijnen, C.J., Kavelaars, A., 2020. Interleukin-10 resolves pain hypersensitivity induced by cisplatin by reversing sensory neuron hyperexcitability. *Pain*. <https://doi.org/10.1097/j.pain.0000000000001921>
- Lazarov, N., 1994. Primary trigeminal afferent neuron of the cat: II. Neuropeptide- and serotonin-like immunoreactivity. *J Hirnforsch* 35, 373–389.
- Leceta, J., Martinez, M.C., Delgado, M., Garrido, E., Gomariz, R.P., 1994. Lymphoid cell subpopulations containing vasoactive intestinal peptide in the rat. *Peptides* 15, 791–797. [https://doi.org/10.1016/0196-9781\(94\)90031-0](https://doi.org/10.1016/0196-9781(94)90031-0)
- Legangneux, E., Mora, J.J., Spreux-Varoquaux, O., Thorin, I., Herrou, M., Alvado, G., Gomeni, C., 2001. Cerebrospinal fluid biogenic amine metabolites, plasma-rich platelet serotonin and [3H]mipramine reuptake in the primary fibromyalgia syndrome. *Rheumatology (Oxford)* 40, 290–296. <https://doi.org/10.1093/rheumatology/40.3.290>
- Legha, W., Gaillard, S., Gascon, E., Malapert, P., Hocine, M., Alonso, S., Moqrich, A., 2010. *stac1* and *stac2* genes define discrete and distinct subsets of dorsal root ganglia neurons. *Gene Expression Patterns* 10, 368–375. <https://doi.org/10.1016/j.gep.2010.08.003>
- Leo, M., Schmitt, L.-I., Kutritz, A., Kleinschnitz, C., Hagenacker, T., 2021. Cisplatin-induced activation and functional modulation of satellite glial cells lead to cytokine-mediated modulation of sensory neuron excitability. *Experimental Neurology* 113695. <https://doi.org/10.1016/j.expneurol.2021.113695>
- Li, Q., Zhu, Z., Lu, J., Chao, Y.-C., Zhou, X., Huang, Y., Chen, X., Su, D., Yu, W., Gu, X., 2019. Sleep deprivation of rats increases postsurgical expression and

activity of L-type calcium channel in the dorsal root ganglion and slows recovery from postsurgical pain. *Acta Neuropathol Commun* 7.

<https://doi.org/10.1186/s40478-019-0868-2>

Li, Z.-H., Cui, D., Qiu, C.-J., Song, X.-J., 2019. Cyclic nucleotide signaling in sensory neuron hyperexcitability and chronic pain after nerve injury. *Neurobiology of Pain* 6, 100028. <https://doi.org/10.1016/j.ynpai.2019.100028>

Lin, S.L., Johnson-Farley, N.N., Lubinsky, D.R., Cowen, D.S., 2003. Coupling of neuronal 5-HT₇ receptors to activation of extracellular-regulated kinase through a protein kinase A-independent pathway that can utilize Epac. *J. Neurochem.* 87, 1076–1085. <https://doi.org/10.1046/j.1471-4159.2003.02076.x>

Lin, S.-Y., Chang, W.-J., Lin, C.-S., Huang, C.-Y., Wang, H.-F., Sun, W.-H., 2011. Serotonin Receptor 5-HT_{2B} Mediates Serotonin-Induced Mechanical Hyperalgesia. *Journal of Neuroscience* 31, 1410–1418. <https://doi.org/10.1523/JNEUROSCI.4682-10.2011>

Linhart, O., Obreja, O., Kress, M., 2003. The inflammatory mediators serotonin, prostaglandin E₂ and bradykinin evoke calcium influx in rat sensory neurons. *Neuroscience* 118, 69–74. [https://doi.org/10.1016/s0306-4522\(02\)00960-0](https://doi.org/10.1016/s0306-4522(02)00960-0)

Linnarsson Lab, n.d. Mousebrain.org [WWW Document]. URL <http://mousebrain.org/genesearch.html> (accessed 9.10.20).

Liu, C.N., Michaelis, M., Amir, R., Devor, M., 2000. Spinal nerve injury enhances subthreshold membrane potential oscillations in DRG neurons: relation to neuropathic pain. *J. Neurophysiol.* 84, 205–215. <https://doi.org/10.1152/jn.2000.84.1.205>

- Liu, C.-N., Wall, P.D., Ben-Dor, E., Michaelis, M., Amir, R., Devor, M., 2000. Tactile allodynia in the absence of C-fiber activation: altered firing properties of DRG neurons following spinal nerve injury. *Pain* 85, 503–521.
[https://doi.org/10.1016/S0304-3959\(00\)00251-7](https://doi.org/10.1016/S0304-3959(00)00251-7)
- Liu, N.J., Gintzler, A.R., 2003. Facilitative interactions between vasoactive intestinal polypeptide and receptor type-selective opioids: implications for sensory afferent regulation of spinal opioid action. *Brain Res* 959, 103–110.
[https://doi.org/10.1016/s0006-8993\(02\)03734-4](https://doi.org/10.1016/s0006-8993(02)03734-4)
- Liu, T., Gao, Y.-J., Ji, R.-R., 2012. Emerging role of Toll-like receptors in the control of pain and itch. *Neurosci Bull* 28, 131–144. <https://doi.org/10.1007/s12264-012-1219-5>
- Liu, X.-J., Zhang, Y., Liu, T., Xu, Z.-Z., Park, C.-K., Berta, T., Jiang, D., Ji, R.-R., 2014. Nociceptive neurons regulate innate and adaptive immunity and neuropathic pain through MyD88 adapter. *Cell Res* 24, 1374–1377.
<https://doi.org/10.1038/cr.2014.106>
- Liu, X.-Y., Wu, S.-X., Wang, Y.-Y., Wang, W., Zhou, L., Li, Y.-Q., 2005. Changes of 5-HT receptor subtype mRNAs in rat dorsal root ganglion by bee venom-induced inflammatory pain. *Neuroscience Letters* 375, 42–46.
<https://doi.org/10.1016/j.neulet.2004.10.064>
- Lorén, I., Emson, P.C., Fahrenkrug, J., Björklund, A., Alumets, J., Håkanson, R., Sundler, F., 1979. Distribution of vasoactive intestinal polypeptide in the rat and mouse brain. *Neuroscience* 4, 1953–1976. [https://doi.org/10.1016/0306-4522\(79\)90068-x](https://doi.org/10.1016/0306-4522(79)90068-x)

- Lotz, M., Vaughan, J.H., Carson, D.A., 1988. Effect of neuropeptides on production of inflammatory cytokines by human monocytes. *Science* 241, 1218–1221.
<https://doi.org/10.1126/science.2457950>
- Lowman, M.A., Benyon, R.C., Church, M.K., 1988. Characterization of neuropeptide-induced histamine release from human dispersed skin mast cells. *Br J Pharmacol* 95, 121–130. <https://doi.org/10.1111/j.1476-5381.1988.tb16555.x>
- Loyd, D.R., Henry, M.A., Hargreaves, K.M., 2013. Serotonergic neuromodulation of peripheral nociceptors. *Semin. Cell Dev. Biol.* 24, 51–57.
<https://doi.org/10.1016/j.semcdb.2012.09.002>
- Loyd, D.R., Weiss, G., Henry, M.A., Hargreaves, K.M., 2011. Serotonin increases the functional activity of capsaicin-sensitive rat trigeminal nociceptors via peripheral serotonin receptors. *Pain* 152, 2267–2276.
<https://doi.org/10.1016/j.pain.2011.06.002>
- Ma, Y., Chen, J., Yu, D., Wei, B., Jin, H., Zeng, J., Liu, X., 2021. cAMP-PKA signaling is involved in regulation of spinal HCN channels function in diabetic neuropathic pain. *Neurosci Lett* 750, 135763. <https://doi.org/10.1016/j.neulet.2021.135763>
- Mann, J.J., McBride, P.A., Brown, R.P., Linnoila, M., Leon, A.C., DeMeo, M., Mieczkowski, T., Myers, J.E., Stanley, M., 1992. Relationship between central and peripheral serotonin indexes in depressed and suicidal psychiatric inpatients. *Arch Gen Psychiatry* 49, 442–446.
<https://doi.org/10.1001/archpsyc.1992.01820060022003>
- Martínez, C., Delgado, M., Pozo, D., Leceta, J., Calvo, J.R., Ganea, D., Gomariz, R.P., 1998. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating

- polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. *J Leukoc Biol* 63, 591–601. <https://doi.org/10.1002/jlb.63.5.591>
- Matern, H., Yang, X., Andrulis, E., Sternglanz, R., Trepte, H.H., Gallwitz, D., 2000. A novel Golgi membrane protein is part of a GTPase-binding protein complex involved in vesicle targeting. *EMBO J* 19, 4485–4492. <https://doi.org/10.1093/emboj/19.17.4485>
- Matsumoto, S., Kiryu-Seo, S., Kiyama, H., 2016. Motor Nerve Arborization Requires Proteolytic Domain of Damage-Induced Neuronal Endopeptidase (DINE) during Development. *J Neurosci* 36, 4744–4757. <https://doi.org/10.1523/JNEUROSCI.3811-15.2016>
- McDougall, J.J., Watkins, L., Li, Z., 2006. Vasoactive intestinal peptide (VIP) is a modulator of joint pain in a rat model of osteoarthritis. *Pain* 123, 98–105. <https://doi.org/10.1016/j.pain.2006.02.015>
- Meacham, K., Shepherd, A., Mohapatra, D.P., Haroutounian, S., 2017. Neuropathic Pain: Central vs. Peripheral Mechanisms. *Curr Pain Headache Rep* 21, 28. <https://doi.org/10.1007/s11916-017-0629-5>
- Megat, S., Ray, P.R., Moy, J.K., Lou, T.-F., Barragán-Iglesias, P., Li, Y., Pradhan, G., Wanghzou, A., Ahmad, A., Burton, M.D., North, R.Y., Dougherty, P.M., Khoutorsky, A., Sonenberg, N., Webster, K.R., Dussor, G., Campbell, Z.T., Price, T.J., 2019. Nociceptor Translational Profiling Reveals the Regulator-Rag GTPase Complex as a Critical Generator of Neuropathic Pain. *J Neurosci* 39, 393–411. <https://doi.org/10.1523/JNEUROSCI.2661-18.2018>
- Metwali, A., Blum, A.M., Elliott, D.E., Weinstock, J.V., 2002. IL-4 inhibits vasoactive intestinal peptide production by macrophages. *American Journal of Physiology-*

Gastrointestinal and Liver Physiology 283, G115–G121.

<https://doi.org/10.1152/ajpgi.00491.2001>

Michel, M.C., Seifert, R., 2015. Selectivity of pharmacological tools: implications for use in cell physiology. A review in the theme: Cell signaling: proteins, pathways and mechanisms. *Am J Physiol Cell Physiol* 308, C505-520.

<https://doi.org/10.1152/ajpcell.00389.2014>

Mifsud, M., Spiteri, M., Camilleri, K., Bonello, M., Azzopardi, T., Abela, M., 2019. The Orthopedic Manifestations of Congenital Insensitivity to Pain: A Population-based Study. *Indian J Orthop* 53, 665–673.

https://doi.org/10.4103/ortho.IJOrtho_378_18

Mizukoshi, K., Sasaki, M., Izumi, Y., Miura, M., Watanabe, M., Amaya, F., 2013.

Activation of p38 mitogen-activated protein kinase in the dorsal root ganglion contributes to pain hypersensitivity after plantar incision. *Neuroscience* 234, 77–87. <https://doi.org/10.1016/j.neuroscience.2013.01.001>

Momin, A., McNaughton, P.A., 2009. Regulation of firing frequency in nociceptive neurons by pro-inflammatory mediators. *Exp Brain Res* 196, 45–52.

<https://doi.org/10.1007/s00221-009-1744-2>

Moody, T.W., Jensen, R.T., 2013. VIP/PACAP Receptors, in: *Handbook of Biologically Active Peptides*. Elsevier, pp. 556–561. <https://doi.org/10.1016/B978-0-12-385095-9.00076-2>

Morita, T., McClain, S.P., Batia, L.M., Pellegrino, M., Wilson, S.R., Kienzler, M.A., Lyman, K., Olsen, A.S.B., Wong, J.F., Stucky, C.L., Brem, R.B., Bautista, D.M., 2015. HTR7 Mediates Serotonergic Acute and Chronic Itch. *Neuron* 87, 124–138. <https://doi.org/10.1016/j.neuron.2015.05.044>

- Muja, N., DeVries, G.H., 2004. Prostaglandin E(2) and 6-keto-prostaglandin F(1alpha) production is elevated following traumatic injury to sciatic nerve. *Glia* 46, 116–129. <https://doi.org/10.1002/glia.10349>
- Mun, K., Punga, T., 2018. Cellular Zinc Finger Protein 622 Hinders Human Adenovirus Lytic Growth and Limits Binding of the Viral pVII Protein to Virus DNA. *J Virol* 93, e01628-18, /jvi/93/3/JVI.01628-18.atom. <https://doi.org/10.1128/JVI.01628-18>
- Murwani, R., Hodgkinson, S., Armati, P., 1996. Tumor necrosis factor alpha and interleukin-6 mRNA expression in neonatal Lewis rat Schwann cells and a neonatal rat Schwann cell line following interferon gamma stimulation. *J Neuroimmunol* 71, 65–71. [https://doi.org/10.1016/s0165-5728\(96\)00131-2](https://doi.org/10.1016/s0165-5728(96)00131-2)
- Nagi, S.S., Marshall, A.G., Makdani, A., Jarocka, E., Liljencrantz, J., Ridderström, M., Shaikh, S., O'Neill, F., Saade, D., Donkervoort, S., Foley, A.R., Minde, J., Trulsson, M., Cole, J., Bönemann, C.G., Chesler, A.T., Bushnell, M.C., McGlone, F., Olausson, H., 2019. An ultrafast system for signaling mechanical pain in human skin. *Sci. Adv.* 5, eaaw1297. <https://doi.org/10.1126/sciadv.aaw1297>
- Naukkarinen, A., Harvima, I., Paukkonen, K., Aalto, M.L., Horsmanheimo, M., 1993. Immunohistochemical analysis of sensory nerves and neuropeptides, and their contacts with mast cells in developing and mature psoriatic lesions. *Arch Dermatol Res* 285, 341–346. <https://doi.org/10.1007/BF00371834>
- Nicholson, R., Small, J., Dixon, A.K., Spanswick, D., Lee, K., 2003. Serotonin receptor mRNA expression in rat dorsal root ganglion neurons. *Neuroscience Letters* 337, 119–122. [https://doi.org/10.1016/S0304-3940\(02\)01256-9](https://doi.org/10.1016/S0304-3940(02)01256-9)

- North, R.Y., Li, Y., Ray, P., Rhines, L.D., Tatsui, C.E., Rao, G., Johansson, C.A., Zhang, H., Kim, Y.H., Zhang, B., Dussor, G., Kim, T.H., Price, T.J., Dougherty, P.M., 2019. Electrophysiological and transcriptomic correlates of neuropathic pain in human dorsal root ganglion neurons. *Brain* 142, 1215–1226. <https://doi.org/10.1093/brain/awz063>
- Numazaki, M., Tominaga, T., Toyooka, H., Tominaga, M., 2002. Direct phosphorylation of capsaicin receptor VR1 by protein kinase Cepsilon and identification of two target serine residues. *J Biol Chem* 277, 13375–13378. <https://doi.org/10.1074/jbc.C200104200>
- Nuwer, M.O., Picchione, K.E., Bhattacharjee, A., 2010. PKA-induced internalization of slack KNa channels produces dorsal root ganglion neuron hyperexcitability. *J. Neurosci.* 30, 14165–14172. <https://doi.org/10.1523/JNEUROSCI.3150-10.2010>
- Ochoa, J., Torebjörk, E., 1989. Sensations evoked by intraneural microstimulation of C nociceptor fibres in human skin nerves. *The Journal of Physiology* 415, 583–599. <https://doi.org/10.1113/jphysiol.1989.sp017737>
- Odem, M.A., Bavencoffe, A.G., Cassidy, R.M., Lopez, E.R., Tian, J., Dessauer, C.W., Walters, E.T., 2018. Isolated nociceptors reveal multiple specializations for generating irregular ongoing activity associated with ongoing pain. *Pain* 159, 2347–2362. <https://doi.org/10.1097/j.pain.0000000000001341>
- Ohta, T., Ikemi, Y., Murakami, M., Imagawa, T., Otsuguro, K.-I., Ito, S., 2006. Potentiation of transient receptor potential V1 functions by the activation of metabotropic 5-HT receptors in rat primary sensory neurons. *J. Physiol. (Lond.)* 576, 809–822. <https://doi.org/10.1113/jphysiol.2006.112250>

- Okamoto, K. a, Imbe, H. a, Morikawa, Y. a, Itoh, M. a, Sekimoto, M. b, Nemoto, K. b, Senba, E. a, 2002. 5-HT_{2A} receptor subtype in the peripheral branch of sensory fibers is involved in the potentiation of inflammatory pain in rats. *Pain* 99, 133–143. [https://doi.org/10.1016/S0304-3959\(02\)00070-2](https://doi.org/10.1016/S0304-3959(02)00070-2)
- Old, E.A., Clark, A.K., Malcangio, M., 2015. The role of glia in the spinal cord in neuropathic and inflammatory pain. *Handb Exp Pharmacol* 227, 145–170. https://doi.org/10.1007/978-3-662-46450-2_8
- Oliveira, S.M., Drewes, C.C., Silva, C.R., Trevisan, G., Boschen, S.L., Moreira, C.G., de Almeida Cabrini, D., Da Cunha, C., Ferreira, J., 2011. Involvement of mast cells in a mouse model of postoperative pain. *European Journal of Pharmacology* 672, 88–95. <https://doi.org/10.1016/j.ejphar.2011.10.001>
- Ossipov, M.H., Morimura, K., Porreca, F., 2014. Descending pain modulation and chronification of pain. *Curr Opin Support Palliat Care* 8, 143–151. <https://doi.org/10.1097/SPC.0000000000000055>
- Pace, M.C., Passavanti, M.B., Nardis, L.D., Bosco, F., Sansone, P., Pota, V., Barbarisi, M., Palagiano, A., Iannotti, F.A., Panza, E., Aurilio, C., 2018. Nociceptor plasticity: A closer look. *Journal of Cellular Physiology* 233, 2824–2838. <https://doi.org/10.1002/jcp.25993>
- Pan, P., Huang, S.-S., Shen, S.-R., Lu, C.-E., Qin, Y.-B., Zhang, J.-L., Cao, S., 2019. Role of p120 Catenin in Epac1-Induced Chronic Postsurgical Pain in Rats. *Pain Res Manag* 2019, 9017931. <https://doi.org/10.1155/2019/9017931>
- Peier, A.M., Moqrich, A., Hergarden, A.C., Reeve, A.J., Andersson, D.A., Story, G.M., Earley, T.J., Dragoni, I., McIntyre, P., Bevan, S., Patapoutian, A., 2002. A TRP

channel that senses cold stimuli and menthol. *Cell* 108, 705–715.

[https://doi.org/10.1016/s0092-8674\(02\)00652-9](https://doi.org/10.1016/s0092-8674(02)00652-9)

Perkins, F.M., Kehlet, H., 2000. Chronic pain as an outcome of surgery. A review of predictive factors. *Anesthesiology* 93, 1123–1133.

<https://doi.org/10.1097/00000542-200010000-00038>

Polster, A., Dittmer, P.J., Perni, S., Bichraoui, H., Sather, W.A., Beam, K.G., 2018.

Stac Proteins Suppress Ca²⁺-Dependent Inactivation of Neuronal L-type Ca²⁺ Channels. *J Neurosci* 38, 9215–9227.

<https://doi.org/10.1523/JNEUROSCI.0695-18.2018>

Polster, A., Perni, S., Bichraoui, H., Beam, K.G., 2015. Stac adaptor proteins regulate trafficking and function of muscle and neuronal L-type Ca²⁺ channels. *Proc Natl Acad Sci U S A* 112, 602–606. <https://doi.org/10.1073/pnas.1423113112>

Price, T.J., Flores, C.M., 2007. Critical evaluation of the colocalization between calcitonin gene-related peptide, substance P, transient receptor potential vanilloid subfamily type 1 immunoreactivities, and isolectin B4 binding in primary afferent neurons of the rat and mouse. *J Pain* 8, 263–272.

<https://doi.org/10.1016/j.jpain.2006.09.005>

Price, T.J., Inyang, K.E., 2015. Commonalities between pain and memory mechanisms and their meaning for understanding chronic pain. *Prog Mol Biol Transl Sci* 131, 409–434. <https://doi.org/10.1016/bs.pmbts.2014.11.010>

Puntillo, F., Giglio, M., Paladini, A., Perchiizzi, G., Viswanath, O., Urits, I., Sabbà, C., Varrassi, G., Brienza, N., 2021. Pathophysiology of musculoskeletal pain: a narrative review. *Ther Adv Musculoskelet Dis* 13, 1759720X21995067.

<https://doi.org/10.1177/1759720X21995067>

- Purves, D., Augustine, G., Fitzpatrick, D., editors, 2001. Central Pain Pathways: The Spinothalamic Tract, in: Neuroscience. Sunderland (MA) : Sinauer Associates.
- Reichling, D.B., Levine, J.D., 2009. Critical role of nociceptor plasticity in chronic pain. Trends Neurosci 32, 611–618. <https://doi.org/10.1016/j.tins.2009.07.007>
- Ren, K., Dubner, R., 2008. Descending Control Mechanisms, in: The Senses: A Comprehensive Reference. pp. 723–749.
- Rosa, A.C., Fantozzi, R., 2013. The role of histamine in neurogenic inflammation. Br J Pharmacol 170, 38–45. <https://doi.org/10.1111/bph.12266>
- Ross, E., Kenakin, T., 2001. Pharmacodynamics, in: The Pharmacological Basis of Therapeutics. McGraw-Hill, pp. 31–44.
- Sadana, R., Dessauer, C.W., 2009. Physiological roles for G protein-regulated adenylyl cyclase isoforms: insights from knockout and overexpression studies. Neurosignals 17, 5–22. <https://doi.org/10.1159/000166277>
- Said, S.I., 1984. Vasoactive intestinal polypeptide (VIP): current status. Peptides 5, 143–150. [https://doi.org/10.1016/0196-9781\(84\)90197-9](https://doi.org/10.1016/0196-9781(84)90197-9)
- Said, S.I., Mutt, V., 1970. Polypeptide with broad biological activity: isolation from small intestine. Science 169, 1217–1218. <https://doi.org/10.1126/science.169.3951.1217>
- Saleem, M., Deal, B., Nehl, E., Janjic, J.M., Pollock, J.A., 2019. Nanomedicine-driven neuropathic pain relief in a rat model is associated with macrophage polarity and mast cell activation. Acta Neuropathol Commun 7, 108. <https://doi.org/10.1186/s40478-019-0762-y>
- Salzer, I., Gantumur, E., Yousuf, A., Boehm, S., 2016. Control of sensory neuron excitability by serotonin involves 5HT_{2C} receptors and Ca⁽²⁺⁾-activated

chloride channels. *Neuropharmacology* 110, 277–286.

<https://doi.org/10.1016/j.neuropharm.2016.08.006>

Schindler, R.F.R., Brand, T., 2016. The Popeye domain containing protein family – A novel class of cAMP effectors with important functions in multiple tissues.

Progress in Biophysics and Molecular Biology 120, 28–36.

<https://doi.org/10.1016/j.pbiomolbio.2016.01.001>

Schmelz, M., Schmidt, R., Weidner, C., Hilliges, M., Torebjörk, H.E., Handwerker, H.O., 2003. Chemical Response Pattern of Different Classes of C-Nociceptors to Pruritogens and Algogens. *Journal of Neurophysiology* 89, 2441–2448.

<https://doi.org/10.1152/jn.01139.2002>

Schmidt, M., Evellin, S., Weernink, P.A., von Dorp, F., Rehmann, H., Lomasney, J.W., Jakobs, K.H., 2001. A new phospholipase-C-calcium signalling pathway mediated by cyclic AMP and a Rap GTPase. *Nat Cell Biol* 3, 1020–1024.

<https://doi.org/10.1038/ncb1101-1020>

Scholzen, T., Armstrong, C.A., Bunnett, N.W., Luger, T.A., Olerud, J.E., Ansel, J.C., 1998. Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune systems. *Exp Dermatol* 7, 81–96.

<https://doi.org/10.1111/j.1600-0625.1998.tb00307.x>

Scroggs, R.S., 2011. Up-regulation of low-threshold tetrodotoxin-resistant Na⁺ current via activation of a cyclic AMP/protein kinase A pathway in nociceptor-like rat dorsal root ganglion cells. *Neuroscience* 186, 13–20.

<https://doi.org/10.1016/j.neuroscience.2011.04.046>

- Seong, H.-A., Gil, M., Kim, K.-T., Kim, S.-J., Ha, H., 2002. Phosphorylation of a novel zinc-finger-like protein, ZPR9, by murine protein serine/threonine kinase 38 (MPK38). *Biochem J* 361, 597–604. <https://doi.org/10.1042/0264-6021:3610597>
- Seong, H.-A., Manoharan, R., Ha, H., 2017. Zinc finger protein ZPR9 functions as an activator of AMPK-related serine/threonine kinase MPK38/MELK involved in ASK1/TGF- β /p53 signaling pathways. *Sci Rep* 7, 42502. <https://doi.org/10.1038/srep42502>
- Serra, J., Bostock, H., Solà, R., Aleu, J., García, E., Cokic, B., Navarro, X., Quiles, C., 2012. Microneurographic identification of spontaneous activity in C-nociceptors in neuropathic pain states in humans and rats. *Pain* 153, 42–55. <https://doi.org/10.1016/j.pain.2011.08.015>
- Shamash, S., Reichert, F., Rotshenker, S., 2002. The cytokine network of Wallerian degeneration: tumor necrosis factor- α , interleukin-1 α , and interleukin-1 β . *J Neurosci* 22, 3052–3060. <https://doi.org/20026249>
- Sharma, H.S., Olsson, Y., Nyberg, F., Dey, P.K., 1993. Prostaglandins modulate alterations of microvascular permeability, blood flow, edema and serotonin levels following spinal cord injury: an experimental study in the rat. *Neuroscience* 57, 443–449. [https://doi.org/10.1016/0306-4522\(93\)90076-r](https://doi.org/10.1016/0306-4522(93)90076-r)
- Shepherd, A.J., Mickle, A.D., Golden, J.P., Mack, M.R., Halabi, C.M., de Kloet, A.D., Samineni, V.K., Kim, B.S., Krause, E.G., Gereau, R.W., Mohapatra, D.P., 2018. Macrophage angiotensin II type 2 receptor triggers neuropathic pain. *Proc Natl Acad Sci U S A* 115, E8057–E8066. <https://doi.org/10.1073/pnas.1721815115>
- Shiers, S., Klein, R.M., Price, T.J., 2020. Quantitative differences in neuronal subpopulations between mouse and human dorsal root ganglia demonstrated

- with RNAscope in situ hybridization. *Pain* 161, 2410–2424.
<https://doi.org/10.1097/j.pain.0000000000001973>
- Siddappa, P.K., Vege, S.S., 2019. Vasoactive Intestinal Peptide-Secreting Tumors: A Review. *Pancreas* 48, 1119–1125.
<https://doi.org/10.1097/MPA.0000000000001402>
- Singhmar, P., Huo, X., Li, Y., Dougherty, P.M., Mei, F., Cheng, X., Heijnen, C.J., Kavelaars, A., 2018. Orally active Epac inhibitor reverses mechanical allodynia and loss of intraepidermal nerve fibers in a mouse model of chemotherapy-induced peripheral neuropathy. *Pain* 159, 884–893.
<https://doi.org/10.1097/j.pain.0000000000001160>
- Sommer, C., 2004. Serotonin in Pain and Analgesia: Actions in the Periphery. *MN* 30, 117–126. <https://doi.org/10.1385/MN:30:2:117>
- Sousa-Valente, J., Calvo, L., Vacca, V., Simeoli, R., Arévalo, J.C., Malcangio, M., 2018. Role of TrkA signalling and mast cells in the initiation of osteoarthritis pain in the monoiodoacetate model. *Osteoarthritis Cartilage* 26, 84–94.
<https://doi.org/10.1016/j.joca.2017.08.006>
- Spray, D.C., Iglesias, R., Shraer, N., Suadecani, S.O., Belzer, V., Hanstein, R., Hanani, M., 2019. Gap junction mediated signaling between satellite glia and neurons in trigeminal ganglia. *Glia* 67, 791–801. <https://doi.org/10.1002/glia.23554>
- Study, R.E., Kral, M.G., 1996. Spontaneous action potential activity in isolated dorsal root ganglion neurons from rats with a painful neuropathy. *Pain* 65, 235–242.
[https://doi.org/10.1016/0304-3959\(95\)00216-2](https://doi.org/10.1016/0304-3959(95)00216-2)
- Sun, J., Ramnath, R.D., Zhi, L., Tamizhselvi, R., Bhatia, M., 2008. Substance P enhances NF-kappaB transactivation and chemokine response in murine

macrophages via ERK1/2 and p38 MAPK signaling pathways. *Am J Physiol Cell Physiol* 294, C1586-1596. <https://doi.org/10.1152/ajpcell.00129.2008>

Suzuki, T., Moriya, K., Nagatoshi, K., Ota, Y., Ezure, T., Ando, E., Tsunasawa, S., Utsumi, T., 2010. Strategy for comprehensive identification of human N-myristoylated proteins using an insect cell-free protein synthesis system. *Proteomics* 10, 1780–1793. <https://doi.org/10.1002/pmic.200900783>

Sweitzer, S.M., Wong, S.M.E., Peters, M.C., Mochly-Rosen, D., Yeomans, D.C., Kendig, J.J., 2004. Protein kinase C epsilon and gamma: involvement in formalin-induced nociception in neonatal rats. *J Pharmacol Exp Ther* 309, 616–625. <https://doi.org/10.1124/jpet.103.060350>

Taiwo, Y.O., Levine, J.D., 1992. Serotonin is a directly-acting hyperalgesic agent in the rat. *Neuroscience* 48, 485–490. [https://doi.org/10.1016/0306-4522\(92\)90508-Y](https://doi.org/10.1016/0306-4522(92)90508-Y)

Takahara, T., Amemiya, Y., Sugiyama, R., Maki, M., Shibata, H., 2020. Amino acid-dependent control of mTORC1 signaling: a variety of regulatory modes. *J Biomed Sci* 27, 87. <https://doi.org/10.1186/s12929-020-00679-2>

Takashima, Y., Daniels, R.L., Knowlton, W., Teng, J., Liman, E.R., McKemy, D.D., 2007. Diversity in the neural circuitry of cold sensing revealed by genetic axonal labeling of transient receptor potential melastatin 8 neurons. *J Neurosci* 27, 14147–14157. <https://doi.org/10.1523/JNEUROSCI.4578-07.2007>

Tasmuth, T., Estlanderb, A.M., Kalso, E., 1996. Effect of present pain and mood on the memory of past postoperative pain in women treated surgically for breast cancer. *Pain* 68, 343–347. [https://doi.org/10.1016/s0304-3959\(96\)03219-8](https://doi.org/10.1016/s0304-3959(96)03219-8)

Tillu, D.V., Melemedjian, O.K., Asiedu, M.N., Qu, N., De Felice, M., Dussor, G., Price, T.J., 2012. Resveratrol Engages AMPK to Attenuate ERK and mTOR Signaling

- in Sensory Neurons and Inhibits Incision-Induced Acute and Chronic Pain. *Mol Pain* 8, 1744-8069-8–5. <https://doi.org/10.1186/1744-8069-8-5>
- Tokunaga, A., Saika, M., Senba, E., 1998. 5-HT_{2A} receptor subtype is involved in the thermal hyperalgesic mechanism of serotonin in the periphery. *Pain* 76, 349–355. [https://doi.org/10.1016/s0304-3959\(98\)00066-9](https://doi.org/10.1016/s0304-3959(98)00066-9)
- Tran, P.V., Johns, M.E., McAdams, B., Abrahante, J.E., Simone, D.A., Banik, R.K., 2020. Global transcriptome analysis of rat dorsal root ganglia to identify molecular pathways involved in incisional pain. *Mol Pain* 16. <https://doi.org/10.1177/1744806920956480>
- Usoskin, D., Furlan, A., Islam, S., Abdo, H., Lönnerberg, P., Lou, D., Hjerling-Leffler, J., Haeggström, J., Kharchenko, O., Kharchenko, P.V., Linnarsson, S., Ernfors, P., 2015. Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing. *Nat. Neurosci.* 18, 145–153. <https://doi.org/10.1038/nn.3881>
- Vadakkan, K.I., Wang, H., Ko, S.W., Zastepa, E., Petrovic, M.J., Sluka, K.A., Zhuo, M., 2006. Genetic reduction of chronic muscle pain in mice lacking calcium/calmodulin-stimulated adenylyl cyclases. *Mol Pain* 2, 7. <https://doi.org/10.1186/1744-8069-2-7>
- van den Bosch, G.E., Baartmans, M.G.A., Vos, P., Dokter, J., White, T., Tibboel, D., 2014. Pain Insensitivity Syndrome Misinterpreted as Inflicted Burns. *PEDIATRICS* 133, e1381–e1387. <https://doi.org/10.1542/peds.2013-2015>
- Vasko, M.R., Habashy Maly, R., Guo, C., Duarte, D.B., Zhang, Y., Nicol, G.D., 2014. Nerve growth factor mediates a switch in intracellular signaling for PGE₂-

- induced sensitization of sensory neurons from protein kinase A to Epac. *PLoS One* 9, e104529. <https://doi.org/10.1371/journal.pone.0104529>
- Vijayaragavan, K., Boutjdir, M., Chahine, M., 2004. Modulation of Nav1.7 and Nav1.8 Peripheral Nerve Sodium Channels by Protein Kinase A and Protein Kinase C. *Journal of Neurophysiology* 91, 1556–1569. <https://doi.org/10.1152/jn.00676.2003>
- Villarreal, C.F., Funez, M.I., Figueiredo, F., Cunha, F.Q., Parada, C.A., Ferreira, S.H., 2009. Acute and persistent nociceptive paw sensitisation in mice: the involvement of distinct signalling pathways. *Life Sci.* 85, 822–829. <https://doi.org/10.1016/j.lfs.2009.10.018>
- Vincent, L., Vang, D., Nguyen, J., Gupta, M., Luk, K., Ericson, M.E., Simone, D.A., Gupta, K., 2013. Mast cell activation contributes to sickle cell pathobiology and pain in mice. *Blood* 122, 1853–1862. <https://doi.org/10.1182/blood-2013-04-498105>
- Walters, E.T., 2021. Nociceptors and chronic pain, in: *Oxford Research Encyclopedia*. Oxford University Press.
- Walters, E.T., 2019. Adaptive mechanisms driving maladaptive pain: how chronic ongoing activity in primary nociceptors can enhance evolutionary fitness after severe injury. *Philos. Trans. R. Soc. Lond., B, Biol. Sci.* 374, 20190277. <https://doi.org/10.1098/rstb.2019.0277>
- Walther, D.J., Peter, J.-U., Bashammakh, S., Hörtnagl, H., Voits, M., Fink, H., Bader, M., 2003. Synthesis of serotonin by a second tryptophan hydroxylase isoform. *Science* 299, 76. <https://doi.org/10.1126/science.1078197>

- Wang, H.-J., Gu, H.-X., Eijkelkamp, N., Heijnen, C.J., Kavelaars, A., 2018. Low GRK2 Underlies Hyperalgesic Priming by Glial Cell-Derived Neurotrophic Factor. *Front Pharmacol* 9, 592. <https://doi.org/10.3389/fphar.2018.00592>
- Weng, X., Smith, T., Sathish, J., Djouhri, L., 2012. Chronic inflammatory pain is associated with increased excitability and hyperpolarization-activated current (I_h) in C- but not A δ -nociceptors. *Pain* 153, 900–914. <https://doi.org/10.1016/j.pain.2012.01.019>
- Wershil, B.K., Turck, C.W., Sreedharan, S.P., Yang, J., An, S., Galli, S.J., Goetzl, E.J., 1993. Variants of vasoactive intestinal peptide in mouse mast cells and rat basophilic leukemia cells. *Cell Immunol* 151, 369–378. <https://doi.org/10.1006/cimm.1993.1246>
- Wu, G., Ringkamp, M., Murinson, B.B., Pogatzki, E.M., Hartke, T.V., Weerahandi, H.M., Campbell, J.N., Griffin, J.W., Meyer, R.A., 2002. Degeneration of myelinated efferent fibers induces spontaneous activity in uninjured C-fiber afferents. *J Neurosci* 22, 7746–7753.
- Xie, W., Li, F., Han, Y., Li, Z., Xiao, J., 2020. Neuropeptides are associated with pain threshold and bone microstructure in ovariectomized rats. *Neuropeptides* 81, 101995. <https://doi.org/10.1016/j.npep.2019.101995>
- Xu, J., Brennan, T.J., 2010. Guarding pain and spontaneous activity of nociceptors after skin versus skin plus deep tissue incision. *Anesthesiology* 112, 153–164. <https://doi.org/10.1097/ALN.0b013e3181c2952e>
- Yadav, V.K., 2013. Serotonin, in: *Translational Endocrinology of Bone*. Elsevier, pp. 51–62. <https://doi.org/10.1016/B978-0-12-415784-2.00005-1>

- Yam, M.F., Loh, Y.C., Tan, C.S., Khadijah Adam, S., Abdul Manan, N., Basir, R.,
2018. General Pathways of Pain Sensation and the Major Neurotransmitters
Involved in Pain Regulation. *Int J Mol Sci* 19.
<https://doi.org/10.3390/ijms19082164>
- Yamakita, S., Matsuda, M., Yamaguchi, Y., Sawa, T., Amaya, F., 2017.
Dexmedetomidine prolongs levobupivacaine analgesia via inhibition of
inflammation and p38 MAPK phosphorylation in rat dorsal root ganglion.
Neuroscience 361, 58–68. <https://doi.org/10.1016/j.neuroscience.2017.08.011>
- Yoon, S.-Y., Patel, D., Dougherty, P.M., 2012. Minocycline blocks lipopolysaccharide
induced hyperalgesia by suppression of microglia but not astrocytes.
Neuroscience 221, 214–224.
<https://doi.org/10.1016/j.neuroscience.2012.06.024>
- Yu, X., Liu, H., Hamel, K.A., Morvan, M.G., Yu, S., Leff, J., Guan, Z., Braz, J.M.,
Basbaum, A.I., 2020. Dorsal root ganglion macrophages contribute to both the
initiation and persistence of neuropathic pain. *Nat Commun* 11, 264.
<https://doi.org/10.1038/s41467-019-13839-2>
- Zhang, H., Li, Y., de Carvalho-Barbosa, M., Kavelaars, A., Heijnen, C.J., Albrecht,
P.J., Dougherty, P.M., 2016. Dorsal Root Ganglion Infiltration by Macrophages
Contributes to Paclitaxel Chemotherapy-Induced Peripheral Neuropathy. *J Pain*
17, 775–786. <https://doi.org/10.1016/j.jpain.2016.02.011>
- Zhang, L., Xie, W., Zhang, J., Shanahan, H., Tonello, R., Lee, S.H., Strong, J.A.,
Berta, T., Zhang, J.-M., 2021. Key role of CCR2-expressing macrophages in a
mouse model of low back pain and radiculopathy. *Brain, Behavior, and
Immunity* 91, 556–567. <https://doi.org/10.1016/j.bbi.2020.11.015>

Elia Rose Lopez was born in Houston, Texas, the daughter of Veronica Marie Lopez. After completing her work at Clear Creek High School, League City, Texas in 2009, she entered Texas State University in San Marcos, Texas. She received the degree of Bachelor of Science with a major in biology and a minor in geography from Texas State in May, 2013. Elia decided to continue pursuing her interest in the biological sciences and entered the graduate program at Texas State University in San Marcos, Texas in January of 2014. She received her Master of Science degree from Texas State in August, 2016 and entered The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences in August, 2016.